US20130019341A1 - Desaturases of a green microalga and uses thereof - Google Patents
Desaturases of a green microalga and uses thereof Download PDFInfo
- Publication number
- US20130019341A1 US20130019341A1 US13/520,607 US201113520607A US2013019341A1 US 20130019341 A1 US20130019341 A1 US 20130019341A1 US 201113520607 A US201113520607 A US 201113520607A US 2013019341 A1 US2013019341 A1 US 2013019341A1
- Authority
- US
- United States
- Prior art keywords
- another embodiment
- plant
- polynucleotide
- alga
- pufa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 230
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 153
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 129
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 129
- 239000002157 polynucleotide Substances 0.000 claims abstract description 129
- 238000000034 method Methods 0.000 claims abstract description 89
- 239000000203 mixture Substances 0.000 claims abstract description 79
- 230000009261 transgenic effect Effects 0.000 claims abstract description 75
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 claims abstract description 33
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 156
- 235000021342 arachidonic acid Nutrition 0.000 claims description 78
- 229940114079 arachidonic acid Drugs 0.000 claims description 78
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 78
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 66
- 238000009825 accumulation Methods 0.000 claims description 55
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 54
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 46
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 42
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 36
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 claims description 35
- 230000001131 transforming effect Effects 0.000 claims description 34
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 claims description 33
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 32
- 150000007523 nucleic acids Chemical group 0.000 claims description 32
- 239000013604 expression vector Substances 0.000 claims description 28
- 229910052757 nitrogen Inorganic materials 0.000 claims description 25
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 24
- 235000003642 hunger Nutrition 0.000 claims description 21
- 230000037351 starvation Effects 0.000 claims description 21
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 20
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 14
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 14
- 238000003860 storage Methods 0.000 claims description 14
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 claims description 13
- 230000002708 enhancing effect Effects 0.000 claims description 13
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 13
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 11
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 11
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 11
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 10
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 8
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 6
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 6
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 6
- 239000005642 Oleic acid Substances 0.000 claims description 6
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 6
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 6
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 6
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 5
- 235000020778 linoleic acid Nutrition 0.000 claims description 5
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 4
- 229960004488 linolenic acid Drugs 0.000 claims description 4
- DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical compound CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 7
- 241000196324 Embryophyta Species 0.000 description 174
- 210000004027 cell Anatomy 0.000 description 143
- 235000018102 proteins Nutrition 0.000 description 135
- 229920001184 polypeptide Polymers 0.000 description 83
- 102000004196 processed proteins & peptides Human genes 0.000 description 83
- 230000014509 gene expression Effects 0.000 description 74
- 108090000765 processed proteins & peptides Proteins 0.000 description 74
- 239000000194 fatty acid Substances 0.000 description 42
- 239000000758 substrate Substances 0.000 description 42
- 240000006542 Prunus incisa Species 0.000 description 41
- 235000014113 dietary fatty acids Nutrition 0.000 description 40
- 229930195729 fatty acid Natural products 0.000 description 40
- 150000004665 fatty acids Chemical class 0.000 description 37
- 230000015572 biosynthetic process Effects 0.000 description 36
- 108010073542 Delta-5 Fatty Acid Desaturase Proteins 0.000 description 31
- 108010037138 Linoleoyl-CoA Desaturase Proteins 0.000 description 30
- 239000013598 vector Substances 0.000 description 30
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 29
- 230000000694 effects Effects 0.000 description 29
- 150000002632 lipids Chemical class 0.000 description 29
- 102100034544 Acyl-CoA 6-desaturase Human genes 0.000 description 27
- 102000004190 Enzymes Human genes 0.000 description 27
- 108090000790 Enzymes Proteins 0.000 description 27
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 27
- 241000195493 Cryptophyta Species 0.000 description 26
- 102100034542 Acyl-CoA (8-3)-desaturase Human genes 0.000 description 23
- 239000003921 oil Substances 0.000 description 23
- 235000019198 oils Nutrition 0.000 description 23
- 238000004519 manufacturing process Methods 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 20
- 235000016709 nutrition Nutrition 0.000 description 20
- 235000001014 amino acid Nutrition 0.000 description 19
- 229940024606 amino acid Drugs 0.000 description 19
- 239000000047 product Substances 0.000 description 19
- 150000001413 amino acids Chemical class 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 240000004313 Mitrasacme polymorpha Species 0.000 description 17
- 239000002299 complementary DNA Substances 0.000 description 17
- 230000009466 transformation Effects 0.000 description 17
- 241001221668 Ostreococcus tauri Species 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- -1 betaine lipid Chemical class 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 238000011529 RT qPCR Methods 0.000 description 13
- 235000013350 formula milk Nutrition 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- 230000004048 modification Effects 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 238000013518 transcription Methods 0.000 description 12
- 108091034117 Oligonucleotide Proteins 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 230000000875 corresponding effect Effects 0.000 description 11
- 230000037361 pathway Effects 0.000 description 11
- 230000035897 transcription Effects 0.000 description 11
- 108010085238 Actins Proteins 0.000 description 10
- 241000907999 Mortierella alpina Species 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 230000002538 fungal effect Effects 0.000 description 10
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 229920001223 polyethylene glycol Polymers 0.000 description 10
- 239000002243 precursor Substances 0.000 description 10
- 239000002202 Polyethylene glycol Substances 0.000 description 9
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 9
- 230000036961 partial effect Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 230000014616 translation Effects 0.000 description 9
- 235000013343 vitamin Nutrition 0.000 description 9
- 239000011782 vitamin Substances 0.000 description 9
- 229940088594 vitamin Drugs 0.000 description 9
- 229930003231 vitamin Natural products 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 8
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 8
- 230000008929 regeneration Effects 0.000 description 8
- 238000011069 regeneration method Methods 0.000 description 8
- 150000003626 triacylglycerols Chemical class 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 108010001949 Algal Proteins Proteins 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 244000062600 Mapania squamata Species 0.000 description 7
- 108700026244 Open Reading Frames Proteins 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 7
- 230000010354 integration Effects 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 210000005253 yeast cell Anatomy 0.000 description 7
- 208000016444 Benign adult familial myoclonic epilepsy Diseases 0.000 description 6
- 108020004635 Complementary DNA Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000206744 Phaeodactylum tricornutum Species 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- 208000016427 familial adult myoclonic epilepsy Diseases 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- 238000010369 molecular cloning Methods 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 235000015112 vegetable and seed oil Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000007469 Actins Human genes 0.000 description 5
- 241000589158 Agrobacterium Species 0.000 description 5
- 102000007605 Cytochromes b5 Human genes 0.000 description 5
- 108010007167 Cytochromes b5 Proteins 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 241000206602 Eukaryota Species 0.000 description 5
- 102000036181 Fatty Acid Elongases Human genes 0.000 description 5
- 108010058732 Fatty Acid Elongases Proteins 0.000 description 5
- 241001251903 Lobosphaera incisa Species 0.000 description 5
- 240000003480 Talinum paniculatum Species 0.000 description 5
- 241001491687 Thalassiosira pseudonana Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 235000021073 macronutrients Nutrition 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000002103 transcriptional effect Effects 0.000 description 5
- 230000014621 translational initiation Effects 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 108091093088 Amplicon Proteins 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000195597 Chlamydomonas reinhardtii Species 0.000 description 4
- 240000009108 Chlorella vulgaris Species 0.000 description 4
- 108700039887 Essential Genes Proteins 0.000 description 4
- 239000001856 Ethyl cellulose Substances 0.000 description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 241001298230 Thraustochytrium sp. Species 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 235000019325 ethyl cellulose Nutrition 0.000 description 4
- 229920001249 ethyl cellulose Polymers 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 229940014259 gelatin Drugs 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 235000020256 human milk Nutrition 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000010473 stable expression Effects 0.000 description 4
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000010474 transient expression Effects 0.000 description 4
- 229940035893 uracil Drugs 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 235000016626 Agrimonia eupatoria Nutrition 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 239000002028 Biomass Substances 0.000 description 3
- 235000007089 Chlorella vulgaris Nutrition 0.000 description 3
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241000196323 Marchantiophyta Species 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 241000723873 Tobacco mosaic virus Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 150000001982 diacylglycerols Chemical class 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000003228 microsomal effect Effects 0.000 description 3
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 3
- 229940033080 omega-6 fatty acid Drugs 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 238000013081 phylogenetic analysis Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229940083542 sodium Drugs 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000015424 sodium Nutrition 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 101100225658 Arabidopsis thaliana ELP4 gene Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000195897 Ceratodon purpureus Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 241000168726 Dictyostelium discoideum Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000195619 Euglena gracilis Species 0.000 description 2
- 108700005088 Fungal Genes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000299507 Gossypium hirsutum Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001501873 Isochrysis galbana Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000222697 Leishmania infantum Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 238000010629 Molecular evolutionary genetics analysis Methods 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 240000007817 Olea europaea Species 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 241001494715 Porphyridium purpureum Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241001505297 Pythium irregulare Species 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 2
- 101000912235 Rebecca salina Acyl-lipid (7-3)-desaturase Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 101100118655 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ELO1 gene Proteins 0.000 description 2
- 241000004258 Schmidingerothrix salina Species 0.000 description 2
- 101000877236 Siganus canaliculatus Acyl-CoA Delta-4 desaturase Proteins 0.000 description 2
- 244000300264 Spinacia oleracea Species 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 238000012197 amplification kit Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 229960004667 ethyl cellulose Drugs 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000012847 fine chemical Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000013505 freshwater Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 2
- 229960002733 gamolenic acid Drugs 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 238000002169 hydrotherapy Methods 0.000 description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 2
- 238000011392 neighbor-joining method Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 2
- 229940012843 omega-3 fatty acid Drugs 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920001987 poloxamine Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 108700022487 rRNA Genes Proteins 0.000 description 2
- 238000000163 radioactive labelling Methods 0.000 description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 229940033663 thimerosal Drugs 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 235000016804 zinc Nutrition 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- WBBQTNCISCKUMU-PDBXOOCHSA-N (13Z,16Z,19Z)-docosatrienoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCCCCC(O)=O WBBQTNCISCKUMU-PDBXOOCHSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- SBQSMJWMEQRETE-HVYQYDHPSA-N (2r)-2-amino-3-[[(2r)-2-amino-2-carboxyethyl]disulfanyl]-4-oxopentanoic acid Chemical compound OC(=O)[C@@H](N)C(C(=O)C)SSC[C@H](N)C(O)=O SBQSMJWMEQRETE-HVYQYDHPSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- FPRKGXIOSIUDSE-SYACGTDESA-N (2z,4z,6z,8z)-docosa-2,4,6,8-tetraenoic acid Chemical compound CCCCCCCCCCCCC\C=C/C=C\C=C/C=C\C(O)=O FPRKGXIOSIUDSE-SYACGTDESA-N 0.000 description 1
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241001466460 Alveolata Species 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 241000191380 Byblis gigantea Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 101000864504 Chlamydomonas reinhardtii Acyl-lipid omega-13 desaturase Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000196319 Chlorophyceae Species 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000251571 Ciona intestinalis Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102100037458 Dephospho-CoA kinase Human genes 0.000 description 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 1
- 235000021292 Docosatetraenoic acid Nutrition 0.000 description 1
- 240000004551 Drosera rotundifolia Species 0.000 description 1
- 235000008497 Drosera rotundifolia Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000009114 Fatty acid desaturases Human genes 0.000 description 1
- 108010087894 Fatty acid desaturases Proteins 0.000 description 1
- 101150094690 GAL1 gene Proteins 0.000 description 1
- 102100028501 Galanin peptides Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 235000009432 Gossypium hirsutum Nutrition 0.000 description 1
- 102100032611 Guanine nucleotide-binding protein G(s) subunit alpha isoforms short Human genes 0.000 description 1
- 241000206759 Haptophyceae Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101100121078 Homo sapiens GAL gene Proteins 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229910009891 LiAc Inorganic materials 0.000 description 1
- 241000209510 Liliopsida Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 240000002129 Malva sylvestris Species 0.000 description 1
- 235000006770 Malva sylvestris Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000196329 Marchantia polymorpha Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 235000002725 Olea europaea Nutrition 0.000 description 1
- 241000277275 Oncorhynchus mykiss Species 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000206765 Pavlova lutheri Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000195887 Physcomitrella patens Species 0.000 description 1
- 241000233624 Phytophthora megasperma Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000037 Polyproline Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000119236 Rhizaria Species 0.000 description 1
- 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 241000592344 Spermatophyta Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical group O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 241000233675 Thraustochytrium Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241001293481 Trebouxiophyceae Species 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010047505 Visceral leishmaniasis Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 101000832077 Xenopus laevis Dapper 1-A Proteins 0.000 description 1
- FKCMADOPPWWGNZ-YUMQZZPRSA-N [(2r)-1-[(2s)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl]boronic acid Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O FKCMADOPPWWGNZ-YUMQZZPRSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000006295 amino methylene group Chemical group [H]N(*)C([H])([H])* 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000003816 axenic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000008133 cognitive development Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 235000014541 cooking fats Nutrition 0.000 description 1
- 239000008162 cooking oil Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 108010005155 delta-12 fatty acid desaturase Proteins 0.000 description 1
- 108010011713 delta-15 desaturase Proteins 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 108010049285 dephospho-CoA kinase Proteins 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- SQNZJJAZBFDUTD-UHFFFAOYSA-N durene Chemical compound CC1=CC(C)=C(C)C=C1C SQNZJJAZBFDUTD-UHFFFAOYSA-N 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 239000001761 ethyl methyl cellulose Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000006052 feed supplement Substances 0.000 description 1
- 229960004642 ferric ammonium citrate Drugs 0.000 description 1
- 229960002413 ferric citrate Drugs 0.000 description 1
- 230000004578 fetal growth Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- ZGNITFSDLCMLGI-UHFFFAOYSA-N flubendiamide Chemical compound CC1=CC(C(F)(C(F)(F)F)C(F)(F)F)=CC=C1NC(=O)C1=CC=CC(I)=C1C(=O)NC(C)(C)CS(C)(=O)=O ZGNITFSDLCMLGI-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 229940098330 gamma linoleic acid Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 230000004545 gene duplication Effects 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000004313 iron ammonium citrate Substances 0.000 description 1
- 235000000011 iron ammonium citrate Nutrition 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical group [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 108010026466 polyproline Proteins 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000012514 protein characterization Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- AUALKMYBYGCYNY-UHFFFAOYSA-E triazanium;2-hydroxypropane-1,2,3-tricarboxylate;iron(3+) Chemical compound [NH4+].[NH4+].[NH4+].[Fe+3].[Fe+3].[Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O AUALKMYBYGCYNY-UHFFFAOYSA-E 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
- C12N15/8247—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified lipid metabolism, e.g. seed oil composition
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0083—Miscellaneous (1.14.99)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
- C12P7/6431—Linoleic acids [18:2[n-6]]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
- C12P7/6432—Eicosapentaenoic acids [EPA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
- C12P7/6434—Docosahexenoic acids [DHA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/19—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with oxidation of a pair of donors resulting in the reduction of molecular oxygen to two molecules of water (1.14.19)
Definitions
- This invention is directed to, inter alia, proteins having ⁇ 2, ⁇ 6, or ⁇ 5 desaturase activity, isolated DNA molecules encoding the same, and methods of making and utilizing the same.
- VLC-PUFA Very long-chain polyunsaturated fatty acids
- EPA eicosapentaenoic acid
- DHA docosahexaenoic acid
- DGLA dihomo-y-linolenic acid
- ARA and DHA are the predominant fatty acids in the human brain and breast milk. ARA is necessary for normal fetal growth, and cognitive development in infants. Many studies highly suggested supplementation of infant formula with DHA and ARA. Besides the structural function in membranes, ARA is the primary substrate in eicosanoids biosynthesis which regulates many physiological processes such as homeostasis, reproduction, immune and inflammatory responses.
- Microalgae are the most efficient producers and one of the richest sources of VLC-PUFAs. Furthermore, algae can be used as sources of genes for the implementation of VLC-PUFA biosynthesis in genetically engineered oil crops. The genetic information on enzymes involved in the biosynthesis of VLC-PUFA in some algae led to in vivo applications of VLC-PUFA production in seed oil.
- the gene pool of the green freshwater microalga Parietochloris incisa (Trebouxiophyceae) is of special interest since it is the only known microalga able to accumulate extraordinary high amounts of ARA-rich triacylglycerols (TAG).
- TAG ARA-rich triacylglycerols
- ARA constitutes about 60 percent of total fatty acids (TFA) and over 95 percent of cellular ARA is deposited in TAG in cytoplasmic lipid bodies.
- VLC-PUFA in microalgae follows two major pathways, designated as ⁇ 6 and ⁇ 3.
- linoleic acid LA; 18:2 ⁇ 6
- ALA ⁇ -linolenic acid
- ARA ARA and EPA
- oleic acid (18:1) is first desaturated to LA and ⁇ -linolenic acid (GLA, 18:3 ⁇ 6) through ⁇ 12 and ⁇ 6 desaturations, followed by elongation to 20:3 ⁇ 6 and ⁇ 5 desaturation to yield ARA via the ⁇ 6 pathway.
- GLA ⁇ -linolenic acid
- VLC-PUFAs may also be generated by an alternative ⁇ 8 desaturation pathway.
- ⁇ 8 desaturation pathway E.g., in the marine haptophyte Isocrysis galbana and in the fresh water euglenophyte Euglena gracilis, where LA and ALA are first elongated by C18 ⁇ 9-specific fatty acid elongase followed by sequential ⁇ 8 and AS desaturations to ARA, DGLA or EPA.
- the extraplastidial ⁇ 12 desaturase is an integral ER-bound protein which is responsible for the desaturation of oleic acid and production of LA, mainly on phosphatidylcholine (PC).
- ⁇ 5 and ⁇ 6 desaturases contain a fused cytochrome b5 domain in their N-terminus, serving as an electron donor, and introduce a double bond at a site closer to the carboxyl group than any of the pre-existing double bonds in the substrate fatty acid, thereby called ‘front-end’ desaturases.
- Desaturases with ⁇ 6 or ⁇ 5 activity have been isolated from various organisms, e.g., the nematode C.
- elegans the fungus Mortierella alpina, the moss Physcomitrella patens, the liverwort Marchantia polymorpha and the algae Phaeodactylum tricornutum, Thalassiosira pseudonana and Ostreococcus tauri.
- Some of these desaturases have been introduced together with PUFA-specific elongases into constructs for transformation of yeast and oil seed plants to reconstitute VLC-PUFA biosynthesis in the heterologous organisms.
- the present invention provides an isolated protein comprising, an amino acid sequence set forth in SEQ ID NO: 1.
- the present invention further provides an isolated protein comprising, an amino acid sequence set forth in SEQ ID NO: 2.
- the present invention further provides an isolated protein comprising, an amino acid sequence set forth in SEQ ID NO: 3.
- the present invention further provides a composition comprising a protein comprising, an amino acid sequence set forth in SEQ ID NO: 1, a composition comprising a protein comprising, an amino acid sequence set forth in SEQ ID NO: 2, a composition comprising a protein comprising, an amino acid sequence set forth in SEQ ID NO: 3, or a composition comprising any combination thereof.
- the present invention further provides a transgenic plant, a transgenic seed, a transformed cell, or a transgenic alga transformed by a polynucleotide encoding: (1) a protein comprising, an amino acid sequence set forth in SEQ ID NO: 1, (2) a protein comprising, an amino acid sequence set forth in SEQ ID NO: 2, (3) a protein comprising, an amino acid sequence set forth in SEQ ID NO: 3, or a transgenic plant, a transgenic seed, or a transgenic alga transformed by any combination of the polynucleotides (1), (2), and (3).
- the present invention further provides a method of producing very long-chain polyunsaturated fatty acid (VLC-PUFA) in a plant, a plant cell, or an alga comprising the step of transforming a plant, an alga, or a plant cell with a polynucleotide encoding: (1) a protein comprising, an amino acid sequence set forth in SEQ ID NO: 1, (2) a protein comprising, an amino acid sequence set forth in SEQ ID NO: 2, (3) a protein comprising, an amino acid sequence set forth in SEQ ID NO: 3, or transforming a plant, a plant cell, or an alga with any combination of the polynucleotides (1), (2), and (3), thereby producing a VLC-PUFA in a plant, a plant cell, or an alga.
- VLC-PUFA very long-chain polyunsaturated fatty acid
- FIG. 1 Depicts the deduced amino acid sequences of P. incisa PiDes12 (A), PiDes6 (B), and PiDes5 (C) are aligned with their closest homologs using CLUSTAL W (1.83) multiple sequence alignment program (default). conserveed motifs characteristic of each desaturase sequence are highlighted.
- GeneBank accession numbers for the sequences are: A) C. reinhardtii (XP 001691669); C. vulgaris (BAB78716), G. hirsutum (AAL37484), S. oleracea (BAC22091), O. europaea (AAW63040).
- tricornutum (AAL92563), T. pseudonana (AAX14505), O. tauri (AAW70159), M. squamata (CAQ30479).
- FIG. 2 Is an unrooted phylogram of PiDes12, PiDes6, PiDes5 and some functionally characterized ⁇ 12, ⁇ 6 and ⁇ 5 desaturases (vertebrate and invertebrate desaturases are not included).
- the alignment was generated by the CLUSTAL W program and the unrooted phylogram was constructed in the neighbor-joining method using the MEGA4 software [47].
- GeneBank sources of the sequences are: BAB78716 ( ⁇ 12, Chlorella vulgaris ), XP — 001691669 ( ⁇ 12, C.
- AAL13311 ⁇ 5, P. irregulare
- CAD53323 ⁇ 5, Phytophthora megasperma
- BA ⁇ 37090 ⁇ 5, Dictyostelium discoideum
- AAC72755 ⁇ 5, M. alpina
- CAQ30478 ⁇ 5, M. squamata
- CAQ30479 ⁇ 6, M. squamata
- AAW70159 ⁇ 6, O. tauri
- CS020055 ⁇ 5, P. patens ).
- FIG. 3 Provides graphs representing GC FAMEs of recombinant yeast harboring pYES2 (control), pY PiDes6 (A) fed with 18:2 or 18:3 ⁇ 3, and pYPiDes5 (B) fed with 20:3 ⁇ 6, 20:4 ⁇ 3 or 18:1.
- FIG. 4 Is a graph showing the changes in expression of the PiDes12, PiDes6, and PiDes5 genes under N-starvation and ARA percent share in total fatty acids. The transcript abundance of the genes was normalized to that of the actin gene.
- FIG. 5 Depicts the amino acid sequence of P. incisa PiELO1 aligned with its closest homologs using CLUSTAL W (1.83) multiple sequence alignment program (default). conserveed motifs characteristic of PUFA elongase sequences are highlighted. GeneBank accession numbers for the sequences are OtELO1 ( O. tauri, AAV67797), MpELO1 ( M. polymorpha, AAT85662), PpELO1 ( P. patens, AAL84174), MpELO2 ( M. polymorpha, BAE71129), and ThrELO1 Thraustochytrium sp. FIN-10, ABC18313).
- OtELO1 O. tauri, AAV67797
- MpELO1 M. polymorpha, AAT85662
- PpELO1 P. patens, AAL84174
- MpELO2 M. polymorpha, BAE71129
- FIG. 6 Is a hydropathy plot of the amino acid sequence of PiELO1.
- the lower dashed line and the upper line represent the loose transmembrane region cutoff and the strict transmembrane region cutoff, respectively.
- FIG. 7 Is an unrooted phylogram of PiELO1 and some other functionally characterized PUFA elongases. The alignment was generated by the CLUSTAL W program and the unrooted phylogram was constructed by the neighbor-joining method using the MEGA4 software.
- GeneBank accession numbers for the PUFA elongases are: ACK99719 ( ⁇ 6, P. incisa ), AAV67797 ( ⁇ 6, O. tauri ), AAV67798 ( ⁇ 5, O. tauri ), AAT85662 ( ⁇ 6, M. polymorpha ), BAE71129 ( ⁇ 5, M. polymorpha ), AAL84174 ( ⁇ 6, P.
- FIG. 8 Is a GC plot of FAMES of recombinant yeast harboring pYES2 and PiELO1 fed with 18:3 ⁇ 6 (A) and 18:4 ⁇ 3 (B) CONTROL.
- FIG. 9 Is a bar graph summarizing the results of quantitative Real-time RT-PCR analysis of PiELO1 gene expression in log phase (Time 0) and N-starved (3, 7 & 14 d) cells of P. incisa. The transcript abundance of the gene was normalized to 18S SSU rRNA gene.
- the present invention provides an isolated protein. In another embodiment, the present invention provides that the isolated protein is a polypeptide. In another embodiment, the present invention provides that the isolated protein is an enzyme. In another embodiment, the present invention provides that the isolated protein is a desaturase. In another embodiment, the present invention provides that the isolated protein is an algal desaturase. In another embodiment, the present invention provides that the isolated protein is a microalgae desaturase. In another embodiment, the present invention provides that the isolated protein is a
- the present invention provides that the isolated protein is a ⁇ 6 desaturase. In another embodiment, the present invention provides that the isolated protein is a ⁇ 5 desaturase. In another embodiment, the present invention provides that the isolated protein is a microalgae desaturase produced in a plant cell. In another embodiment, the present invention provides that the isolated protein is a microalgae desaturase produced in an algal cell.
- the present invention provides a ⁇ 12 desaturase comprising the amino acid sequence:
- the present invention provides a ⁇ 6 desaturase comprising the amino acid sequence:
- the present invention provides a AS desaturase comprising the amino acid sequence:
- the desaturase of the present invention comprises an amino acid sequence that is at least 60% homologous to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In another embodiment, the desaturase comprises an amino acid sequence that is at least 70% homologous to the amino acid sequence of SEQ ID NO: 1, SEQ NO: 2, or SEQ ID NO: 3. In another embodiment, the desaturase comprises an amino acid sequence that is at least 75% homologous to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.
- the desaturase comprises an amino acid sequence that is at least 80% homologous to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In another embodiment, the desaturase comprises an amino acid sequence that is at least 85% homologous to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In another embodiment, the desaturase comprises an amino acid sequence that is at least 90% homologous to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO:
- the desaturase comprises an amino acid sequence that is at least 95% homologous to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In another embodiment, the desaturase comprises an amino acid sequence that is at least 98% homologous to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.
- the desaturase of the present invention comprises an amino acid sequence that is at least 60% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In another embodiment, the desaturase comprises an amino acid sequence that is at least 70% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In another embodiment, the desaturase comprises an amino acid sequence that is at least 75% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In another embodiment, the desaturase comprises an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.
- the desaturase comprises an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In another embodiment, the desaturase comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In another embodiment, the desaturase comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In another embodiment, the desaturase comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.
- the desaturase as described herein comprises at least a portion of the amino acid shown in SEQ ID. NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In another embodiment, the desaturase as described herein is a variant of SEQ ID. NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.
- variants in relation to a certain sequence means a protein or a polypeptide which is derived from the sequence through the insertion or deletion of one or more amino acid residues or the substitution of one or more amino acid residues with amino acid residues having similar properties, e.g., the replacement of a polar amino acid residue with another polar amino acid residue, or the replacement of a non-polar amino acid residue with another non-polar amino acid residue.
- variants must have a desaturase function as defined herein.
- the desaturase as described herein further comprises a leader peptide.
- the leader peptide allows the polypeptide to be specifically located or targeted to a target organelle within the cell.
- the desaturase as described herein further comprises a sequence motif responsible for microsomal localization.
- a desaturase as described herein further comprises chemical modification such as glycosylation that increases its stability.
- a desaturase as described herein further comprises a peptide unrelated to desaturase which increases its stability.
- the present invention provides an isolated PUFA desaturase.
- the present invention provides an isolated polypeptide comprising a functional long chain polyunsaturated fatty acid (PUFA) desaturase.
- PUFA long chain polyunsaturated fatty acid
- the present invention provides that the polypeptide has the function of desaturating a chain longer than 18 carbons fatty acid.
- the present invention provides that the polypeptide has the function of desaturating a chain longer than 20 carbons fatty acid.
- the present invention provides an isolated PUFA desaturase comprising a fused N-terminal cytochrome b5 domain. In another embodiment, the present invention provides an isolated PUFA desaturase which desaturates ⁇ 6 substrates. In another embodiment, the present invention provides an isolated PUFA desaturase which desaturates both ⁇ 3 substrates. In another embodiment, the present invention provides an isolated PUFA desaturase which desaturates both ⁇ 3 and ⁇ 6 substrates. In another embodiment, the present invention provides an isolated PUFA desaturase encoded by SEQ ID NO: 1 (PiDes12 or ⁇ 12).
- the present invention provides an isolated PUFA desaturase encoded by SEQ ID NO: 2 (PiDes6 or ⁇ 6). In another embodiment, the present invention provides an isolated PUFA desaturase encoded by SEQ ID NO: 3 (PiDes5 or ⁇ 5). In another embodiment, the substrate for the present invention isolated PUFA desaturase is 18:2 ⁇ 6, 20:3 ⁇ 6, 20:4 ⁇ 3, and 20:3 ⁇ 3
- the present invention provides an isolated PUFA desaturase which desaturates 20:3 ⁇ 3 to a non-methylene-interrupted 20:4 ⁇ 5 .
- the present invention provides that PiDes5 desaturates 20:3 ⁇ 3 to a non-methylene-interrupted 20:4 ⁇ 5 .
- the present invention provides that PiDes5 converts 20:4 ⁇ 3 into the respective ⁇ 5 product, 20:5 ⁇ 3 (EPA) as well as the added 18:1 into the non-methylene-interrupted 18:2 ⁇ 5, 9 .
- the present invention provides a protein comprising a desaturase activity. In another embodiment, the present invention provides a protein consisting a desaturase activity. In another embodiment, the present invention provides that the protein of the invention is a recombinant desaturase. In another embodiment, the present invention provides that the desaturase is a polyunsaturated fatty acid (PUFA)-specific desaturase. In another embodiment, the present invention provides that the desaturase desaturates precursors of arachidonic acid. In another embodiment, the present invention provides that the desaturase desaturates precursors of EPA. In another embodiment, the present invention provides that the desaturase desaturates immediate precursors of arachidonic acid (ARA). In another embodiment, the present invention provides that the protein as described herein is used to elevate PUFA levels in animals, thereby providing a ready source of PUFAs.
- PUFA polyunsaturated fatty acid
- ARA arachidonic acid
- the present invention provides that the protein as described herein is
- the expression and/or transcription of the desaturase as described herein is up-regulated during nitrogen starvation. In another embodiment, the expression and/or transcription of the desaturase as described herein is up-regulated under oleogenic conditions. In another embodiment, oleogenic conditions comprise the presence of a ⁇ 6 substrate for ⁇ 6 or ⁇ 5 fatty acid desaturase. In another embodiment, oleogenic conditions comprise 18:2 ⁇ 6 and 20:3 ⁇ 6. In another embodiment, oleogenic conditions comprise nitrogen starvation. In another embodiment, the expression and/or transcription level of the desaturases as described herein correlates with the production of ARA precursors. In another embodiment, oleogenic conditions comprise nitrogen starvation. In another embodiment, the expression and/or transcription level of the desaturases as described herein correlates with the production of DGLA precursors, EPA precursors, DHA precursors, ARA precursors, or any combination thereof.
- the present invention provides an isolated polynucleotide encoding the protein as described herein.
- an isolated polynucleotide is an isolated DNA molecule.
- an isolated polynucleotide is an isolated cDNA molecule.
- the isolated polynucleotide comprises a sequence encoding the protein as described herein.
- the isolated polynucleotide comprises a DNA sequence encoding a desaturase as described herein.
- the isolated polynucleotide comprises a DNA sequence encoding a polypeptide comprising a desaturase activity.
- the isolated polynucleotide comprises a DNA sequence encoding a polypeptide consisting a desaturase activity.
- the isolated polynucleotide comprises a DNA sequence comprising the sequence:
- the isolated polynucleotide comprises a DNA sequence comprising the sequence:
- the isolated polynucleotide comprises a DNA sequence comprising the sequence:
- the isolated polynucleotide comprises a DNA sequence that is at least 60% homologous to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 8. In another embodiment, the isolated polynucleotide comprises a DNA sequence that is at least 70% homologous to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 8. In another embodiment, the isolated polynucleotide comprises a DNA sequence that is at least 75% homologous to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 8.
- the isolated polynucleotide comprises a DNA sequence that is at least 80% homologous to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 8. In another embodiment, the isolated polynucleotide comprises a DNA sequence that is at least 85% homologous to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 8. In another embodiment, the isolated polynucleotide comprises a DNA sequence that is at least 90% homologous to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 8.
- the isolated polynucleotide comprises a DNA sequence that is at least 95% homologous to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO:. 5, SEQ ID NO: 6, or SEQ ID NO: 8. In another embodiment, the isolated polynucleotide comprises a DNA sequence that is at least 98% homologous to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 8.
- the isolated polynucleotide comprises a DNA sequence that is at least 60% identical to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 8. In another embodiment, the isolated polynucleotide comprises a DNA sequence that is at least 70% identical to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 8. In another embodiment, the isolated polynucleotide comprises a DNA sequence that is at least 75% identical to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 8.
- the isolated polynucleotide comprises a DNA sequence that is at least 80% identical to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 8. In another embodiment, the isolated polynucleotide comprises a DNA sequence that is at least 85% identical to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 8. In another embodiment, the isolated polynucleotide comprises a DNA sequence that is at least 90% identical to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 8.
- the isolated polynucleotide comprises a DNA sequence that is at least 95% identical to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 8. In another embodiment, the isolated polynucleotide comprises a DNA sequence that is at least 98% identical to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ NO: 6, or SEQ ID NO: 8.
- the present invention comprises a desaturase or a nucleic acid molecule encoding the same combined with additional proteins and/or enzymes and/or substrates that are involved in the biosynthesis of VLC-PUFA.
- the present invention comprises a composition comprising a desaturase or a nucleic acid molecule encoding the same combined with additional proteins and/or enzymes and/or substrates that are involved in the biosynthesis of VLC-PUFA.
- the present invention comprises a transgenic plant comprising a desaturase or a nucleic acid molecule encoding the same combined with additional proteins and/or enzymes and/or substrates that are involved in the biosynthesis of VLC-PUFA.
- the present invention comprises a transgenic alga comprising a desaturase or a nucleic acid molecule encoding the same combined with additional proteins and/or enzymes and/or substrates that are involved in the biosynthesis of VLC-PUFA.
- the present invention comprises a transfected or a transformed cell comprising a desaturase or a nucleic acid molecule encoding the same combined with additional proteins and/or enzymes and/or substrates that are involved in the biosynthesis of VLC-PUFA.
- the present invention comprises a desaturase or a nucleic acid molecule encoding the same combined with additional proteins and/or enzymes and/or substrates that are involved in the biosynthesis of VLC-PUFA.
- the present invention comprises an algal desaturase or a nucleic acid molecule encoding the same combined with additional algal proteins and/or enzymes and/or substrates that are involved in the biosynthesis of VLC-PUFA.
- the present invention provides that the alga is a microalga.
- the present invention comprises a microalgae desaturase or a nucleic acid molecule encoding the same combined with additional microalgae proteins and/or enzymes and/or substrates that are involved in the biosynthesis of VLC-PUFA.
- the present invention provides that algae proteins comprise an elongase.
- an elongase is described in PCT/IL2009/001117 which is hereby incorporated in its entirety by reference.
- the present invention provides that microalgae proteins comprise the P. incisa PiELO1 gene product.
- elongase as described herein comprises the amino acid sequence:
- the elongase as described herein id encoded by a polynucleotide comprising a DNA sequence comprising the sequence:
- the present invention provides a composition comprising a desaturase as described herein. In another embodiment, the present invention provides a composition comprising the desaturase as described herein and a VLC-PUFA elongase. In another embodiment, the present invention provides a composition comprising a protein as described herein. In another embodiment, the present invention provides a composition comprising the polynucleotide as described herein. In another embodiment, the present invention provides a composition comprising a polynucleotide encoding an elongase and the polynucleotide as described herein. In another embodiment, the present invention provides a composition comprising a vector comprising the polynucleotide as described herein.
- the present invention provides a composition comprising a vector comprising a polynucleotide encoding an elongase and a polynucleotide as described herein.
- the present invention provides a composition comprising a combination of vectors which comprise polynucleotides encoding an elongase and polynucleotides encoding desaturases.
- a composition such as described herein comprises a carrier.
- a carrier stabilizes a protein or a nucleic acid molecule of the invention.
- a carrier is a buffer such as but not limited to a phosphate buffer.
- one of skill in the art is able to prepare a composition comprising a desaturase as described herein. In another embodiment, one of skill in the art is able to prepare a composition comprising a combination of elongases and desaturases as described herein. In another embodiment, one of skill in the art is able to prepare a composition comprising a polynucleotide as described herein. In another embodiment, one of skill in the art is able to prepare a composition comprising a combination of polynucleotides, plasmids, vectors etc. as described herein. In another embodiment, the present invention provides a composition comprising the protein as described herein to be used in foodstuffs, dietary supplements or pharmaceutical compositions.
- the present invention provides a composition comprising the protein as described herein to be used in industrial applications for the manufacturing of VLC-PUFAs.
- the present invention provides a composition comprising the VLC-PUFAs, the products of the enzymes of the present invention.
- a composition comprising VLC-PUFAs is used in foodstuffs, dietary supplements or pharmaceutical compositions.
- the invention includes a combination of ⁇ 5, ⁇ 6, and/or ⁇ 12 desaturases. In another embodiment, the invention includes a composition comprising the combination of ⁇ 5, ⁇ 6, and/or ⁇ 12 desaturases. In another embodiment, the invention includes a composition comprising the combination of ⁇ 5, ⁇ 6, and/or ⁇ 12 desaturases and either ⁇ 3 or ⁇ 6 C18 substrates. In another embodiment, the invention provides that a composition comprising the combination of ⁇ 5, ⁇ 6, and/or ⁇ 12 desaturases and either ⁇ 3 or ⁇ 6 C18 substrates yields DGLA, ARA, DHA and/or EPA.
- the invention provides conjunction of P. incisa ⁇ 12, ⁇ 6, and ⁇ 5 desaturases, which are set of P. incisa genes involved in the biosynthesis of ARA.
- the invention provides conjunction of P. incisa ⁇ 12, ⁇ 6, and ⁇ 5 desaturase and ⁇ 6 specific PUFA elongase (as described herein), which are set of P. incisa genes involved in the biosynthesis of DGLA, ARA, DHA, EPA, or any combination thereof.
- a desaturase as described herein comprises three histidine rich motifs (his-boxes).
- ⁇ 6 (PiDes6) and ⁇ 5 (PiDes5) desaturases comprise fused cytochrome b5 at their N-terminus, supporting their microsomal localization.
- ⁇ 6 (PiDes6) and ⁇ 5 (PiDes5) desaturases comprise a HPGG quartet along with four amino acids conserved in all cytochrome b5 fusion desaturases ( FIG. 1 ).
- transforming a plant with an algal-derived gene such as described herein produces better results in comparison to fungal genes.
- transforming a plant with an algal-derived gene such as described herein in combination with additional genes that encode proteins that are involved in the biosynthesis of VLC-PUFA produces better results in comparison to fungal or wild-type genes.
- transforming a plant with an algal-derived gene such as described herein (desaturase) in combination with an elongase as described herein produces better results in comparison to fungal or wild-type genes.
- transforming a plant with a combination of algal-derived genes such as described herein produces better results (such as ARA production) in comparison to fungal or wild-type genes.
- transforming a plant with a combination of algal-derived desaturase genes such as described herein produces better results (such as ARA production) in comparison to fungal or wild-type genes.
- P. incisa is the richest plant source of ARA.
- P. incisa is the richest algal source of ARA.
- algal-derived genes such as described herein are more effective alone or in combination than those of other sources.
- algae as described herein are eukaryotic organisms. In another embodiment, algae as described herein are photoautotrophic. In another embodiment, algae as described herein are mixotrophic. In another embodiment, algae as described herein are unicellular. In another embodiment, algae as described herein are multicellular. In another embodiment, algae as described herein are Excavata algae. In another embodiment, algae as described herein are Rhizaria algae. In another embodiment, algae as described herein are Chromista algae. In another embodiment, algae as described herein are Alveolata algae.
- an algal gene and protein of the present invention is superior when compared to its homologues with respect to efficient production of PUFAs.
- transforming a first alga with an algal gene derived from a second alga such as described herein produces better results in comparison to fungal genes.
- a second algal gene is a gene as described herein.
- a first and a second algal are of different species.
- transforming a first alga with an algal gene derived from a second alga such as described herein in combination with additional genes that encode proteins that are involved in the biosynthesis of VLC-PUFA produces better results in comparison to fungal or wild-type genes.
- transforming an alga with an algal gene (such as desaturase) derived from a second alga such as described herein in combination with an elongase as described herein produces better results in comparison to fungal or wild-type genes.
- transforming a first alga with a combination of algal genes derived from a second alga, a third alga, etc., such as described herein produces better results (such as ARA production) in comparison to fungal or wild-type genes.
- transforming a first alga with a combination of algal desaturase genes derived from a second alga such as described herein produces better results (such as ARA production) in comparison to fungal or wild-type genes.
- P. incisa is the second alga. In another embodiment, P. incisa is the source of choice for genes that are involved in the biosynthesis of VLC-PUFA. In another embodiment, P. incisa is the source of choice for genes that are involved in the biosynthesis of ARA, DHA, EPA, DGLA, or any combination thereof. In another embodiment, P. incisa -derived genes such as described herein are more effective alone or in combination than those of other sources.
- a DNA sequence as described herein such as but not limited to SEQ ID NO: 4-6 is used to engineer a transgenic organism.
- DNA sequences as described herein such as but not limited to SEQ ID NO: 4-6 are used to engineer a transgenic organism or transform a cell.
- DNA sequences as described herein such as but not limited to SEQ ID NO: 4-6 and 8 are used to engineer a transgenic organism or transform a cell.
- the DNA sequences comprise the sequences provided in SEQ ID NO: 4-6 and 8 or variants of these sequences due, for example: base substitutions, deletions, and/or additions.
- the present invention provides transgenic plant oils enriched with VLC-PUFA. In another embodiment, the present invention provides transgenic alga oils enriched with VLC-PUFA. In another embodiment, the present invention provides the reconstitution of C20-VLC-PUFA biosynthesis in oil-synthesizing seeds of higher plants. In another embodiment, the present invention provides expanded use by enhancement of the levels of ARA, DGLA, DHA, EPA, or a combination thereof in the transgenic plants.
- the present invention provides an expression vector comprising the polynucleotide as described herein. In another embodiment, the present invention provides a combination of expression vectors each comprising a polynucleotide as described herein. In another embodiment, the present invention provides an expression vector comprising a combination of polynucleotides as described herein. In another embodiment, the present invention provides a plant specific expression vector comprising the polynucleotide or combination of polynucleotides as described herein. In another embodiment, the present invention provides an algal specific expression vector comprising the polynucleotide or combination of polynucleotides as described herein. In another embodiment, the present invention provides a cell comprising the expression vector/s as described herein. In another embodiment, the expression vector/s is contained within an agrobacterium. In another embodiment, a cell is a plant cell or an algal cell. In another embodiment, a plant is an oil crop. In another embodiment, the transformed plant is an oil crop.
- the present invention provides a transgenic plant, a transgenic seed, or a transgenic alga transformed by a polynucleotide as described herein. In another embodiment, the present invention provides a transgenic plant, a transgenic seed, or a transgenic alga transformed by any combination of polynucleotides as described herein. In another embodiment, the present invention provides that the transgenic plant is a true-breeding for the polynucleotide/s as described herein. In another embodiment, the present invention provides a transgenic seed, produced by a transgenic plant transformed by the polynucleotide/s as described herein.
- a transgenic plant, a transgenic seed, or a transgenic alga as described herein produces very long-chain polyunsaturated fatty acid (VLC-PUFA).
- a transgenic plant, a transgenic seed, or a transgenic alga as described herein produces arachidonic acid.
- a transgenic plant or a transgenic seed as described herein produces DHA.
- a transgenic plant, a transgenic seed, or a transgenic alga as described herein produces DGLA.
- the present invention provides a method of producing very long-chain polyunsaturated fatty acid (VLC-PUFA) in a plant, a plant cell, or an alga comprising the step of transforming a plant, a plant cell, or an alga with a polynucleotide as described herein.
- the present invention unexpectedly provides an utmost efficient method of producing very long-chain polyunsaturated fatty acid (VLC-PUFA) in a plant, a plant cell, or an alga comprising the step of transforming a plant, a plant cell, or an alga with a polynucleotide as described herein.
- a VLC-PUFA is produced from ⁇ -linolenic acid (GLA).
- a VLC-PUFA is produced from stearidonic acid (SDA). In another embodiment, a VLC-PUFA is produced from GLA, SDA, or their combination. In another embodiment, a VLC-PUFA comprises 20 carbons. In another embodiment, a VLC-PUFA is 20:3 ⁇ 6 or 20:4 ⁇ 3. In another embodiment, a VLC-PUFA is produced by the protein/s as described herein in a cell or a plant, a plant cell, or an alga. In another embodiment, a VLC-PUFA is produced by the protein/s as described herein in a cell, a plant, a plant cell, or an alga under oleogenic conditions. In another embodiment, an unexpected amount of VLC-PUFA is produced by the protein/s as described herein in a cell, an alga, or a plant under nitrogen starvation conditions.
- a cell is a eukaryotic cell. In another embodiment, a cell is a prokaryotic cell. In another embodiment, a cell is a plant cell. In another embodiment, a cell is an algal cell. In another embodiment, a cell is a transfected cell. In another embodiment, a cell is transiently transfected with a polynucleotide or a combination of polynucleotides as described herein. In another embodiment, a cell is stably transfected with a polynucleotide or a combination of polynucleotides as described herein.
- the present invention provides a method of enhancing oil storage, EPA accumulation, DHA accumulation, ARA accumulation, DGLA accumulation, or a combination thereof in a cell, comprising the step of transforming a cell with a polynucleotide as described herein.
- the present invention provides a method of enhancing oil storage, EPA accumulation, DHA accumulation, ARA accumulation, DGLA accumulation, or a combination thereof in a cell, comprising the step of transfecting a cell with a polynucleotide as described herein.
- the present invention provides a method of enhancing oil storage, EPA accumulation, DHA accumulation, DGLA accumulation, ARA accumulation, or a combination thereof in a cell, comprising the step of transforming a cell with a combination of polynucleotides as described herein.
- the present invention provides a method of enhancing oil storage, EPA accumulation, DHA accumulation, ARA accumulation, DGLA accumulation, or a combination thereof in a cell or a multicellular organism, comprising the step of transforming a cell or a multicellular organism with a polynucleotide as described herein.
- the present invention provides a method of enhancing oil storage, EPA accumulation, DGLA accumulation, DHA accumulation, ARA accumulation, or a combination thereof in a multicellular organism, comprising the step of transforming a multicellular organism with a combination of polynucleotides as described herein.
- the multicellular organism or cell is grown under nitrogen starvation conditions, oleogenic conditions, or a combination thereof.
- transformation as used herein comprises “transduction”. In another embodiment, transformation as used herein comprises transfection. In another embodiment, transformation as used herein comprises “conjugation”. In another embodiment, transformation as used herein applies to eukaryotic and prokaryotic cells. In another embodiment, transformation as used herein comprises the insertion of new genetic material into nonbacterial cells including animal and plant cells.
- the present invention provides a method of enhancing oil storage, EPA accumulation, DHA accumulation, DGLA accumulation, ARA accumulation, or a combination thereof in a plant cell, comprising the step of transforming a plant cell with a polynucleotide as described herein.
- the present invention provides a method of enhancing oil storage, EPA accumulation, DHA accumulation, ARA accumulation, DGLA accumulation, or a combination thereof in a plant cell, comprising the step of transforming a plant cell with a combination of polynucleotides as described herein.
- the present invention provides a method of enhancing oil storage, EPA accumulation, DHA accumulation, ARA accumulation, DGLA accumulation, or a combination thereof in a plant, comprising the step of transforming a plant with a polynucleotide as described herein.
- the present invention provides a method of enhancing oil storage, EPA accumulation, DHA accumulation, ARA accumulation, DGLA accumulation, or a combination thereof in a plant, comprising the step of transforming a plant with a combination of polynucleotides as described herein.
- the plant or plant cell is grown under nitrogen starvation conditions, oleogenic conditions, or a combination thereof.
- the invention further provides an engineered organism, such as a transgenic plant.
- the invention further provides an engineered organism, such as a transgenic seed.
- the invention further provides an engineered organism, such as a transgenic alga.
- the invention further provides an engineered organism, such as a transgenic animal.
- an engineered organism is engineered to express a protein as described herein.
- an engineered organism is engineered to express a combination of proteins as described herein.
- an engineered organism is engineered to express elevated levels of the protein or a combination of proteins.
- an engineered plant as described herein is used for manufacturing desired PUFAs such as but not limited to ARA.
- an engineered plant as described herein is used for manufacturing desired PUFAs such as ARA at a reduced cost.
- an engineered organism comprises a synthetic pathway for the production of a protein.
- an engineered organism comprising a synthetic pathway for the production of the protein allows greater control over the production of PUFAs by the pathway by an organism.
- the pathway includes but is not limited to A′-fatty acid desaturase, and/or A′-fatty acid desaturase.
- an engineered cell, plant or seed comprises an oligonucleotide as described herein.
- an engineered plant or seed produces a protein as described herein and comprises an oligonucleotide as described herein.
- an engineered plant or seed produces proteins as described herein and comprises oligonucleotides as described herein.
- the invention provides a method of producing very long-chain polyunsaturated fatty acid (VLC-PUFA) in a cell, a plant, a plant cell, or an alga, comprising the step of transforming a plant, a plant cell, or an alga with a polynucleotide as described herein, thereby producing a VLC-PUFA in a plant, a plant cell, or an alga.
- VLC-PUFA very long-chain polyunsaturated fatty acid
- the invention provides a method of producing very long-chain polyunsaturated fatty acid (VLC-PUFA) in a cell, a plant, a plant cell, or an alga, comprising the step of transforming a plant, a plant cell, or an alga with an exogenous polynucleotide as described herein, thereby producing a VLC-PUFA in a cell, a plant, a plant cell, or an alga.
- VLC-PUFA very long-chain polyunsaturated fatty acid
- the invention provides a method of producing very long-chain polyunsaturated fatty acid (VLC-PUFA) in a cell, a plant, a plant cell, or an alga, comprising the step of transforming a plant, a plant cell, or an alga with a vector comprising an exogenous polynucleotide as described herein, thereby producing a VLC-PUFA in a cell; a plant, a plant cell, or an alga.
- VLC-PUFA very long-chain polyunsaturated fatty acid
- the invention provides a method of producing very long-chain polyunsaturated fatty acid (VLC-PUFA) in a cell, a plant, a plant cell, or an alga, comprising the step of transforming a plant, a plant cell, or an alga with a combination of vectors comprising a combination of exogenous polynucleotides as described herein, thereby producing a VLC-PUFA in a cell, a plant, a plant cell, or an alga.
- VLC-PUFA very long-chain polyunsaturated fatty acid
- the invention provides a method of producing very long-chain polyunsaturated fatty acid (VLC-PUFA) in a cell, a plant, a plant cell, or an alga, comprising the step of transforming a cell, a plant, a plant cell, or an alga with a combination of exogenous polynucleotides as described herein, thereby producing a VLC-PUFA in a cell, a plant, a plant cell, or an alga.
- VLC-PUFA very long-chain polyunsaturated fatty acid
- the invention provides that a plant, a cell, a plant cell, or an alga as described herein is treated or supplemented with linoleic acid (LA; 18:2 ⁇ 6), ⁇ -linolenic acid (ALA; 18:3 ⁇ 3), oleic acid (18:1), dihomo-gamma-linolenic acid (20:3 ⁇ 6), phosphatidylcholine (PC), diacylglyceroltrimethylhomoserine (DGTS), phosphatidylethanolamine (PE), or any combination thereof, before transformation, after transformation, during transformation or a combination thereof.
- LA linoleic acid
- ALA ⁇ -linolenic acid
- oleic acid (18:1
- dihomo-gamma-linolenic acid (20:3 ⁇ 6) phosphatidylcholine
- DGTS diacylglyceroltrimethylhomoserine
- PE phosphatidylethanolamine
- the invention provides that the VLC-PUFA is eicosapentaenoic acid (EPA, 20:5 ⁇ 3). In another embodiment, the invention provides that the VLC-PUFA is docosahexaenoic acid (DHA, 22:6 ⁇ 3). In another embodiment, the invention provides that the VLC-PUFA is arachidonic acid (ARA, 20:4 ⁇ 6). In another embodiment, the invention provides that a cell, a plant, or an alga transformed by a polynucleotide or a combination of polynucleotides as described herein, is grown under oleogenic conditions. In another embodiment, the invention provides that a cell, a plant, or an alga transformed by a polynucleotide or a combination of polynucleotides as described herein, is grown under nitrogen starvation conditions.
- EPA eicosapentaenoic acid
- DHA docosahexaenoic acid
- ARA arachidonic acid
- the invention provides that producing very long-chain polyunsaturated fatty acid (VLC-PUFA) is enhancing oil storage, arachidonic acid accumulation, eicosapentaenoic acid accumulation, docosahexaenoic acid accumulation, or a combination thereof that a cell, a plant, or an alga transformed by a polynucleotide or a combination of polynucleotides as described herein
- a PUFA is di-homo-gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid, docosatrienoic acid, docosatetraenoic acid, docosapentaenoic acid or docosahexaenoic acid.
- a PUFA is a 24 carbon fatty acid with at least 4 double bonds.
- expression of the protein/s of the invention in plants or seed requires subcloning an ORF/s sequence encoding the protein/s into a plant expression vector, which may comprise a viral 35S promoter, and a Nos terminator.
- a cassette or promoter/coding sequence/terminator is then be subcloned into the plant binary transformation vector, and the resulting plasmid introduced into Agrobacterium.
- the Agrobacterium strain transforms the plant.
- the. Agrobacterium strain transforms the plant by the vacuum-infiltration of inflorescences, and the seeds harvested and plated onto selective media containing an antibiotic.
- the plasmid confers resistance to an antibiotic, thus only transformed plant material will grow in the presence of an antibiotic.
- resistant lines are identified and self-fertilized to produce homozygous material.
- leaf material is analyzed for expression of the protein comprising desaturase activity.
- leaf material is analyzed for expression of a combination of protein comprising desaturase and elongase activities.
- protein “desaturase”, or “polypeptide” are used interchangeably.
- protein “desaturase”, or “polypeptide” as used herein encompasses native polypeptides (either degradation products, synthetically synthesized polypeptides or recombinant polypeptides) and peptidomimetics (typically, synthetically synthesized polypeptides), as well as peptoids and semipeptoids which are polypeptide analogs, which have, in some embodiments, modifications rendering the polypeptides/proteins even more stable while in a body or more capable of penetrating into cells.
- modifications include, but are not limited to N terminus modification, C terminus modification, polypeptide bond modification, including, but not limited to, CH2—NH, CH2—S, CH2—S ⁇ O, O ⁇ C—NH, CH2—O, CH2—CH2, S ⁇ C—NH, CH ⁇ CH or CF ⁇ CH, backbone modifications, and residue modification.
- Methods for preparing peptidomimetic compounds are well known in the art and are specified, for example, in Quantitative Drug Design, C. A. Ramsden Gd., Chapter 17.2, F. Choplin Pergamon Press (1992), which is incorporated by reference as if fully set forth herein. Further details in this respect are provided hereinunder.
- polypeptide bonds (—CO—NH—) within the polypeptide are substituted.
- the polypeptide bonds are substituted by N-methylated bonds (—N(CH3)—CO—).
- the polypeptide bonds are substituted by ester bonds (—C(R)H—C—O—O—C(R)—N—).
- the polypeptide bonds are substituted by ketomethylene bonds (—CO—CH2—).
- the polypeptide bonds are substituted by ⁇ -aza bonds (—NH—N(R)—CO—), wherein R is any alkyl, e.g., methyl, carbo bonds (—CH2—NH—).
- natural aromatic amino acids of the polypeptide such as Trp, Tyr and Phe
- synthetic non-natural acid such as Phenylglycine, TIC, naphthylelanine (Nol), ring-methylated derivatives of Phe, halogenated derivatives of Phe or o-methyl-Tyr.
- the polypeptides of the present invention include one or more modified amino acid or one or more non-amino acid monomers (e.g., fatty acid, complex carbohydrates, etc.).
- amino acid or “amino acids” is understood to include the 20 naturally occurring amino acid; those amino acid often modified post-translationally in vivo, including, for example, hydroxyproline, phosphoserine and phosphothreonine; and other unusual amino acid including, but not limited to, 2-aminoadipic acid, hydroxylysine, isodesmosine, nor-valine, nor-leucine and ornithine.
- amino acid includes both D- and L-amino acid.
- polypeptides or proteins of the present invention are utilized in a soluble form.
- the polypeptides or proteins of the present invention include one or more non-natural or natural polar amino acid, including but not limited to serine and threonine which are capable of increasing polypeptide or protein solubility due to their hydroxyl-containing side chain.
- polypeptides or proteins of the present invention are utilized in a linear form, although it will be appreciated by one skilled in the art that in cases where cyclization does not severely interfere with polypeptide characteristics, cyclic forms of the polypeptide can also be utilized.
- the polypeptides or proteins of present invention are biochemically synthesized such as by using standard solid phase techniques.
- these biochemical methods include exclusive solid phase synthesis, partial solid phase synthesis, fragment condensation, or classical solution synthesis.
- these methods are used when the polypeptide is relatively short (about 5-15 kDa) and/or when it cannot be produced by recombinant techniques (i.e., not encoded by a nucleic acid sequence) and therefore involves different chemistry.
- solid phase polypeptide or protein synthesis procedures are well known to one skilled in the art and further described by John Morrow Stewart and Janis Dillaha Young, Solid Phase Polypeptide Syntheses (2nd Ed., Pierce Chemical Company, 1984).
- synthetic polypeptides or proteins are purified by preparative high performance liquid chromatography [Creighton T. (1983) Proteins, structures and molecular principles. WH Freeman and Co. N.Y.], and the composition of which can be confirmed via amino acid sequencing by methods known to one skilled in the art.
- recombinant protein techniques are used to generate the polypeptides of the present invention. In some embodiments, recombinant protein techniques are used for generation of relatively long polypeptides (e.g., longer than 18-25 amino acid). In some embodiments, recombinant protein techniques are used for the generation of large amounts of the polypeptide of the present invention. In some embodiments, recombinant techniques are described by Bitter et al., (1987) Methods in Enzymol. 153:516-544, Studier et al. (1990) Methods in Enzymol. 185:60-89, Brisson et al. (1984) Nature 310:511-514, Takamatsu et al. (1987) EMBO J.
- a polypeptide or protein of the present invention is synthesized using a polynucleotide encoding a polypeptide or protein of the present invention.
- the polynucleotide encoding a polypeptide of the present invention is ligated into an expression vector, comprising a transcriptional control of a cis-regulatory sequence (e.g., promoter sequence).
- a cis-regulatory sequence e.g., promoter sequence
- the cis-regulatory sequence is suitable for directing constitutive expression of the polypeptide of the present invention.
- the cis-regulatory sequence is suitable for directing tissue specific expression of the polypeptide of the present invention.
- the cis-regulatory sequence is suitable for directing inducible expression of the polypeptide of the present invention.
- a polypeptide is a protein comprising a desaturase as described herein.
- the polynucleotide comprises a genomic polynucleotide sequence. In another embodiment, the polynucleotide comprises a composite polynucleotide sequence.
- a polynucleotide refers to a single or double stranded nucleic acid sequence which be isolated and provided in the form of an RNA sequence, a complementary polynucleotide sequence (cDNA), a genomic polynucleotide sequence and/or a composite polynucleotide sequences (e.g., a combination of the above).
- genomic polynucleotide sequence refers to a sequence derived (isolated) from a chromosome and thus it represents a contiguous portion of a chromosome.
- composite polynucleotide sequence refers to a sequence, which is at least partially complementary and at least partially genomic.
- a composite sequence can include some exonal sequences required to encode the polypeptide of the present invention, as well as some intronic sequences interposing there between.
- the intronic sequences can be of any source, including of other genes, and typically will include conserved splicing signal sequences.
- intronic sequences include cis acting expression regulatory elements.
- the polynucleotides of the present invention further comprise a signal sequence encoding a signal peptide for the secretion of the polypeptides of the present invention.
- the signal peptides are cleaved from the precursor proteins resulting in the mature proteins.
- polynucleotides of the present invention are prepared using PCR techniques or any other method or procedure known to one skilled in the art.
- the procedure involves the legation of two different DNA sequences (See, for example, “Current Protocols in Molecular Biology”, eds. Ausubel et al., John Wiley & Sons, 1992).
- polynucleotides of the present invention are inserted into expression vectors (i.e., a nucleic acid construct) to enable expression of the recombinant polypeptide.
- the expression vector of the present invention includes additional sequences which render this vector suitable for replication and integration in prokaryotes.
- the expression vector of the present invention includes additional sequences which render this vector suitable for replication and integration in eukaryotes.
- the expression vector of the present invention includes a shuttle vector which renders this vector suitable for replication and integration in both prokaryotes and eukaryotes.
- cloning vectors comprise transcription and translation initiation sequences (e.g., promoters, enhancers) and transcription and translation terminators (e.g., polyadenylation signals).
- prokaryotic or eukaryotic cells can be used as host-expression systems to express the polypeptides of the present invention.
- these include, but are not limited to, microorganisms, such as bacteria transformed with a recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vector containing the polypeptide coding sequence; yeast transformed with recombinant yeast expression vectors containing the polypeptide coding sequence; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors, such as Ti plasmid, containing the polypeptide coding sequence.
- microorganisms such as bacteria transformed with a recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vector containing the polypeptide coding sequence
- yeast transformed with recombinant yeast expression vectors containing the polypeptide coding sequence e.
- non-bacterial expression systems are used (e.g., plant expression systems) to express the polypeptide of the present invention.
- yeast expression systems are used.
- algae expression systems are used.
- plant expression systems are used.
- a number of vectors containing constitutive or inducible promoters can be used in yeast as disclosed in U.S. Pat. No. 5,932,447 which is hereby incorporated in its entirety by reference.
- vectors which promote integration of foreign DNA sequences into the yeast chromosome are used.
- expression in a host cell can be accomplished in a transient or a stable fashion.
- a host cell is a cell as described herein.
- transient expression is from introduced constructs which contain expression signals functional in the host cell, but which constructs do not replicate and rarely integrate in the host cell, or where the host cell is not proliferating.
- transient expression also can be accomplished by inducing the activity of a regulatable promoter operably linked to the gene of interest.
- stable expression is achieved by introduction of a construct that integrates into the host genome.
- stable expression comprises autonomously replication within the host cell.
- stable expression of the polynucleotide of the invention is selected for through the use of a selectable marker located on or transfected with the expression construct, followed by selection for cells expressing the marker.
- stable expression results from integration, the site of the construct's integration can occur randomly within the host genome or can be targeted through the use constructs containing regions of homology with the host genome sufficient to target recombination with the host locus.
- constructs are targeted to an endogenous locus, all or some of the transcriptional and translational regulatory regions can be provided by the endogenous locus.
- an expression of a protein as described herein comprising desaturase activity includes functional transcriptional and translational initiation and termination regions that are operably, linked to the DNA encoding the protein comprising a desaturase activity.
- an expression of proteins as described herein comprising various desaturase activities includes functional transcriptional and translational initiation and termination regions that are operably linked to the DNA encoding the proteins comprising desaturase activity.
- an expression of proteins as described herein comprising desaturase and elongase activities includes functional transcriptional and translational initiation and termination regions that are operably linked to the DNA encoding each protein comprising a desaturase or elongase activity.
- transcriptional and translational initiation and termination regions are derived from a variety of nonexclusive sources, including the DNA to be expressed, genes known or suspected to be capable of expression in the desired system, expression vectors, chemical synthesis, or from an endogenous locus in a host cell.
- expression in a plant tissue and/or plant part presents certain efficiencies, particularly where the tissue or part is one which is harvested early, such as seed, leaves, fruits, flowers, roots, etc.
- expression can be targeted to that location in a plant by utilizing specific regulatory sequences that are lcnown to one of skill in the art.
- the expressed protein is an enzyme which produces a product which may be incorporated, either directly or upon further modifications, into a fluid fraction from the host plant.
- expression of a protein of the invention, or antisense thereof alters the levels of specific PUFAs, or derivatives thereof, found in plant parts and/or plant tissues.
- the desaturase coding region in some embodiments, may be expressed either by itself or with other genes such as but not limited to elongase, in order to produce cells, tissues, algae, and/or plant parts containing higher proportions of desired PUFAs or in which the PUFA composition more closely resembles that of human breast milk.
- the termination region is derived from the 3′ region of the gene from which the initiation region was obtained or from a different gene. In another embodiment, the termination region usually is selected as a matter of convenience rather than because of any particular property.
- a plant or plant tissue is utilized as a host or host cell, respectively, for expression of the protein of the invention which may, in turn, be utilized in the production of polyunsaturated fatty acids.
- desired PUFAS are expressed in seed.
- methods of isolating seed oils are known in the art.
- seed oil components are manipulated through the expression of the protein of the invention in order to provide seed oils that can be added to nutritional compositions, pharmaceutical compositions, animal feeds and cosmetics.
- a vector which comprises a DNA sequence encoding the protein as described herein is linked to a promoter, and is introduced into the plant tissue or plant for a time and under conditions sufficient for expression of the protein.
- a vector as described herein comprises additional genes that encode other enzymes, for example, elongase, ⁇ 4-desaturase, a different ⁇ 5-desaturase, a different ⁇ 6-desaturase, ⁇ 10-desaturase, a different ⁇ 12-desaturase, ⁇ 15-desaturase, ⁇ 17-desaturase, ⁇ 19-desaturase, or any combination thereof.
- the plant tissue or plant produces the relevant substrate upon which the enzymes act or a vector encoding enzymes which produce such substrates may be introduced into the plant tissue, plant cell or plant.
- a substrate is sprayed on plant tissues expressing the appropriate enzymes.
- the invention is directed to a transgenic plant comprising the above-described vector, wherein expression of the nucleotide sequence of the vector results in production of a polyunsaturated fatty acid in, for example, the seeds of the transgenic plant.
- regeneration and growth process comprises the steps of selection of transformed cells, culturing those individualized cells through the usual stages of embryonic development through the rooted plantlet stage.
- transgenic embryos and seeds are similarly regenerated.
- resulting transgenic rooted shoots are thereafter planted in an appropriate plant growth medium such as soil.
- regeneration and growth process of algae are known to one of skill in the art.
- identification, selection, of transgenic algae are known to one of skill in the art.
- development or regeneration of plants containing an exogenous polynucleotide as described herein encodes a protein as described herein and is well known in the art.
- development or regeneration of algae containing an exogenous polynucleotide as described herein encodes a protein as described herein and is well known in the art.
- the regenerated plants are self-pollinated to provide homozygous transgenic plants.
- pollen obtained from the regenerated plants is crossed to seed-grown plants of agronomically important lines.
- pollen from plants of these important lines is used to pollinate regenerated plants.
- a transgenic plant of the present invention containing a desired polypeptide is cultivated using methods well known to one skilled in the art.
- a variety of methods can be utilized for the regeneration of plants from plant tissue.
- the method of regeneration will depend on the starting plant tissue and the particular plant species to be regenerated.
- methods for transforming dicots, primarily by use of Agrobacterium tumefaciens, and obtaining transgenic plants are known in the art McCabe et al., Biol. Technology 6:923 (1988), Christou et al., Plant Physiol. 87:671-674 (1988)); Cheng et al., Plant Cell Rep. 15:653657 (1996), McKently et al., Plant Cell Rep. 14:699-703 (1995)); Grant et al., Plant Cell Rep. 15:254-258, (1995).
- transformation of monocotyledons using electroporation, particle bombardment, and Agrobacterium are known.
- transformation and plant regeneration are well established in the art.
- assays for gene expression based on the transient expression of cloned nucleic acid constructs have been developed by introducing the nucleic acid molecules into plant cells by polyethylene glycol treatment, electroporation, or particle bombardment (Marcotte et al., Nature 335:454-457 (1988); Marcotte et al., Plant Cell 1:523-532 (1989); McCarty et al., Cell 66:895-905 (1991); Hattori et al., Genes Dev. 6:609-618 (1992); Goff et al., EMBO J. 9:2517-2522 (1990)).
- transient expression systems are used to functionally dissect the oligonucleotides constructs.
- practitioners are familiar with the standard resource materials which describe specific conditions and procedures for the construction, manipulation and isolation of macromolecules (e.g., DNA molecules, plasmids, etc.), generation of recombinant organisms and the screening and isolating of clones, (see for example,: Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press (1989); Maliga et al., Methods in Plant Molecular Biology, Cold Spring Harbor Press (1995); Birren et al., Genome Analysis: Detecting Genes, 1, Cold Spring Harbor, N.Y. (1998); Birren et al., Genome Analysis: Analyzing DNA, 2, Cold Spring Harbor, N.Y. (1998); Plant Molecular Biology: A Laboratory Manual, eds. Clark, Springer, N.Y. (1997)).
- the expression vector of the present invention can further include additional polynucleotide sequences that allow, for example, the translation of several proteins from a single mRNA such as an internal ribosome entry site (IBES) and sequences for genomic integration of the promoter-chimeric polypeptide.
- IBES internal ribosome entry site
- expression vectors containing regulatory elements from eukaryotic viruses such as retroviruses are used by the present invention.
- recombinant viral vectors are useful for in vivo expression of the polypeptides of the present invention since they offer advantages such as lateral infection and targeting specificity.
- lateral infection is inherent in the life cycle of, for example, retrovirus, and is the process by which a single infected cell produces many progeny virions that bud off and infect neighboring cells.
- the result is that a large area becomes rapidly infected, most of which was not initially infected by the original viral particles.
- viral vectors are produced that are unable to spread laterally. In one embodiment, this characteristic can be useful if the desired purpose is to introduce a specified gene into only a localized number of targeted cells.
- various methods can be used to introduce the expression vector of the present invention into cells. Such methods are generally described in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Springs Harbor Laboratory, New York (1989, 1992), in Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, Md. (1989), Chang et al., Somatic Gene Therapy, CRC Press, Ann Arbor, Mich. (1995), Vega et al., Gene Targeting, CRC Press, Ann Arbor Mich. (1995), Vectors: A Survey of Molecular Cloning Vectors and Their Uses, Butterworths, Boston Mass. (1988) and Gilboa et al.
- plant expression vectors are used.
- the expression of a polypeptide coding sequence is driven by a number of promoters.
- viral promoters such as the 35S RNA and 19S RNA promoters of CaMV [Brisson et al., Nature 310:511-514 (1984)], or the coat protein promoter to TMV [Takamatsu et al., EMBO J. 3:17-311 (1987)] are used.
- plant promoters are used such as, for example, the small subunit of RUBISCO [Coruzzi et al., EMBO J.
- constructs are introduced into plant cells using Ti plasmid, Ri plasmid, plant viral vectors, direct DNA transformation, microinjection, electroporation and other techniques well known to the skilled artisan. See, for example, Weissbach & Weissbach [Methods for Plant Molecular Biology, Academic Press, NY, Section VIII, pp 421-463(1988)].
- Other expression systems such as insects and mammalian host cell systems, which are well known in the art, can also be used by the present invention.
- the expression construct of the present invention can also include sequences engineered to optimize stability, production, purification, yield or activity of the expressed polypeptide or protein.
- transformed cells are cultured under effective conditions, which allow for the expression of high amounts of recombinant polypeptide or protein.
- effective culture conditions include, but are not limited to, effective media, bioreactor, temperature, pH and oxygen conditions that permit protein production.
- an effective medium refers to any medium in which a cell is cultured to produce the recombinant polypeptide or protein of the present invention.
- a medium typically includes an aqueous solution having assimilable carbon, nitrogen and phosphate sources, and appropriate salts, minerals, metals and other nutrients, such as vitamins.
- cells of the present invention can be cultured in conventional fermentation bioreactors, shake flasks, test tubes, microtiter dishes and petri plates.
- culturing is carried out at a temperature, pH and oxygen content appropriate for a recombinant cell.
- culturing conditions are within the expertise of one of ordinary skill in the art.
- resultant polypeptides or proteins of the present invention either remain within the recombinant cell, secreted into the fermentation medium, secreted into a space between two cellular membranes, or retained on the outer surface of a cell or viral membrane.
- recovery of the recombinant polypeptide or protein is effected.
- the phrase “recovering the recombinant polypeptide or protein” used herein refers to collecting the whole fermentation medium containing the polypeptide or protein and need not imply additional steps of separation or purification.
- polypeptides or proteins of the present invention are purified using a variety of standard protein purification techniques, such as, but not limited to, affinity chromatography, ion exchange chromatography, filtration, electrophoresis, hydrophobic interaction chromatography, gel filtration chromatography, reverse phase chromatography, concanavalin A chromatography, chromatofocusing and differential solubilization.
- standard protein purification techniques such as, but not limited to, affinity chromatography, ion exchange chromatography, filtration, electrophoresis, hydrophobic interaction chromatography, gel filtration chromatography, reverse phase chromatography, concanavalin A chromatography, chromatofocusing and differential solubilization.
- the expressed coding sequence can be engineered to encode the polypeptide or proteins of the present invention and fused cleavable moiety.
- a fusion protein can be designed so that the polypeptide or protein can be readily isolated by affinity chromatography; e.g., by immobilization on a column specific for the cleavable moiety.
- a cleavage site is engineered between the polypeptide or protein and the cleavable moiety and the polypeptide or protein can be released from the chromatographic column by treatment with an appropriate enzyme or agent that specifically cleaves the fusion protein at this site [e.g., see Booth et al., Immunol. Lett. 19:65-70 (1988); and Gardella et al., J. Biol. Chem. 265:15854-15859 (1990)].
- polypeptide or protein of the present invention is retrieved in “substantially pure” form.
- the phrase “substantially pure” refers to a purity that allows for the effective use of the protein in the applications described herein.
- polypeptide or protein of the present invention can also be synthesized using in vitro expression systems.
- in vitro synthesis methods are well known in the art and the components of the system are commercially available.
- the invention comprises a process for making a very long-chain polyunsaturated fatty acid produced by the protein or combination of proteins of the invention in a cell as described herein.
- the resulting very long-chain polyunsaturated fatty acid produced by the transgenic cell or organism as described herein is utilized as a food additive.
- a very long-chain polyunsaturated fatty acid produced by the transgenic cell or organism as described herein is utilized as a supplement.
- a very long-chain polyunsaturated fatty acid produced by the transgenic cell or organism as described herein is administered to a human subject.
- a very long-chain polyunsaturated fatty acid produced by the transgenic cell or organism as described herein is administered to a baby. In another embodiment, a very long-chain polyunsaturated fatty acid produced by the transgenic cell or organism as described herein is administered to an infant. In another embodiment, a very long-chain polyunsaturated fatty acid produced by the transgenic cell or organism as described herein is administered to an animal. In another embodiment, a very long-chain polyunsaturated fatty acid produced by the transgenic cell or organism as described herein is administered to a mammal. In another embodiment, a very long-chain polyunsaturated fatty acid produced by the transgenic cell or organism as described herein is administered to a farm animal, a rodent, a pet, or a lab animal.
- the described pharmaceutical and nutritional compositions are utilized in connection with animals (i.e., domestic or non-domestic), as well as humans, as animals experience many of the same needs and conditions as humans.
- animals i.e., domestic or non-domestic
- the oil or acids of the present invention may be utilized in animal or aquaculture feed supplements, animal feed substitutes, animal vitamins or in animal topical ointments.
- a very long-chain polyunsaturated fatty acid produced by a protein or a combination of proteins of the invention is utilized in an infant formula.
- a very long-chain polyunsaturated fatty acid produced by a protein or a combination of proteins of the invention is administered to a subject having a deficiency in very long-chain polyunsaturated fatty acid.
- a very long-chain polyunsaturated fatty acid is a polyunsaturated C20 fatty acid.
- the isolated protein comprising desaturase activity is used indirectly or directly in the production of polyunsaturated fatty acids.
- the isolated protein or a combination of isolated proteins comprising desaturase and/or desaturase/elongase activities are used indirectly or directly in the production of polyunsaturated fatty acids.
- “Directly” is meant to encompass the situation where the enzyme directly desaturates the acid. In another embodiment, the latter of which is utilized in a composition.
- “Indirectly” is meant to encompass the situation where an acid is converted to another acid (i.e., a pathway intermediate) by the enzyme and then the latter acid is converted to another acid by use of a non-desaturase enzyme.
- a very long-chain polyunsaturated fatty acid produced either directly or indirectly is added to a nutritional composition, pharmaceutical compositions, cosmetics, and animal feeds, all of which are encompassed by the present invention.
- nutritional compositions include any food or preparation for human or animal consumption including for enteral or parenteral consumption, which when taken into the body (a) serve to nourish or build up tissues or supply energy and/or (b) maintain, restore or support adequate nutritional status or metabolic functions.
- the nutritional composition of the present invention comprises at least one oil or acid produced directly or indirectly by use of the protein of the invention and may either be in a solid or liquid form.
- the composition includes edible macronutrients, vitamins and minerals in amounts desired for a particular use.
- the amount of such ingredients will vary depending on whether the composition is intended for use with normal, healthy infants, children or adults having specialized needs such as those which accompany certain metabolic conditions (e.g., metabolic disorders).
- the macronutrients include edible fats, carbohydrates and proteins.
- edible fats include but are not limited to coconut oil, soy oil, and mono- and diglycerides.
- carbohydrates include but are not limited to glucose, edible lactose and hydrolyzed search.
- proteins which are utilized in the nutritional composition of the invention include but are not limited to soy proteins, electrodialysed whey, electrodialysed skim milk, milk whey, or the hydrolysates of these proteins.
- vitamins and minerals are added to the nutritional compositions of the present invention and include but are not limited to: calcium, phosphorus, potassium, sodium, chloride, magnesium, manganese, iron, copper, zinc, selenium, iodine, and Vitamins A, E, D, C, and the B complex. Other such vitamins and minerals may also be added.
- components utilized in the nutritional compositions of the present invention will be of semi-purified or purified origin.
- semi-purified or purified is meant a material which has been prepared by purification of a natural material or by synthesis.
- nutritional compositions of the present invention include but are not limited to infant formulas, dietary supplements, dietary substitutes, and rehydration compositions.
- a nutritional composition of the present invention may also be added to food even when supplementation of the diet is not required.
- a composition is added to food of any type including but not limited to margarines, modified butters, cheeses, milk, yogurt, chocolate, candy, snacks, salad oils, cooking oils, cooking fats, meats, fish and beverages.
- a nutritional composition is an enteral nutritional product.
- a nutritional composition is an adult or pediatric enteral nutritional product.
- a composition is administered to adults or children experiencing stress or having specialized needs due to chronic or acute disease states.
- a composition comprises, in addition to polyunsaturated fatty acids produced in accordance with the present invention, macronutrients, vitamins and minerals as described above.
- the macronutrients may be present in amounts equivalent to those present in human milk or on an energy basis, i.e., on a per calorie basis.
- the present invention includes an enteral formula comprising polyunsaturated fatty acids produced in accordance with the present invention.
- an enteral formula is sterilized and subsequently utilized on a ready-to-feed basis or stored in a concentrated liquid or powder.
- a powder is prepared by spray drying the formula prepared as indicated above, and reconstituting it by rehydrating the concentrate.
- the present invention includes an adult and pediatric nutritional formulas.
- adult and pediatric nutritional formulas are known in the art and are commercially available (e.g., Similac®, Ensure®, Jevity® and Alimentum® from Ross Products Division, Abbott Laboratories).
- an oil or acid produce in accordance with the present invention may be add to any of these formulas.
- a nutritional formula comprises macronutrients, vitamins, and minerals, as provided herein, in addition to the PUFAs produced in accordance with the present invention.
- the presence of additional components helps the individual ingest the minimum daily requirements of these elements.
- an adult and pediatric nutritional formulas comprises the PUFAs as described herein and zinc, copper, folic acid and antioxidants, or any combination thereof.
- PUFAs produced in accordance with the present invention, or derivatives thereof are added to a dietary substitute or supplement, particularly an infant formula, for patients undergoing intravenous feeding or for preventing or treating malnutrition or other conditions or disease states.
- PUFAs produced in accordance with the present invention are used to alter, the composition of infant formulas in order to better replicate the PUFA content of human breast milk or to alter the presence of PUFAs normally found in a non-human mammal's milk.
- parenteral nutritional compositions comprising from about 2 to about 30 weight percent fatty acids calculated as triglycerides are encompassed by the present invention.
- other vitamins particularly fat-soluble vitamins such as vitamin A, D, E and L-carnitine are also included.
- a preservative such as alpha-tocopherol is added in an amount of about 0.05-0.5% by weight.
- the present invention includes a PUFA produced in accordance with the present invention or host cells containing them, used as animal food supplements to alter an animal's tissue or milk fatty acid composition to one more desirable for human or animal consumption.
- polypeptides or protein of the present invention can be provided to the individual per se. In one embodiment, the polypeptides or proteins of the present invention can be provided to the individual as part of a pharmaceutical composition where it is mixed with a pharmaceutically acceptable carrier.
- a “pharmaceutical composition” refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.
- “active ingredient” refers to the polypeptide or protein sequence of interest.
- the present invention provides combined preparations.
- a combined preparation defines especially a “kit of parts” in the sense that the combination partners as defined above can be dosed independently or by use of different fixed combinations with distinguished amounts of the combination partners i.e., simultaneously, concurrently, separately or sequentially.
- the parts of the kit of parts can then, e.g., be administered simultaneously or chronologically staggered, that is at different time points and with equal or different time intervals for any part of the kit of parts.
- the ratio of the total amounts of the combination partners in some embodiments, can be administered in the combined preparation.
- the combined preparation can be varied, e.g., in order to cope with the needs of a patient subpopulation to be treated or the needs of the single patient which different needs can be due to a particular disease, severity of a disease, age, sex, or body weight as can be readily made by a person skilled in the art.
- physiologically acceptable carrier refers to a carrier or a diluent that does not cause significant irritation to a tissue such as a plant tissue or a cell such as a plant cell; and does not abrogate the biological activity and properties of the protein or polynucleotide of the invention.
- An adjuvant is included under these phrases.
- one of the ingredients included in the physiologically acceptable carrier can be for example polyethylene glycol (PEG), a biocompatible polymer with a wide range of solubility in both organic and aqueous media (Mutter et al. (1979).
- excipient refers to an inert substance added to the composition to further facilitate administration of an active ingredient.
- excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.
- compositions of the present invention are manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, or lyophilizing processes.
- compositions for use in accordance with the present invention is formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the proteins/polynucleotides into preparations.
- formulation is dependent upon the method of administration chosen.
- compositions also comprise, in some embodiments, preservatives, such as benzalkonium chloride and thimerosal and the like; chelating agents, such as edetate sodium and others; buffers such as phosphate, citrate and acetate; tonicity agents such as sodium chloride, potassium chloride, glycerin, mannitol and others; antioxidants such as ascorbic acid, acetylcystine, sodium metabisulfote and others; aromatic agents; viscosity adjustors, such as polymers, including cellulose and derivatives thereof; and polyvinyl alcohol and acid and bases to adjust the pH of these aqueous compositions as needed.
- the compositions also comprise, in some embodiments, local anesthetics or other actives.
- the compositions can be used as sprays, mists, drops, and the like.
- suspensions of the active ingredients are prepared as appropriate oily or water based suspensions.
- Suitable lipophilic solvents or vehicles include, in some embodiments, fatty oils such as sesame oil, or synthetic fatty acid esters such as ethyl oleate, triglycerides or liposomes.
- Aqueous injection suspensions contain, in some embodiments, substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol or dextran.
- the suspension also contains suitable stabilizers or agents, which increase the solubility of the active ingredients to allow for the preparation of highly concentrated solutions.
- the proteins as described herein can be delivered in a vesicle, in particular a liposome (see Langer, Science 249:1527-1533 (1990); Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, N.Y., pp. 353-365 (1989); Lopez-Berestein, ibid., pp. 317-327; see generally ibid).
- a liposome see Langer, Science 249:1527-1533 (1990); Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, N.Y., pp. 353-365 (1989); Lopez-Berestein, ibid., pp. 317-327; see generally ibid).
- the protein as described herein is in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water based solution, before use.
- a suitable vehicle e.g., sterile, pyrogen-free water based solution
- compositions are contained in a container with attached atomizing means.
- compositions suitable for use in context of the present invention include compositions wherein the proteins or oligonucleotides are contained in an amount effective to achieve the intended purpose. In one embodiment, determination of the effective amount is well within the capability of those skilled in the art.
- substances which can serve as carriers or components thereof are sugars, such as lactose, glucose and sucrose; starches, such as com starch and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and methyl cellulose; powdered tragacanth; malt; gelatin; talc; solid lubricants, such as stearic acid and magnesium stearate; calcium sulfate; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and oil of theobroma; polyols such as propylene glycol, glycerine, sorbitol, mannitol, and polyethylene glycol; alginic acid; emulsifiers, such as the Tween brand emulsifiers; wetting agents, such sodium lauryl sulfate; coloring agents; flavoring agents; tableting agents, stabilizers; antioxidants; preservatives; pyrogen-
- a pharmaceutically-acceptable carrier to be used in conjunction with the compound is basically determined by the way the compound is to be administered. If the subject compound is to be injected, in one embodiment, the pharmaceutically-acceptable carrier is sterile, physiological saline, with a blood-compatible suspending agent, the pH of which has been adjusted to about 7.4.
- compositions further comprise binders (e.g., acacia, cornstarch, gelatin, carbomer, ethyl cellulose, guar gum, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, povidone), disintegrating agents (e.g., cornstarch, potato starch, alginic acid, silicon dioxide, croscarmelose sodium, crospovidone, guar gum, sodium starch glycolate), buffers (e.g., Tris-HCl, acetate, phosphate) of various pH and ionic strength, additives such as albumin or gelatin to prevent absorption to surfaces, detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile acid salts), protease inhibitors, surfactants (e.g., sodium lauryl sulfate), permeation enhancers, solubilizing agents (e.g., glycerol, polyethylene glycerol), anti-binders
- compositions also include incorporation of the proteins or oligonucleotides of the invention into or onto particulate preparations of polymeric compounds such as polylactic acid, polglycolic acid, hydrogels, etc., or onto liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts, or spheroplasts.)
- polymeric compounds such as polylactic acid, polglycolic acid, hydrogels, etc.
- liposomes such as polylactic acid, polglycolic acid, hydrogels, etc.
- Such compositions will influence the physical state, solubility, stability, rate of in vivo release, and rate of in vivo clearance.
- particulate compositions coated with polymers e.g. poloxamers or poloxamines
- polymers e.g. poloxamers or poloxamines
- proteins or oligonucleotides of the invention coupled to antibodies directed against tissue-specific receptors, ligands or antigens or coupled to ligands of tissue-specific receptors.
- the proteins or oligonucleotides of the invention modified by the covalent attachment of water-soluble polymers such as polyethylene glycol, copolymers of polyethylene, glycol and polypropylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone or polyproline.
- the modified proteins or oligonucleotides of the invention exhibit substantially longer half-lives in blood following intravenous injection than do the corresponding unmodified compounds.
- modifications also increase the proteins or oligonucleotides solubility in aqueous solution, eliminate aggregation, enhance the physical and chemical stability of the compound, and greatly reduce the immunogenicity and reactivity of the compound.
- the desired in vivo biological activity is achieved by the administration of such polymer-compound abducts less frequently or in lower doses than with the unmodified compound.
- Axenic cultures of P. incisa were cultivated on BG-11 nutrient medium in 250 ml Erlenmeyer glass flasks in an incubator shaker at controlled temperature (25° C.) and illumination (115 ⁇ mol quanta m ⁇ 2 S ⁇ 1 ) under an air/CO 2 atmosphere (99:1, v/v) and a speed of 170 rpm.
- N-starvation experiments cells of daily-diluted cultures were collected by centrifugation, washed three times in sterile DDW and resuspended in N-free BG11 medium. To prepare N-free BG-11 medium, sodium nitrate was omitted and ferric ammonium citrate was substituted with ferric citrate.
- Biomass was sampled at time 0, and in 1.5, 3, 7 and 14 days from the onset of N-starvation for determination of growth parameters, and was further used for fatty acid analysis and RNA isolation. Duplicate samples were collected from 3 separate flasks for each time point and measurement.
- Dry weight and chlorophyll contents were determined as previously described in A. E. Solovchenko, I. Khozin-Goldberg, Z. Cohen, M. N. Merzlyak, Carotenoid-to-chlorophyll ratio as a proxy for assay of total fatty acids and arachidonic acid content in the green micro-alga, Parietochloris incisa, J. Appl. Phycol. (2008) 361-366.
- RNA samples were filtered through a glass fiber filter (GF-52, Schleicher & Schuell, Germany); cells were collected by scraping and immediately flash-frozen in liquid nitrogen and stored at ⁇ 80° C. for further use.
- Total RNA was isolated by the procedure described by Bekesiova et al. (I. Bekesiova, J. P. Nap, L. Mlynarova, Isolation of high quality DNA and RNA from leaves of the carnivorous plant Drosera rotundifolia, Plant. Mol. Biol. Rep. 17 (1999) 269-277), with minor modifications. Three independent RNA isolations were conducted for each time point. The total RNA samples were treated with RNAase-free Baseline-ZEROTM DNAase (Epicentre Technologies, Madison, Wis., USA) before being used in cDNA synthesis for real-time PCR experiments.
- Partial sequences of the ⁇ 12, ⁇ 6, ⁇ 5 desaturase and actin genes were obtained by PCR (ReddyMix PCR Master Mix, Thermo Scientific, Surrey, UK) using the degenerated primers listed in the Table 1.
- RACE 3′- and 5′-rapid amplification of the cDNA ends (RACE) was performed using a BD SmartTM RACE cDNA Amplification Kit (BD Biosciences Clontech, Foster City, Calif., USA).
- ORFs open reading frames encoding for the ⁇ 2, ⁇ 6, and ⁇ 5 desaturases were amplified using PfuUltra II fusion HS DNA polymerase (Stratagene, La Jolla, Calif., USA) with the respective primer pairs (Table 1).
- the forward primers contained a restriction site (underlined) and a yeast translation consensus (double underlined) followed by ATG.
- the reverse primers contained a restriction site (underlined) and a stop codon (double underlined).
- the constructs were used to transform S. cerevisiae strain W303 by the PEG/lithium acetate method [R. D.
- a minimal selection medium containing 2% (w/v) raffinose was inoculated with the pYPiDes ⁇ 12, pYPiDes ⁇ 6 or pYPiDes ⁇ 5 transformants and grown at 27° C. for 24 h in a water bath shaker.
- Five ml of sterile YSM, containing 1% (w/v) Tergitol-40 and 250 ⁇ M of the appropriate fatty acid substrate was inoculated with raffinose-grown cultures to obtain an OD of 0.2 at 600 nm.
- Expression was induced by adding galactose to a final concentration of 2% (w/v) and cultures were further grown at 27° C. for 48 h. Cells were harvested by centrifugation, washed twice with 0.1% NaHCO 3 , freeze-dried and used for fatty acid analysis.
- RACE 3′-and 5′-rapid amplification of the cDNA ends
- GSP reverse gene-specific primers
- E5R1 5′-CCCGGCTGCTGCCATGCTTCTGTG
- E5RN 5′-TGGGGTAGGGAGAGTAGGCCCAAGT
- the PCR products of the expected size were excised and purified from the gel (NucleoSpin Extract II purification kit, Machery-Nagel, Duren, Germany) and ligated into a pGEM T-Easy vector (Promega, Madison, Wis.).
- the full length cDNA corresponding to the P. incisa putative PUFA elongase (designated PiELO1) was assembled from the 5′ and 3′ RACE fragments and its ORF was further subcloned into a pYES2 vector (Invitrogen, Carlsbad, Calif.).
- the ORF encoding for PiELO1 was amplified using PfuUltra II fusion HS DNA polymerase (Stratagene, La Jolla, Calif.) with the forward primer, 5′-AG GAATTCAAA ATGGCATTGACGGCGGCCT (PUFAEL5RES1) (SEQ ID NO: 33), containing a restriction site (underlined) and a yeast translation consensus followed by ATG (double underlined) and the reverse primer 5′-CAT TCTAGATTA CTGCAGCTTTTGCTTGGCTGC (PUFAEL3RES2) (SEQ ID NO: 34) containing a restriction site (underlined) and a stop codon (double underlined).
- PfuUltra II fusion HS DNA polymerase (Stratagene, La Jolla, Calif.) with the forward primer, 5′-AG GAATTCAAA ATGGCATTGACGGCGGCCT (PUFAEL5RES1) (SEQ ID NO: 33), containing a restriction site (underlined) and a yeast
- the amplified sequence was then restricted with EcoRI and XbaI (NEB, Ipswich, Mass.).
- the expected bands were gel-purified with NucleoSpin Extract II purification kit (Machery-Nagel GmbH, Duren, Germany) and ligated into a EcoRI-Xbal cut pYES2 vector, yielding YpPiELO1.
- Saccharomyces cerevisiae strain W303 was transformed with YpPiELO1 by the PEG/lithium acetate method.
- the yeast cells harboring the empty pYES2 vector were used as control. Transformants were selected by uracil prototrophy on yeast synthetic medium (YSM) lacking uracil (Invitrogen, Carlsbad, Calif.).
- a minimal selection medium containing 2% (w/v) raffinose was inoculated with the YpPiELO1-transformants and grown at 27° C. for 24 h in a water bath shaker.
- Five ml of sterile YSM, containing 1% (w/v) Tergitol-40 and 250 ⁇ M of the appropriate fatty acid was inoculated with raffinose-grown cultures to obtain an OD of 0.2 at 600 nm.
- Expression was induced by adding galactose to a final concentration of 2% (w/v) and cultures were further grown at 27° C. for 48 h. Cells were harvested by centrifugation, washed twice with 0.1% NaHCO 3 , freeze-dried and used for fatty acid analysis.
- Real-Time Quantitative PCR primer pairs were designed for the PiELOJ and the house keeping gene 18S SSU rRNA using the PrimerQuest tool (http://test.idtdna.com/Scitools/Applications/Primerquest/). Parameters were set for a primer length of 19 to 26 bp, primer melting temperature of 60.0 ⁇ 1.0° C., and amplicon length of 90 to 150 bases. Primer pairs were validated using seven serial fifty-fold dilutions of cDNA samples and standard curves were plotted to test for linearity of the response. The primer pairs and primer concentrations with reaction efficiencies of 100 ⁇ 10% were chosen for quantitative RT-PCR analysis of relative gene expression. The nucleotide sequences and characteristics of primers used for quantitative RT-PCR analysis are presented in Table 2.
- the mean fold changes in gene expression were calculated according to the 2 - ⁇ Ct method using the average of threshold cycle (Ct) values from triplicate cDNA-primer samples.
- the ACt followed by the AACt was calculated from the average Ct values of the target and the endogenous genes.
- the transcript abundance of the PiELO1 gene was normalized to the endogenous control 18S SSU rRNA gene.
- the fold-change in gene expression was calculated using 2 - ⁇ Ct to find the expression level of the target gene which was normalized to the endogenous gene, relative to the expression of the target gene at time 0.
- Fatty acid methyl esters were obtained by transmethylation of the freeze-dried P. incisa or yeast biomass, with dry methanol containing 2% H 2 SO4 (v/v) and heating at 80° C. for 1.5 h while stirring under an argon atmosphere.
- Gas chromatographic analysis of FAMEs was performed on a Thermo Ultra Gas chromatograph (Thermo Scientific, Italy) equipped with PTV injector, FID detector and a fused silica capillary column (30 m ⁇ 0.32 mm; ZB WAXplus, Phenomenex).
- FAMEs were identified by co-chromatography with authentic standards (Sigma Chemical Co., St.
- Polar lipids were separated into individual lipids by two dimensional TLC on Silica Gel 60 glass plates (10 ⁇ 10 cm, 0.25 mm thickness (Merck, Darmstadt, Germany) according to Khozin et al. [I. Khozin, D. Adlerstein, C. Bigogno, Y. M. Heimer, Z. Cohen, Elucidation of the Biosynthesis of Eicosapentaenoic Acid in the Microalga Porphyridium cruentum (II. Studies with Radiolabeled Precursors), Plant Physiol. 114 (1997) 223-230].
- Neutral lipids were resolved with petroleum ether:diethyl ether:acetic acid (70:30:1, v/v/v). Lipids on TLC plates were visualized by brief exposure to iodine vapors, scraped from the plates and were transmethylated for the fatty acid analysis as previously described.
- RTQPCR real-time quantitative PCR
- RTQPCR Real-Time Quantitative PCR
- primer pairs were designed for the PiDes12, PiDes6, and PiDes5 genes and the house keeping gene actin, PiAct using the PrimerQuest tool (http://test.idtdna.com/Scitools/Applications/Primerquest/).
- Primer pairs were validated as described by Iskandarov et al. [U. Iskandarov, I. Khozin-Goldberg, R. Ofir, Z. Cohen, Cloning and Characterization of the ⁇ 6 Polyunsaturated Fatty Acid Elongase from the Green Microalga Parietochloris incisa, Lipids 44 (2009) 545-554].
- the nucleotide sequences of primer pairs and the amplicon sizes are presented in Table 3.
- the partial sequences of the ⁇ 12 , ⁇ 6 and ⁇ 5 desaturase gene homologues were isolated using degenerate oligonucleotides (Table 1) targeting conserved amino acid motifs identified in algae, lower plants and fungi.
- Table 1 degenerate oligonucleotides targeting conserved amino acid motifs identified in algae, lower plants and fungi.
- a partial sequence of the actin gene was amplified to be used as a house keeping gene in RTQPCR experiments.
- the ORFs for PiDes12, PiDes6 and PiDes5 genes were 1140, 1443, and 1446 by in length, respectively, coding for the corresponding predicted proteins of 380, 481 and 482 amino acids.
- the predicted amino acid sequence of PiDes12 is 64% and 62% identical to that of Chlorella vulgaris (BAB78716) and Chlamydomonas reinhardtii (XP — 001691669), respectively, while it shares more than 50% identity with those of higher plants. It contains three conserved histidine motifs HxxxH, HxxHII and HxxHH.
- the deduced amino acid sequence of PiDes6 is 52% and 51% identical to those of the ⁇ 6 desaturases from the liverwort M.
- Both PiDes6 and PiDes5 contain N-terminal fused cytochrome b5 domain including the HPGG motif and the three histidine boxes found to be conserved in front-end desaturases.
- the three characteristically conserved histidine-rich motifs with amino acid patterns of HD (E) xxH, HxxHH,, QxxHH in ⁇ 6 desaturases, and HDxxH, QHxxxHH, QxxHH in ⁇ 5 desaturases are also present in PiDes6 and PiDes5, respectively ( FIG. 1 ).
- FIG. 2 An unrooted phylogenetic tree ( FIG. 2 ) of PiDes12, PiDes6, PiDes5 and several functionally characterized desaturases from all three groups were constructed to identify their functional and phylogenetic relationships by the neighbor-joining program in MEGA4 [K. Tamura, J. Dudley, M. Nei, S. Kumar, MEGA4: Molecular evolutionary genetics analysis (MEGA) software version 4.0, Mol. Biol. Evol. 24 (2007) 1596-1599].
- the deduced amino acid sequence of PiDes12 is closely related to ⁇ 12 desaturases of green algae and very similar to those of higher plants.
- PiDes6 The sequences of PiDes6 and PiDes5 cluster with ⁇ 6 and ⁇ 5 desaturases, respectively, from algae, moss and fungi.
- PiDes6 is highly similar to the M. polymorpha (MpDEs6) and P. tricornutum (PtD6p) ⁇ 6 desaturases
- PiDes5 appears to be closely related to the ⁇ 5 desaturase from the moss M. polymorpha and shares more sequence similarity with the ⁇ 5 desaturase from the chlorophytes M. squamata and O. tauri than with those of fungal origin.
- both ⁇ 6 or ⁇ 5 desaturases from M. squamata and O. tauri appear to be structurally more similar to each other than to any of the known desaturases from either group.
- the functional activities of the proteins encoded by PiDes12, PiDes6 and PiDes5 were examined by heterologous expression in S. cerevisiae.
- the pYES2 constructs pYPiDes12, pYPiDes6 and pYPiDes5 containing the ORFs for PiDes12, PiDes6, and PiDes5, respectively, were transformed into S. cerevisiae.
- GC analysis of the FAMEs of the yeast transformed with pYPiDes12 revealed an appearance of a small peak corresponding to 18:2 (0.3% of TFA; not shown).
- An attempt to improve the expression of the recombinant protein and to increase the activity by the modification of yeast translation consensus was not successful.
- the yeast cells harboring the empty vector, pYES2 (control) did not demonstrate desaturation activity on the added substrates ( FIG. 3 ).
- PiDes6 and PiDes5 expressions were induced in the presence of the main ⁇ 6 substrates for ⁇ 6 or ⁇ 5 fatty acid desaturases, 18:2 ⁇ 6 and 20:3 ⁇ 6, respectively. New peaks corresponding to 18:3 ⁇ 6 and 20:4 ⁇ 6, respectively, were detected, confirming the predicted function of PiDes6 and PiDes5.
- the expression of PiDes6 in the presence of 18:3 ⁇ 3 resulted in the appearance of the corresponding ⁇ 6 desaturation product 18:4 ⁇ 3 ( FIG. 3 ).
- PiDes6 desaturase was neither active on endogenous yeast fatty acids nor on external 18:1.
- PiDes6 was not active on 20:36 ⁇ 3 either, whereas PiDes5 desaturated it to the non-methylene-interrupted 20:4 ⁇ 5,11,14,17 .
- PiDes5 converted 20:4 ⁇ 3 into the respective ⁇ 5 product, 20:5 ⁇ 3 (EPA) as well as the added 18:1 into the non-methylene-interrupted 18:2 ⁇ 5,9 ( FIG. 3 ).
- the presence of 18:2 ⁇ 5,9 was also observed in the chromatograms of the PiDes5 transformant supplied with C20 fatty acids.
- a tiny peak, tentatively identified as 18:4 ⁇ 5,9,12,15 was present on the chromatogram of the PiDes5 transformant fed with 18:30 (Table 4).
- PC a major phospholipid of S. cerevisiae, constituted for about 16% of total lipids (Table 5), it is obvious that PC allocated the main part of ARA attached to phospholipids.
- actin As a house-keeping gene in quantitative real-time PCR experiments, a partial fragment (503 bp) of the P. incisa actin gene was amplified using the primers whose design was based on the C. reinhardtii actin cDNA (XM — 001699016). Indeed, the expression level of the actin gene did not significantly change throughout the nitrogen starvation. PiDes12, PiDes6, and PiDes5 were upregulated following the transfer to Nitrogen starvation, reaching the highest expression level on day 3 and decreasing thereafter to a level about 15 to 20 fold higher than that at time 0 ( FIG. 4 ).
- PiDes12 and PiDes5 genes were expressed at levels approximately 65 to 70 fold higher on day 3 than at time 0, while the PiDes6 transcript was about 45 fold higher ( FIG. 4 ).
- the expression patterns of PiDes12, PiDes6, and PiDes5 correlated with the enhanced biosynthesis of ARA in P. incisa cells (Table 6).
- PiELO1 The assembled complete 867 by cDNA sequence, designated as PiELO1, preceded and followed by 22 and 150 by nucleotides at 5′ and 3′ UTR, respectively.
- PiELO1 contained an ORF of 289 predicted amino acid residues consistent with functionally characterized PUFA elongase ORFs from fungi, lower plants and algae ( FIG. 5 ).
- the deduced amino acid sequence of the PiELO1 was 50% identical to O. tauri and M. polymorpha ⁇ 6 PUFA elongase, while sharing 48 and 44% identity with P. patens ⁇ 6 elongase and M. polymorpha ⁇ 5 elongase, respectively.
- the PiELO1 is also similar, yet with a lower score, to ⁇ 6 elongases of fungal origin. It shares 40 and 36% identity with the ⁇ 6 PUFA elongases of Thraustochytrium and M. alpina (not included in the alignment), respectively.
- the predicted amino acid sequence of the PiELO1 contained four conserved motifs that are characteristic for PUFA elongases ( FIG. 5 , highlighted).
- the hydropathy plot of the PiELO1 deduced amino acid sequences was obtained using the algorithm available in the DAS transmembrane prediction server (http://www.sbc.su.se/ ⁇ miklos/DAS/).
- the two strictly hydrophobic transmembrane domains were found about 50 amino acids downstream and upstream from the N and C termini, respectively, while the two less hydrophobic domains were located about 100 amino acids downstream and upstream from the N and C termini, respectively ( FIG. 6 ).
- PiELO1 falls into a group of PUFA elongases of lower eukaryotes. Although the group contains mostly PUFA elongases with ⁇ 6 activity, some ⁇ 5 elongases, e.g., that of M. polymorpha and Leishmania infantum, are more related to ⁇ 6 elongases of lower eukaryotes than to ⁇ 5 elongases of higher eukaryotes.
- PiELO1 makes a closely related subgroup with OtELO1, MpELO1, MpELO2 and PpELO1, the OtELO1 being the closest one.
- the pYES2 plasmid containing the PiELO1 ORF downstream of the GAL1 promoter was transformed into S. cerevisiae.
- the PiELO1 was expressed in the presence of the ⁇ 6 PUFA elongase substrates, 18:3 ⁇ 6 ( ⁇ -linolenic acid, GLA) and 18:4 ⁇ 3 (stearidonic acid, STA).
- GC analysis of the FAMEs of transformed yeast cells showed that PiELO1 elongated GLA and STA, converting them into dihomo- ⁇ -linoleic acid (DGLA, 20:3 ⁇ 6) and eicosatetraenoic acid (20:4 ⁇ 3), respectively ( FIG. 8 ).
- the yeast cells harboring the empty vector alone did not demonstrate any elongation activity on the added substrates, confirming that the PiELO1 encoded enzyme has a ⁇ 6 PUFA elongase activity. Feeding the PiELO1 transformants with the ⁇ 6 fatty acids, LA and ARA, did not result in their elongation (not shown).
- the level of expression of the PiELO1 gene correlated with the increase in the share of ARA and the C20/(C16+C18) elongation ratio (Table 7).
- the share of the elongation product, DGLA increased sharply at day 3 (50% increase over time 0) and decreased thereafter.
- cysteine (C) in the first his-box and the first histidine (H) in the third his-boxes, respectively, are conserved only in ⁇ 12 desaturases.
- the second residue in the first his-box of the all three types of desaturases is acidic; in ⁇ 6 and ⁇ 5 desaturases it is mostly aspartic acid (D), and in ⁇ 12 desaturases mostly glutamic acid (E). This indicates the importance of an acidic residue at this position for desaturation.
- glutamine (Q) is found in the third his-box of PiDes6 and PiDes5 ( FIG. 1 ; Table 8) and in the second his-box of ⁇ 5 desaturases.
- PiDes6 and PiDes5 were heterologous expression of PiDes6 and PiDes5 in yeast cells confirmed their ⁇ 6 and ⁇ 5 activity by conversion of supplemented fatty acids to the corresponding desaturation products.
- PiDes12 demonstrated very low desaturation activity, which could not be enhanced by the 5′ modification of the inserted sequence.
- a similar low activity in yeast was also demonstrated in some cases, such as for ⁇ 5 and ⁇ 12 desaturases of O. tauri and Chlorella vulgaris NJ-7, respectively.
- PiDes6 and PiDes5 desaturated both ⁇ 3 and ⁇ 6 fatty acids with similar efficiency ( FIG. 3 ; Table 4).
- Various results concerning ⁇ 3/ ⁇ 6 substrate preference were reported for functionally characterized ⁇ 6 and ⁇ 5 desaturases from different organisms that were expressed in yeast.
- a front-end PiDes5 desaturated its principal substrate 20:3 ⁇ 6 as well as 20:4 ⁇ 3; in addition, non-methylene interrupted fatty acids were also produced as a result of its activity on 20:3 ⁇ 3, and on both endogenous and exogenous 18:1, but with lower efficiency.
- PiDes5 produced 18:2 ⁇ 5,9 from 18:1 but was more active when 18:1 was exogenously supplied.
- CrDES did insert ⁇ 5 double bond on both 18:1 and 18:2 producing the non-methylene interrupted 18:2 ⁇ 5,9 and 18:3 ⁇ 5,9,12 , while adding a ⁇ 7 double bond to 20:2 ⁇ 6 and 20:30 ⁇ .
- the location and number of double bond, and the form of the substrate are also crucial for ⁇ 5 desaturation.
- PiDes6 desaturated neither the yeast major monounsaturated fatty acids nor the exogenously supplied 18:1. PiDes6 did not act on 20:3 ⁇ 3, indicating that it is specific for ⁇ 9 C18 PUFA. It appears that not only the organisms being transformed, but also the gene origin, determine the substrate specificity of the recombinant ⁇ 6 and ⁇ 5 desaturase. Functional characterization of PiDes6 and PiDes5 confirmed the previously reported substrate specificities of these desaturases which were generally restricted to C18 and C20 substrates, respectively.
- PiELO1 A cDNA (PiELO1) of an elongase encoding for a deduced protein was isolated from P. incisa, structurally similar to 46 PUFA elongase gene products from microalgae, lower plants and fungi ( FIG. 5 ).
- the deduced amino acid sequence of the PiELO1 ORF was about 50% identical to that of 46 elongases from the liverwort M. polymorpha (AAT85662), the green marine microalga O. tauri (AAV67797) and the moss P. patens (AAL84174).
- the predicted protein is highly hydrophobic and has two strongly hydrophobic transmembrane regions, the first one located about 50 amino acids downstream of the N-terminus and the second one in the vicinity of the C-terminus.
- the PiELO1 sequence was identified in a C-terminal lysine-rich motif, important for the endoplamic reticulum targeting, as well as four conserved motifs FYxSKxxEFxDT, QxxxLHVYHHxxI, NSxxHVxMYxYY and TxxQxxQF, including a highly conserved histidine box suggested to be functionally important for PUFA elongation ( FIG. 5 ).
- PiELO1 is another example of a single step ⁇ 6 PUFA elongases cloned from an algal species. Similarly to GLELO of M. alpina, PiELO1 prefers the ⁇ 6 C18 PUFA substrates, GLA and STA. Only these ⁇ 6 fatty acids were, when exogenously added, elongated to the respective products by S. cerevisiae cells transformed with PiELO1 ( FIG. 8 ). Transformation of a higher plant so as to render it to produce ⁇ 6 PUFA requires that the elongase used will have a high selectivity for ⁇ 6 PUFA, thereby reducing the appearance of side products in the transformed plant. Bifunctional invertebrate PUFA elongases with both ⁇ 6 and ⁇ 5 activities (OmELO, XiELO, and CiELO) are less desirable in plant transformations.
- FIG. 6 Phylogenetic analysis showed ( FIG. 6 ) that the PUFA elongases are not strictly divided according to their substrate specificity.
- the ⁇ 6 elongases of algal (OtELO1, TpELO1, PiELO1) and moss (PpELO1) origin are functionally restricted to the elongation of ⁇ 6-C18-PUFAs, however these elongases are placed in separate groups on the phylogenetic tree ( FIG. 7 ).
- PiELO1 is closely related to OtELO1 isolated from a chloropyte and a lower plant rather than to ELO1 genes isolated from a diatom, although both are specific for the elongation of ⁇ 6-C18-PUFAs ( FIG. 7 ).
- PiELO1 is highly similar to and is placed in the same group with both ⁇ 6 and ⁇ 5 elongases of the liverwort M. polymorpha. Kajikawa et al. suggested that MpELO2, a ⁇ 5 elongase, is likely to have originated through gene duplication of the MpELO1 gene.
- the algal ⁇ 5 PUFA elongases, OtELO2, TpELO2 and the P. salina ELO1 are more likely to share a common branch with the mammalian and animal ⁇ 5 PUFA elongases, OmELO and HsELO2, while they are also similar to bifunctional PUFA elongases such as CiELO1/2.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Abstract
Isolated proteins which are at least partially encoded by polynucleotide sequences encoding novel desaturases are provided together with a composition which includes these isolated proteins. A transgenic plant, a transgenic alga, or a transgenic seed transformed by the polynucleotides encoding proteins which are at least partially encoded by novel desaturases are also provided. The invention also includes a process for making a very long-chain polyunsaturated fatty acid in a transformed cell, a transgenic alga, or a transgenic plant expressing the isolated protein or proteins which are at least partially encoded by the polynucleotide sequences encoding novel Δ5, Δ6, or Δ12 desaturases.
Description
- This invention is directed to, inter alia, proteins having Δ2, Δ6, or Δ5 desaturase activity, isolated DNA molecules encoding the same, and methods of making and utilizing the same.
- Very long-chain polyunsaturated fatty acids (VLC-PUFA) of 20 or 22 carbon atoms are indispensable components of human nutrition. They are necessary for normal life-long physiology and benefit the well-being of the human body. Nutritionally important VLC-PUFAs include the ω3-fatty acids, eicosapentaenoic acid (EPA, 20:5ω3) and docosahexaenoic acid (DHA, 22:6ω3) and the ω6-fatty acid, arachidonic acid (ARA, 20:4ω6) and dihomo-y-linolenic acid (DGLA, 20:3ω6) which are the major components of membrane phospholipids of the retina, brain and testis. ARA and DHA are the predominant fatty acids in the human brain and breast milk. ARA is necessary for normal fetal growth, and cognitive development in infants. Many studies highly suggested supplementation of infant formula with DHA and ARA. Besides the structural function in membranes, ARA is the primary substrate in eicosanoids biosynthesis which regulates many physiological processes such as homeostasis, reproduction, immune and inflammatory responses.
- Microalgae are the most efficient producers and one of the richest sources of VLC-PUFAs. Furthermore, algae can be used as sources of genes for the implementation of VLC-PUFA biosynthesis in genetically engineered oil crops. The genetic information on enzymes involved in the biosynthesis of VLC-PUFA in some algae led to in vivo applications of VLC-PUFA production in seed oil. The gene pool of the green freshwater microalga Parietochloris incisa (Trebouxiophyceae) is of special interest since it is the only known microalga able to accumulate extraordinary high amounts of ARA-rich triacylglycerols (TAG). When P. incisa is cultivated under nitrogen starvation, the condition triggering storage oil accumulation, ARA constitutes about 60 percent of total fatty acids (TFA) and over 95 percent of cellular ARA is deposited in TAG in cytoplasmic lipid bodies.
- The biosynthesis of VLC-PUFA in microalgae follows two major pathways, designated as ω6 and ω3. In these pathways, linoleic acid (LA; 18:2ω6) and α-linolenic acid (ALA; 18:3ω3) go through sequential, Δ6 desaturation, Δ6 elongation and Δ5 desaturation, yielding ARA and EPA, respectively. E.g., in the red microalga Porphyridium cruentum and the green microalga P. incisa, oleic acid (18:1) is first desaturated to LA and γ-linolenic acid (GLA, 18:3ω6) through Δ12 and Δ6 desaturations, followed by elongation to 20:3ω6 and Δ5 desaturation to yield ARA via the ω6 pathway. In P. incisa, the extraplastidial lipids, phosphatidylcholine (PC) and the betaine lipid, diacylglyceroltrimethylhomoserine (DGTS), are involved in the Δ12 and, subsequently, the Δ6 desaturations, whereas phosphatidylethanolamine (PE) along with PC are the suggested major substrates for the Δ5 desaturation of 20:3ω6 to 20:4ω6. The same enzymes are involved in the biosynthesis of VLC-PUFA through the ω3 pathway in the green microalga Ostreococcus tauri.
- VLC-PUFAs may also be generated by an alternative Δ8 desaturation pathway. E.g., in the marine haptophyte Isocrysis galbana and in the fresh water euglenophyte Euglena gracilis, where LA and ALA are first elongated by C18 Δ9-specific fatty acid elongase followed by sequential Δ8 and AS desaturations to ARA, DGLA or EPA. The extraplastidial Δ12 desaturase is an integral ER-bound protein which is responsible for the desaturation of oleic acid and production of LA, mainly on phosphatidylcholine (PC). Δ5 and Δ6 desaturases contain a fused cytochrome b5 domain in their N-terminus, serving as an electron donor, and introduce a double bond at a site closer to the carboxyl group than any of the pre-existing double bonds in the substrate fatty acid, thereby called ‘front-end’ desaturases. Desaturases with Δ6 or Δ5 activity have been isolated from various organisms, e.g., the nematode C. elegans, the fungus Mortierella alpina, the moss Physcomitrella patens, the liverwort Marchantia polymorpha and the algae Phaeodactylum tricornutum, Thalassiosira pseudonana and Ostreococcus tauri. Some of these desaturases have been introduced together with PUFA-specific elongases into constructs for transformation of yeast and oil seed plants to reconstitute VLC-PUFA biosynthesis in the heterologous organisms.
- In one embodiment, the present invention provides an isolated protein comprising, an amino acid sequence set forth in SEQ ID NO: 1.
- In another embodiment, the present invention further provides an isolated protein comprising, an amino acid sequence set forth in SEQ ID NO: 2.
- In another embodiment, the present invention further provides an isolated protein comprising, an amino acid sequence set forth in SEQ ID NO: 3.
- In another embodiment, the present invention further provides a composition comprising a protein comprising, an amino acid sequence set forth in SEQ ID NO: 1, a composition comprising a protein comprising, an amino acid sequence set forth in SEQ ID NO: 2, a composition comprising a protein comprising, an amino acid sequence set forth in SEQ ID NO: 3, or a composition comprising any combination thereof.
- In another embodiment, the present invention further provides a transgenic plant, a transgenic seed, a transformed cell, or a transgenic alga transformed by a polynucleotide encoding: (1) a protein comprising, an amino acid sequence set forth in SEQ ID NO: 1, (2) a protein comprising, an amino acid sequence set forth in SEQ ID NO: 2, (3) a protein comprising, an amino acid sequence set forth in SEQ ID NO: 3, or a transgenic plant, a transgenic seed, or a transgenic alga transformed by any combination of the polynucleotides (1), (2), and (3).
- In another embodiment, the present invention further provides a method of producing very long-chain polyunsaturated fatty acid (VLC-PUFA) in a plant, a plant cell, or an alga comprising the step of transforming a plant, an alga, or a plant cell with a polynucleotide encoding: (1) a protein comprising, an amino acid sequence set forth in SEQ ID NO: 1, (2) a protein comprising, an amino acid sequence set forth in SEQ ID NO: 2, (3) a protein comprising, an amino acid sequence set forth in SEQ ID NO: 3, or transforming a plant, a plant cell, or an alga with any combination of the polynucleotides (1), (2), and (3), thereby producing a VLC-PUFA in a plant, a plant cell, or an alga.
-
FIG. 1 . Depicts the deduced amino acid sequences of P. incisa PiDes12 (A), PiDes6 (B), and PiDes5 (C) are aligned with their closest homologs using CLUSTAL W (1.83) multiple sequence alignment program (default). Conserved motifs characteristic of each desaturase sequence are highlighted. GeneBank accession numbers for the sequences are: A) C. reinhardtii (XP 001691669); C. vulgaris (BAB78716), G. hirsutum (AAL37484), S. oleracea (BAC22091), O. europaea (AAW63040). B) M. polymorpha (AAT85661), P. tricornutum (AAL92563), T. pseudonana (AAX14505), O. tauri (AAW70159), M. squamata (CAQ30479). C) O. tauri (CAL57370), M. squamata (CAQ30478), M. polymorpha (AAT85663), D. discoideum (BAA37090), M. alpina (AAC72755), P. tricornutum (AY082392). -
FIG. 2 . Is an unrooted phylogram of PiDes12, PiDes6, PiDes5 and some functionally characterized Δ12, Δ6 and Δ5 desaturases (vertebrate and invertebrate desaturases are not included). The alignment was generated by the CLUSTAL W program and the unrooted phylogram was constructed in the neighbor-joining method using the MEGA4 software [47]. GeneBank sources of the sequences are: BAB78716 (Δ12, Chlorella vulgaris), XP—001691669 (Δ12, C. reinhardtii), BAC22091 (Δ12, Spinacia oleracea), AAL37484 (Δ12, Gossypium hirsutum), AAW63040 (Δ12, Olea europaea), CAB94993 (Δ6, Ceratodon purpureus), AAT85661 (Δ6, M. polymorpha), BAΔ85588 (Δ6, M. alpina), AAL92563 (Δ6, P. tricornutum), AAX14505 (Δ6, T. pseudonana), (Δ6, Pythium irregulare), CAL57370 (Δ5, O. tauri), AAT85663 (Δ5, M. polymorpha), AAL13311 (Δ5, P. irregulare), CAD53323 (Δ5, Phytophthora megasperma), BAΔ37090 (Δ5, Dictyostelium discoideum), AAC72755 (Δ5, M. alpina), CAQ30478 (Δ5, M. squamata), CAQ30479 (Δ6, M. squamata), AAW70159 (Δ6, O. tauri), CS020055 (Δ5, P. patens). -
FIG. 3 . Provides graphs representing GC FAMEs of recombinant yeast harboring pYES2 (control), pY PiDes6 (A) fed with 18:2 or 18:3ω3, and pYPiDes5 (B) fed with 20:3ω6, 20:4ω3 or 18:1. -
FIG. 4 . Is a graph showing the changes in expression of the PiDes12, PiDes6, and PiDes5 genes under N-starvation and ARA percent share in total fatty acids. The transcript abundance of the genes was normalized to that of the actin gene. -
FIG. 5 . Depicts the amino acid sequence of P. incisa PiELO1 aligned with its closest homologs using CLUSTAL W (1.83) multiple sequence alignment program (default). Conserved motifs characteristic of PUFA elongase sequences are highlighted. GeneBank accession numbers for the sequences are OtELO1 (O. tauri, AAV67797), MpELO1 (M. polymorpha, AAT85662), PpELO1 (P. patens, AAL84174), MpELO2 (M. polymorpha, BAE71129), and ThrELO1 Thraustochytrium sp. FIN-10, ABC18313). -
FIG. 6 . Is a hydropathy plot of the amino acid sequence of PiELO1. The lower dashed line and the upper line represent the loose transmembrane region cutoff and the strict transmembrane region cutoff, respectively. -
FIG. 7 . Is an unrooted phylogram of PiELO1 and some other functionally characterized PUFA elongases. The alignment was generated by the CLUSTAL W program and the unrooted phylogram was constructed by the neighbor-joining method using the MEGA4 software. GeneBank accession numbers for the PUFA elongases are: ACK99719 (Δ6, P. incisa), AAV67797 (Δ6, O. tauri), AAV67798 (Δ5, O. tauri), AAT85662 (Δ6, M. polymorpha), BAE71129 (Δ5, M. polymorpha), AAL84174 (Δ6, P. patens), CAJ 30819 (Δ6, Thraustochytrium sp.), CAM55873 (Δ5, Thraustochytrium sp.), AAF70417 (Δ6, M. alpina), XP—001467802 (L. infantum), AAV67803 (Δ6/Δ5, O. mykiss), NP—001029014 (Δ6/Δ5, C. intestinalis), NP—068586 (Δ6/Δ5, H. sapiens), AAY15135 (Δ5, P. salina), CAM55851 (Δ6 P. tricornutum), AAL37626 (Δ9, I. galbana), AAV67799 (Δ6, T. pseudonana), AAV67800 (Δ5, T. pseudonana), CAΔ92958 (Δ6, C. elegans), NP —599209 (Δ6/Δ5, R. norvegicus). -
FIG. 8 . Is a GC plot of FAMES of recombinant yeast harboring pYES2 and PiELO1 fed with 18:3ω6 (A) and 18:4ω3 (B) CONTROL. -
FIG. 9 . Is a bar graph summarizing the results of quantitative Real-time RT-PCR analysis of PiELO1 gene expression in log phase (Time 0) and N-starved (3, 7 & 14 d) cells of P. incisa. The transcript abundance of the gene was normalized to 18S SSU rRNA gene. - In one embodiment, the present invention provides an isolated protein. In another embodiment, the present invention provides that the isolated protein is a polypeptide. In another embodiment, the present invention provides that the isolated protein is an enzyme. In another embodiment, the present invention provides that the isolated protein is a desaturase. In another embodiment, the present invention provides that the isolated protein is an algal desaturase. In another embodiment, the present invention provides that the isolated protein is a microalgae desaturase. In another embodiment, the present invention provides that the isolated protein is a
- Δ12 desaturase. In another embodiment, the present invention provides that the isolated protein is a Δ6 desaturase. In another embodiment, the present invention provides that the isolated protein is a Δ5 desaturase. In another embodiment, the present invention provides that the isolated protein is a microalgae desaturase produced in a plant cell. In another embodiment, the present invention provides that the isolated protein is a microalgae desaturase produced in an algal cell.
- In another embodiment, the present invention provides a Δ12 desaturase comprising the amino acid sequence:
-
(SEQ ID NO: 1) MGKGGCYQAGPPSAKKWESRVPTAKPEFTIGTLRKAIPVHCFERSIPRSF AYLAADLAAIAVMYYLSTFIDHPAVPRVLAWGLLWPAYWYFQGAVATGVW VIAHECGHQAFSPYQWLNDAVGLVLHSCLLVPYYSWKHSHRRHHSNTGST TKDEVFVPREAAMVESDFSLMQTAPARFLVIFVSLTAGWPAYLFANASGR KYGKWANHFDPYSPIFTKRERSEIVVSDVALTVVIAGLYSLGKAFGWAWL VKEYVIPYLIVNMWLVMITLLQHTHPELPHYADKEWDWLRGALATCDRSY GGMPDHLHHHIADTHVAHHLFSTMPHYHAQEATEAIKPILGKYYKQDKRN VWAALWEDFSLCRYVAPDTAGSGILWFRA. - In another embodiment, the present invention provides a Δ6 desaturase comprising the amino acid sequence:
-
(SEQ ID NO: 2) MCQGQAVQGLRRRSSFLKLTGDAIKGAVAAISDFNKLPAATPVFARRSLS DSALQQRDGPRSKQQVTLEELAQHNTPEDCWLVIKNKVYDVSGWGPQHPG GHVIYTYAGKDATDVFACFHAQTTWSQLRPFCIGDIVEEEPMPALLKDFR ELRTRLQQQGLFRSNKLYYLYKVASTLSLLAAALAVLITQRDSWLGLVGG AFLLGLFWQQSGWLAHDFLHHQVFTDRQWNNVMGYFLGNVCQGFSTDWWK SKHNVHHAVPNELDSDSKAARDPDIDTLPLLAWSSEMLDSMSNSGARLFV RMQHYFFFPILLFARMSWCQQSVAHASDLSRTSKAGVYELAYLALHYAWF LGAAFSVLPPLKAVVFALLSQMFSGFLLSIVFVQSHNGMEVYSDTKDFVT AQIVSTRDILSNVWNDWFTGGLNYQIEHHLFPTLPRHNLGKVQKSIMELC HKHGLVYENCGMATGTYRVLQRLANVAAEA. - In another embodiment, the present invention provides a AS desaturase comprising the amino acid sequence:
-
(SEQ ID NO: 3) MMAVTEGAGGVTAEVGLHKRSSQPRPAAPRSKLFTLDEVAKHDSPTDCWV VIRRRVYDVTAWVPQHPGGNLIFVKAGRDCTQLFDSYHPLSARAVLDKFY IGEVDVRPGDEQFLVAFEEDTEEGQFYTVLKKRVEKYFRENKLNPRATGA MYAKSLTILAGLALSFYGTFFAFSSAPASLLSAVLLGICMAEVGVSIMHD ANHGAFARNTWASHALGATLDIVGASSFMWRQQHVVGHHAYTNVDGQDPD LRVKDPDVRRVTKFQPQQSYQAYQHIYLAFLYGLLAIKSVLLDDFMALSS GAIGSVKVAKLTPGEKLVFWGGKALWLGYFVLLPVVKSRHSWPLLAACWL LSEFVTGWMLAFMFQVAHVTSDVSYLEADKTGKVPRGWAAAQAATTADFA HGSWFWTQISGGLNYQVVHHLFPGICHLHYPAIAPIVLDTCKEFNVPYHV YPTFVRALAAHFKHLKDMGAPTAIPSLATVG. - In another embodiment, the desaturase of the present invention comprises an amino acid sequence that is at least 60% homologous to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In another embodiment, the desaturase comprises an amino acid sequence that is at least 70% homologous to the amino acid sequence of SEQ ID NO: 1, SEQ NO: 2, or SEQ ID NO: 3. In another embodiment, the desaturase comprises an amino acid sequence that is at least 75% homologous to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In another embodiment, the desaturase comprises an amino acid sequence that is at least 80% homologous to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In another embodiment, the desaturase comprises an amino acid sequence that is at least 85% homologous to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In another embodiment, the desaturase comprises an amino acid sequence that is at least 90% homologous to the amino acid sequence of SEQ ID NO: 1, SEQ ID
- NO: 2, or SEQ ID NO: 3. In another embodiment, the desaturase comprises an amino acid sequence that is at least 95% homologous to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In another embodiment, the desaturase comprises an amino acid sequence that is at least 98% homologous to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.
- In another embodiment, the desaturase of the present invention comprises an amino acid sequence that is at least 60% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In another embodiment, the desaturase comprises an amino acid sequence that is at least 70% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In another embodiment, the desaturase comprises an amino acid sequence that is at least 75% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In another embodiment, the desaturase comprises an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In another embodiment, the desaturase comprises an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In another embodiment, the desaturase comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In another embodiment, the desaturase comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In another embodiment, the desaturase comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.
- In another embodiment, the desaturase as described herein comprises at least a portion of the amino acid shown in SEQ ID. NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In another embodiment, the desaturase as described herein is a variant of SEQ ID. NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In another embodiment, the term “variant” in relation to a certain sequence means a protein or a polypeptide which is derived from the sequence through the insertion or deletion of one or more amino acid residues or the substitution of one or more amino acid residues with amino acid residues having similar properties, e.g., the replacement of a polar amino acid residue with another polar amino acid residue, or the replacement of a non-polar amino acid residue with another non-polar amino acid residue. In all cases, variants must have a desaturase function as defined herein.
- In another embodiment, the desaturase as described herein further comprises a leader peptide. In another embodiment, the leader peptide allows the polypeptide to be specifically located or targeted to a target organelle within the cell. In another embodiment, the desaturase as described herein further comprises a sequence motif responsible for microsomal localization. In another embodiment, a desaturase as described herein further comprises chemical modification such as glycosylation that increases its stability. In another embodiment, a desaturase as described herein further comprises a peptide unrelated to desaturase which increases its stability.
- In another embodiment, the present invention provides an isolated PUFA desaturase. In another embodiment, the present invention provides an isolated polypeptide comprising a functional long chain polyunsaturated fatty acid (PUFA) desaturase. In another embodiment, the present invention provides that the polypeptide has the function of desaturating a chain longer than 18 carbons fatty acid. In another embodiment, the present invention provides that the polypeptide has the function of desaturating a chain longer than 20 carbons fatty acid.
- In another embodiment, the present invention provides an isolated PUFA desaturase comprising a fused N-terminal cytochrome b5 domain. In another embodiment, the present invention provides an isolated PUFA desaturase which desaturates ω6 substrates. In another embodiment, the present invention provides an isolated PUFA desaturase which desaturates both ω3 substrates. In another embodiment, the present invention provides an isolated PUFA desaturase which desaturates both ω3 and ω6 substrates. In another embodiment, the present invention provides an isolated PUFA desaturase encoded by SEQ ID NO: 1 (PiDes12 or Δ12). In another embodiment, the present invention provides an isolated PUFA desaturase encoded by SEQ ID NO: 2 (PiDes6 or Δ6). In another embodiment, the present invention provides an isolated PUFA desaturase encoded by SEQ ID NO: 3 (PiDes5 or Δ5). In another embodiment, the substrate for the present invention isolated PUFA desaturase is 18:2ω6, 20:3ω6, 20:4ω3, and 20:3ω3
- In another embodiment, the present invention provides an isolated PUFA desaturase which desaturates 20:3ω3 to a non-methylene-interrupted 20:4Δ5. In another embodiment, the present invention provides that PiDes5 desaturates 20:3ω3 to a non-methylene-interrupted 20:4Δ5. In another embodiment, the present invention provides that PiDes5 converts 20:4ω3 into the respective Δ5 product, 20:5ω3 (EPA) as well as the added 18:1 into the non-methylene-interrupted 18:2Δ5, 9.
- In another embodiment, the present invention provides a protein comprising a desaturase activity. In another embodiment, the present invention provides a protein consisting a desaturase activity. In another embodiment, the present invention provides that the protein of the invention is a recombinant desaturase. In another embodiment, the present invention provides that the desaturase is a polyunsaturated fatty acid (PUFA)-specific desaturase. In another embodiment, the present invention provides that the desaturase desaturates precursors of arachidonic acid. In another embodiment, the present invention provides that the desaturase desaturates precursors of EPA. In another embodiment, the present invention provides that the desaturase desaturates immediate precursors of arachidonic acid (ARA). In another embodiment, the present invention provides that the protein as described herein is used to elevate PUFA levels in animals, thereby providing a ready source of PUFAs.
- In another embodiment, the expression and/or transcription of the desaturase as described herein is up-regulated during nitrogen starvation. In another embodiment, the expression and/or transcription of the desaturase as described herein is up-regulated under oleogenic conditions. In another embodiment, oleogenic conditions comprise the presence of a Δ6 substrate for Δ6 or Δ5 fatty acid desaturase. In another embodiment, oleogenic conditions comprise 18:2ω6 and 20:3ω6. In another embodiment, oleogenic conditions comprise nitrogen starvation. In another embodiment, the expression and/or transcription level of the desaturases as described herein correlates with the production of ARA precursors. In another embodiment, oleogenic conditions comprise nitrogen starvation. In another embodiment, the expression and/or transcription level of the desaturases as described herein correlates with the production of DGLA precursors, EPA precursors, DHA precursors, ARA precursors, or any combination thereof.
- In another embodiment, the present invention provides an isolated polynucleotide encoding the protein as described herein. In another embodiment, an isolated polynucleotide is an isolated DNA molecule. In another embodiment, an isolated polynucleotide is an isolated cDNA molecule. In another embodiment, the isolated polynucleotide comprises a sequence encoding the protein as described herein. In another embodiment, the isolated polynucleotide comprises a DNA sequence encoding a desaturase as described herein. In another embodiment, the isolated polynucleotide comprises a DNA sequence encoding a polypeptide comprising a desaturase activity. In another embodiment, the isolated polynucleotide comprises a DNA sequence encoding a polypeptide consisting a desaturase activity.
- In another embodiment, the isolated polynucleotide comprises a DNA sequence comprising the sequence:
-
(SEQ ID NO: 4, PiDes12) atggggaaaggaggctgttaccaggccgggcctcctagcgcaaagaaatg ggagagtagggtgcccactgccaaacccgagttcacgatcggaaccctcc gcaaagctataccggtccactgcttcgaacggtccatccctcggtcattg cctaccttgcggcagacctggcggctattgcggtcatgtactacctgagc actttcatcgatcatcccgccgtgccgcgggtcctggcctggggtttgct gtggcctgcctactggtacttccaaggtgctgtggcgacaggcgtctggg tgattgctcacgagtgcggccaccaggcgttctcgccctaccagtggctc aacgacgctgtggggcttgtgctgcactcctgcttgctggtgccctatta ctcctggaagcactcacacagacggcaccactccaacaccggaagcacca ccaaggatgaggtgtttgtcccccgggaagcagccatggtggagtcggac ttctccttgatgcagacagctcccgcgcggttcctggtcatcttcgtctc gctgaccgctggctggcctgcctacctgtttgccaatgcatctggccgca agtatggcaagtgggccaaccactttgacccctactcacccatcttcacc aagcgcgagcgcagcgagatcgttgtcagcgatgtcgcgctgacggtggt catcgcggggctctactcgctgggcaaggcgtttggctgggcctggctgg tcaaggagtatgtgatcccctacctcatcgtcaacatgtggctggtcatg atcacgctgctgcagcacacgcaccccgagctgccgcactacgccgacaa ggagtgggactggctgcgcggcgcgctggccacctgcgatcgcagctacg gcggcatgccggaccacctgcaccaccacatcgccgacacgcacgtcgct caccacctgttctccaccatgccgcactaccatgcgcaggaggcgactga ggcgatcaagcccatcctgggcaagtactacaagcaggacaagcgcaacg tctgggcagcgctctgggaggatttcagcctgtgccgctatgtggcgcct gacacagcaggctcgggcatcctgtggttccgcgcttga. In another embodiment, SEQ ID NO: 4 encodes the amino acid sequence of SEQ ID NO: 1. - In another embodiment, the isolated polynucleotide comprises a DNA sequence comprising the sequence:
-
(SEQ ID NO: 5, PiDes6) atgtgccagggacaggcagtccagggtctgaggcgccggagttcattatg aagctcaccggggacgctatcaaaggggccgttgccgcaatatcagactt caacaagctcccggccgcaacgccagtgttcgccaggcggtcactttccg acagcgctctgcagcagcgagatggcccgcgcagcaagcagcaggtcacc ctggaagagctagcgcagcataatacgcctgaggattgctggctggtcat caagaacaaggtgtacgacgtcagcggttggggaccgcagcaccccggtg ggcacgtgatctatacgtatgctggcaaagacgccacggacgtttttgcc tgatccatgcccagaccacttggtcgcagttgagacccttctgcatcggg gacattgtggaggaggagccaatgccggcgctgctcaaagacttccgcga gctgcgcacccggctgcagcagcagggcctgtttcgcagcaacaagagta ctacagtacaaggtggccagcacgctgagcctactggcggccgcgctggc agtgctgatcacgcagcgcgactcctggctgggtctcgtcggcggcgcgt tcctgctgggcctcttaggcagcagtcgggctggctggcgcacgacttcc tgcaccaccaggtcttcaccgaccgccagtggaacaacgtgatgggctac ttcctgggcaacgtctgccagggcttcagcacggactggtggaagagcaa gcacaacgtgcaccacgcggtgcccaacgagctcgacagcgacagcaagg cggcgcgggaccccgacatcgacacgctgcccctgctggcctggagctcg gagatgctggacagcatgagcaactcgggcgcgcgcctgtttgtgcgcat gcagcactacttcttcttccccatcctgctcttcgcgcgcatgtcctggt gccagcagtctgtcgcgcacgcctcggacctgtccaggacctcaaaggcg ggcgtgtatgagctggcgtatcttgcgctgcattatgcctggttcctggg cgcggccttcagcgtgctcccgcccctcaaggcggtcgtgttcgcgctgc tcagccagatgttttccggcttcctgctctccatcgtctttgtgcagagc cacaacggcatggaggtgtacagcgacacaaaggactttgtgacggccca gattgtgtccacgcgcgacatattgtcaaacgtctggaacgactggttca caggcgggctgaactaccagatcgagcaccacctgttccccacgctgccg cgccacaacctgggcaaggtccagaagtccatcatggagctgtgccacaa gcatggcctggtgtacgaaaactgcggcatggctactggcacctatcgtg tgctgcagcgcctggcaaacgtggcagctgaggcctag. In another embodiment. SEQ ID NO; 5 encodes the amino acid sequence of SEQ ID NO: 2. - In another embodiment, the isolated polynucleotide comprises a DNA sequence comprising the sequence:
-
(SEQ ID NO: 6, PiDes5) atgatggctgtaacagagggcgctgggggtgtaacggccgaggttggttt gcacaaacgcagttctcagccgcgtcccgcagctccccgcagcaagctgt tcacgttggatgaggttgcaaagcacgacagcccgactgactgctgggtg gtcattcggcggagggtttacgacgtgacgcgtgggtgccgcagcatcct ggcggaaacctgatctttgtgaaagctggccgcgactgtacccagctgtt cgattcctaccaccccttaagtgccagggctgtgctagacaagttctaca tcggtgaagtcgatgtaaggcctggggacgagcagttccttgtggctttc gaagaggacacagaggagggtcagttctacacggtcctcaagaagcgtgt ggagaagtacttcagggagaacaagctcaacccgcggcaacaggcgccat gtacgccaagtcgctgaccatcctggcgggcctggcgttgagcttctatg gtacgttctttgccttcagcagcgcaccggcctcgctgctcagcgctgtg ctgctcggcatttgcatggcggaggtgggcgtgtccatcatgcacgatgc caaccacggcgcatttgcccgcaacacgtgggcctcgcatgccctgggcg ccacgctggacatcgtgggggcatcctccttcatgtggcgccagcagcat gtcgtgggccaccatgcatacaccaacgtggacggtcaggacccagacct gcgagttaaggaccccgacgttcgccgcgtgaccaagttccagccccagc agtcgtaccaggcgtaccagcacatctacctggccttcctgtacggcctg ctggccatcaagagcgtgctgctggacgactttatggccctcagctccgg cgccatcggctccgtgaaagtggccaagctgacgcccggcgagaagctcg tgttctggggcggcaaggcgctctggctcggctactttgtgctgctgccg gtggtgaagagccgccactcctggccgctgctggcggcctgctggctgct gagcgagtttgtcacgggctggatgctggccttcatgttccaggtggcgc acgtgaccagcgatgtgagctacctggaggctgacaagacaggcaaggtc ccgaggggctgggctgccgcacaggccgccaccaccgccgactttgcgca tggctcctggttctggacccaaatttctggcggccttaactaccaggtgg tgcaccatctgttcccgggcatctgccatctgcactacccggccatcgcc ccatcgtgctggacacctgcaaggagtttaacgtgccctaccatgtgtac cccacgtttgtcagggcactcgccgcacacttcaagcatctcaaggacat gggcgccccaactgccatcccttcgctggccaccgtgggatag. In another embodiment, SEQ ID NO: 6 encodes the amino acid sequence of SEQ ID NO: 3. - In another embodiment, the isolated polynucleotide comprises a DNA sequence that is at least 60% homologous to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 8. In another embodiment, the isolated polynucleotide comprises a DNA sequence that is at least 70% homologous to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 8. In another embodiment, the isolated polynucleotide comprises a DNA sequence that is at least 75% homologous to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 8. In another embodiment, the isolated polynucleotide comprises a DNA sequence that is at least 80% homologous to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 8. In another embodiment, the isolated polynucleotide comprises a DNA sequence that is at least 85% homologous to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 8. In another embodiment, the isolated polynucleotide comprises a DNA sequence that is at least 90% homologous to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 8. In another embodiment, the isolated polynucleotide comprises a DNA sequence that is at least 95% homologous to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO:. 5, SEQ ID NO: 6, or SEQ ID NO: 8. In another embodiment, the isolated polynucleotide comprises a DNA sequence that is at least 98% homologous to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 8.
- In another embodiment, the isolated polynucleotide comprises a DNA sequence that is at least 60% identical to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 8. In another embodiment, the isolated polynucleotide comprises a DNA sequence that is at least 70% identical to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 8. In another embodiment, the isolated polynucleotide comprises a DNA sequence that is at least 75% identical to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 8. In another embodiment, the isolated polynucleotide comprises a DNA sequence that is at least 80% identical to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 8. In another embodiment, the isolated polynucleotide comprises a DNA sequence that is at least 85% identical to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 8. In another embodiment, the isolated polynucleotide comprises a DNA sequence that is at least 90% identical to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 8. In another embodiment, the isolated polynucleotide comprises a DNA sequence that is at least 95% identical to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 8. In another embodiment, the isolated polynucleotide comprises a DNA sequence that is at least 98% identical to the nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ NO: 6, or SEQ ID NO: 8.
- In another embodiment, the present invention comprises a desaturase or a nucleic acid molecule encoding the same combined with additional proteins and/or enzymes and/or substrates that are involved in the biosynthesis of VLC-PUFA. In another embodiment, the present invention comprises a composition comprising a desaturase or a nucleic acid molecule encoding the same combined with additional proteins and/or enzymes and/or substrates that are involved in the biosynthesis of VLC-PUFA. In another embodiment, the present invention comprises a transgenic plant comprising a desaturase or a nucleic acid molecule encoding the same combined with additional proteins and/or enzymes and/or substrates that are involved in the biosynthesis of VLC-PUFA. In another embodiment, the present invention comprises a transgenic alga comprising a desaturase or a nucleic acid molecule encoding the same combined with additional proteins and/or enzymes and/or substrates that are involved in the biosynthesis of VLC-PUFA. In another embodiment, the present invention comprises a transfected or a transformed cell comprising a desaturase or a nucleic acid molecule encoding the same combined with additional proteins and/or enzymes and/or substrates that are involved in the biosynthesis of VLC-PUFA.
- In another embodiment, the present invention comprises a desaturase or a nucleic acid molecule encoding the same combined with additional proteins and/or enzymes and/or substrates that are involved in the biosynthesis of VLC-PUFA. In another embodiment, the present invention comprises an algal desaturase or a nucleic acid molecule encoding the same combined with additional algal proteins and/or enzymes and/or substrates that are involved in the biosynthesis of VLC-PUFA. In another embodiment, the present invention provides that the alga is a microalga. In another embodiment, the present invention comprises a microalgae desaturase or a nucleic acid molecule encoding the same combined with additional microalgae proteins and/or enzymes and/or substrates that are involved in the biosynthesis of VLC-PUFA.
- In another embodiment, the present invention provides that algae proteins comprise an elongase. In another embodiment an elongase is described in PCT/IL2009/001117 which is hereby incorporated in its entirety by reference. In another embodiment, the present invention provides that microalgae proteins comprise the P. incisa PiELO1 gene product. In another embodiment, the present invention provides that elongase as described herein comprises the amino acid sequence:
-
(SEQ ID NO: 7) MALTAAWHKYDAIVSRFVFDGLRRVGLQEIQGHPSVITAHLPFIASPTPQ VTFVLAYLLIVVCGVAALRTRKSSAPREDPAWLRLLVQAHNLVLISLSAY MSSAACYYAWKYGYRFWGTNYSPKERDMGGLIYTFYVSKLYEFVDTLIML LKGKVEQVSFLHVYHHASISTIWWAIAYVAPGGDAWYCCFLNSLVHVLMY TYYLLATLLGKDAKARRKYLWWGRYLTQFQMFQFVTMMLEAAYTWAYSPY PKFLSKLLFFYMITLLALFANFYAQKHGSSRAAKQKLQ. - In another embodiment, the elongase as described herein id encoded by a polynucleotide comprising a DNA sequence comprising the sequence:
-
(SEQ ID NO: 8) atggcattgacggcggcctggcacaagtacgacgctatcgttagtcgctt tgttttcgatggcttgcgcagggttggcctgcaagagattcaaggccacc cctcggtgatcaccgcccaccttcccttcatagcctccccaacgccacaa gtgacgttcgtgctggcctatctgctgattgttgtctgcggggttgccgc tctgcgtacgagaaagtcgtccgcacctcgcgaggatccggcgtggctgc gactgcttgtgcaagcgcacaacttggtgctaatcagccttagcgcctac atgtcctctgccgcctgctactatgcttggaaatacggctataggttttg gggcacaaactatagccccaaggagcgggacatgggagggctcatctata ccttttacgtgtccaagctgtacgagtttgtggatacgctgatcatgctg ctcaagggcaaggtggagcaggtttcttttttgcacgtctaccaccacgc ttccatatccacgatctggtgggcaatcgcatacgtcgcacctggtggtg acgcctggtactgctgcttcctgaactcgctggtccacgtactcatgtac acatactacctgcttgcgacgctgctgggaaaggacgccaaggcgcggcg caagtatttgtggtggggacgctacctcactcagttccagatgttccagt ttgtgacgatgatgctcgaggcagcgtacacttgggcctactctccctac cccaagtttttatcaaagctgctgttatttaCatgatcactctgttggcc ctgtttgcaaacttctatgcacagaagcatggcagcagccgggcagccaa gcaaaagctgcagtaa. - In another embodiment, the present invention provides a composition comprising a desaturase as described herein. In another embodiment, the present invention provides a composition comprising the desaturase as described herein and a VLC-PUFA elongase. In another embodiment, the present invention provides a composition comprising a protein as described herein. In another embodiment, the present invention provides a composition comprising the polynucleotide as described herein. In another embodiment, the present invention provides a composition comprising a polynucleotide encoding an elongase and the polynucleotide as described herein. In another embodiment, the present invention provides a composition comprising a vector comprising the polynucleotide as described herein. In another embodiment, the present invention provides a composition comprising a vector comprising a polynucleotide encoding an elongase and a polynucleotide as described herein. In another embodiment, the present invention provides a composition comprising a combination of vectors which comprise polynucleotides encoding an elongase and polynucleotides encoding desaturases. In another embodiment, a composition such as described herein comprises a carrier. In another embodiment, a carrier stabilizes a protein or a nucleic acid molecule of the invention. In another embodiment, one of skill in the art will readily identify a known suitable carrier to be used with the composition as described herein. In another embodiment, a carrier is a buffer such as but not limited to a phosphate buffer.
- In another embodiment, one of skill in the art is able to prepare a composition comprising a desaturase as described herein. In another embodiment, one of skill in the art is able to prepare a composition comprising a combination of elongases and desaturases as described herein. In another embodiment, one of skill in the art is able to prepare a composition comprising a polynucleotide as described herein. In another embodiment, one of skill in the art is able to prepare a composition comprising a combination of polynucleotides, plasmids, vectors etc. as described herein. In another embodiment, the present invention provides a composition comprising the protein as described herein to be used in foodstuffs, dietary supplements or pharmaceutical compositions. In another embodiment, the present invention provides a composition comprising the protein as described herein to be used in industrial applications for the manufacturing of VLC-PUFAs. In another embodiment, the present invention provides a composition comprising the VLC-PUFAs, the products of the enzymes of the present invention. In another embodiment, a composition comprising VLC-PUFAs is used in foodstuffs, dietary supplements or pharmaceutical compositions.
- In another embodiment, the invention includes a combination of Δ5, Δ6, and/or Δ12 desaturases. In another embodiment, the invention includes a composition comprising the combination of Δ5, Δ6, and/or Δ12 desaturases. In another embodiment, the invention includes a composition comprising the combination of Δ5, Δ6, and/or Δ12 desaturases and either ω3 or ω6 C18 substrates. In another embodiment, the invention provides that a composition comprising the combination of Δ5, Δ6, and/or Δ12 desaturases and either ω3 or ω6 C18 substrates yields DGLA, ARA, DHA and/or EPA.
- In another embodiment, the invention provides conjunction of P. incisa Δ12, Δ6, and Δ5 desaturases, which are set of P. incisa genes involved in the biosynthesis of ARA. In another embodiment, the invention provides conjunction of P. incisa Δ12, Δ6, and Δ5 desaturase and Δ6 specific PUFA elongase (as described herein), which are set of P. incisa genes involved in the biosynthesis of DGLA, ARA, DHA, EPA, or any combination thereof.
- In another embodiment, a desaturase as described herein comprises three histidine rich motifs (his-boxes). In another embodiment, Δ6 (PiDes6) and Δ5 (PiDes5) desaturases comprise fused cytochrome b5 at their N-terminus, supporting their microsomal localization. In another embodiment, Δ6 (PiDes6) and Δ5 (PiDes5) desaturases comprise a HPGG quartet along with four amino acids conserved in all cytochrome b5 fusion desaturases (
FIG. 1 ). - In another embodiment, transforming a plant with an algal-derived gene such as described herein produces better results in comparison to fungal genes. In another embodiment, transforming a plant with an algal-derived gene such as described herein in combination with additional genes that encode proteins that are involved in the biosynthesis of VLC-PUFA produces better results in comparison to fungal or wild-type genes. In another embodiment, transforming a plant with an algal-derived gene such as described herein (desaturase) in combination with an elongase as described herein produces better results in comparison to fungal or wild-type genes. In another embodiment, transforming a plant with a combination of algal-derived genes such as described herein produces better results (such as ARA production) in comparison to fungal or wild-type genes. In another embodiment, transforming a plant with a combination of algal-derived desaturase genes such as described herein produces better results (such as ARA production) in comparison to fungal or wild-type genes. In another embodiment, P. incisa is the richest plant source of ARA. In another embodiment, P. incisa is the richest algal source of ARA. In another embodiment, algal-derived genes such as described herein are more effective alone or in combination than those of other sources.
- In another embodiment, algae as described herein are eukaryotic organisms. In another embodiment, algae as described herein are photoautotrophic. In another embodiment, algae as described herein are mixotrophic. In another embodiment, algae as described herein are unicellular. In another embodiment, algae as described herein are multicellular. In another embodiment, algae as described herein are Excavata algae. In another embodiment, algae as described herein are Rhizaria algae. In another embodiment, algae as described herein are Chromista algae. In another embodiment, algae as described herein are Alveolata algae.
- In another embodiment, an algal gene and protein of the present invention is superior when compared to its homologues with respect to efficient production of PUFAs. In another embodiment, transforming a first alga with an algal gene derived from a second alga such as described herein produces better results in comparison to fungal genes. In another embodiment, a second algal gene is a gene as described herein. In another embodiment, a first and a second algal are of different species. In another embodiment, transforming a first alga with an algal gene derived from a second alga such as described herein in combination with additional genes that encode proteins that are involved in the biosynthesis of VLC-PUFA produces better results in comparison to fungal or wild-type genes. In another embodiment, transforming an alga with an algal gene (such as desaturase) derived from a second alga such as described herein in combination with an elongase as described herein produces better results in comparison to fungal or wild-type genes. In another embodiment, transforming a first alga with a combination of algal genes derived from a second alga, a third alga, etc., such as described herein produces better results (such as ARA production) in comparison to fungal or wild-type genes. In another embodiment, transforming a first alga with a combination of algal desaturase genes derived from a second alga such as described herein produces better results (such as ARA production) in comparison to fungal or wild-type genes. In another embodiment, P. incisa is the second alga. In another embodiment, P. incisa is the source of choice for genes that are involved in the biosynthesis of VLC-PUFA. In another embodiment, P. incisa is the source of choice for genes that are involved in the biosynthesis of ARA, DHA, EPA, DGLA, or any combination thereof. In another embodiment, P. incisa-derived genes such as described herein are more effective alone or in combination than those of other sources.
- In another embodiment, a DNA sequence as described herein such as but not limited to SEQ ID NO: 4-6 is used to engineer a transgenic organism. In another embodiment, DNA sequences as described herein such as but not limited to SEQ ID NO: 4-6 are used to engineer a transgenic organism or transform a cell. In another embodiment, DNA sequences as described herein such as but not limited to SEQ ID NO: 4-6 and 8 are used to engineer a transgenic organism or transform a cell. In another embodiment, the DNA sequences comprise the sequences provided in SEQ ID NO: 4-6 and 8 or variants of these sequences due, for example: base substitutions, deletions, and/or additions.
- In another embodiment, the present invention provides transgenic plant oils enriched with VLC-PUFA. In another embodiment, the present invention provides transgenic alga oils enriched with VLC-PUFA. In another embodiment, the present invention provides the reconstitution of C20-VLC-PUFA biosynthesis in oil-synthesizing seeds of higher plants. In another embodiment, the present invention provides expanded use by enhancement of the levels of ARA, DGLA, DHA, EPA, or a combination thereof in the transgenic plants.
- In another embodiment, the present invention provides an expression vector comprising the polynucleotide as described herein. In another embodiment, the present invention provides a combination of expression vectors each comprising a polynucleotide as described herein. In another embodiment, the present invention provides an expression vector comprising a combination of polynucleotides as described herein. In another embodiment, the present invention provides a plant specific expression vector comprising the polynucleotide or combination of polynucleotides as described herein. In another embodiment, the present invention provides an algal specific expression vector comprising the polynucleotide or combination of polynucleotides as described herein. In another embodiment, the present invention provides a cell comprising the expression vector/s as described herein. In another embodiment, the expression vector/s is contained within an agrobacterium. In another embodiment, a cell is a plant cell or an algal cell. In another embodiment, a plant is an oil crop. In another embodiment, the transformed plant is an oil crop.
- In another embodiment, the present invention provides a transgenic plant, a transgenic seed, or a transgenic alga transformed by a polynucleotide as described herein. In another embodiment, the present invention provides a transgenic plant, a transgenic seed, or a transgenic alga transformed by any combination of polynucleotides as described herein. In another embodiment, the present invention provides that the transgenic plant is a true-breeding for the polynucleotide/s as described herein. In another embodiment, the present invention provides a transgenic seed, produced by a transgenic plant transformed by the polynucleotide/s as described herein. In another embodiment, a transgenic plant, a transgenic seed, or a transgenic alga as described herein produces very long-chain polyunsaturated fatty acid (VLC-PUFA). In another embodiment, a transgenic plant, a transgenic seed, or a transgenic alga as described herein produces arachidonic acid. In another embodiment, a transgenic plant or a transgenic seed as described herein produces DHA. In another embodiment, a transgenic plant, a transgenic seed, or a transgenic alga as described herein produces DGLA.
- In another embodiment, the present invention provides a method of producing very long-chain polyunsaturated fatty acid (VLC-PUFA) in a plant, a plant cell, or an alga comprising the step of transforming a plant, a plant cell, or an alga with a polynucleotide as described herein. In another embodiment, the present invention unexpectedly provides an utmost efficient method of producing very long-chain polyunsaturated fatty acid (VLC-PUFA) in a plant, a plant cell, or an alga comprising the step of transforming a plant, a plant cell, or an alga with a polynucleotide as described herein. In another embodiment, a VLC-PUFA is produced from γ-linolenic acid (GLA).
- In another embodiment, a VLC-PUFA is produced from stearidonic acid (SDA). In another embodiment, a VLC-PUFA is produced from GLA, SDA, or their combination. In another embodiment, a VLC-PUFA comprises 20 carbons. In another embodiment, a VLC-PUFA is 20:3ω6 or 20:4ω3. In another embodiment, a VLC-PUFA is produced by the protein/s as described herein in a cell or a plant, a plant cell, or an alga. In another embodiment, a VLC-PUFA is produced by the protein/s as described herein in a cell, a plant, a plant cell, or an alga under oleogenic conditions. In another embodiment, an unexpected amount of VLC-PUFA is produced by the protein/s as described herein in a cell, an alga, or a plant under nitrogen starvation conditions.
- In another embodiment, a cell is a eukaryotic cell. In another embodiment, a cell is a prokaryotic cell. In another embodiment, a cell is a plant cell. In another embodiment, a cell is an algal cell. In another embodiment, a cell is a transfected cell. In another embodiment, a cell is transiently transfected with a polynucleotide or a combination of polynucleotides as described herein. In another embodiment, a cell is stably transfected with a polynucleotide or a combination of polynucleotides as described herein. In another embodiment, the present invention provides a method of enhancing oil storage, EPA accumulation, DHA accumulation, ARA accumulation, DGLA accumulation, or a combination thereof in a cell, comprising the step of transforming a cell with a polynucleotide as described herein. In another embodiment, the present invention provides a method of enhancing oil storage, EPA accumulation, DHA accumulation, ARA accumulation, DGLA accumulation, or a combination thereof in a cell, comprising the step of transfecting a cell with a polynucleotide as described herein. In another embodiment, the present invention provides a method of enhancing oil storage, EPA accumulation, DHA accumulation, DGLA accumulation, ARA accumulation, or a combination thereof in a cell, comprising the step of transforming a cell with a combination of polynucleotides as described herein. In another embodiment, the present invention provides a method of enhancing oil storage, EPA accumulation, DHA accumulation, ARA accumulation, DGLA accumulation, or a combination thereof in a cell or a multicellular organism, comprising the step of transforming a cell or a multicellular organism with a polynucleotide as described herein. In another embodiment, the present invention provides a method of enhancing oil storage, EPA accumulation, DGLA accumulation, DHA accumulation, ARA accumulation, or a combination thereof in a multicellular organism, comprising the step of transforming a multicellular organism with a combination of polynucleotides as described herein. In another embodiment, the multicellular organism or cell is grown under nitrogen starvation conditions, oleogenic conditions, or a combination thereof.
- In another embodiment, transformation as used herein comprises “transduction”. In another embodiment, transformation as used herein comprises transfection. In another embodiment, transformation as used herein comprises “conjugation”. In another embodiment, transformation as used herein applies to eukaryotic and prokaryotic cells. In another embodiment, transformation as used herein comprises the insertion of new genetic material into nonbacterial cells including animal and plant cells.
- In another embodiment, the present invention provides a method of enhancing oil storage, EPA accumulation, DHA accumulation, DGLA accumulation, ARA accumulation, or a combination thereof in a plant cell, comprising the step of transforming a plant cell with a polynucleotide as described herein. In another embodiment, the present invention provides a method of enhancing oil storage, EPA accumulation, DHA accumulation, ARA accumulation, DGLA accumulation, or a combination thereof in a plant cell, comprising the step of transforming a plant cell with a combination of polynucleotides as described herein. In another embodiment, the present invention provides a method of enhancing oil storage, EPA accumulation, DHA accumulation, ARA accumulation, DGLA accumulation, or a combination thereof in a plant, comprising the step of transforming a plant with a polynucleotide as described herein. In another embodiment, the present invention provides a method of enhancing oil storage, EPA accumulation, DHA accumulation, ARA accumulation, DGLA accumulation, or a combination thereof in a plant, comprising the step of transforming a plant with a combination of polynucleotides as described herein. In another embodiment, the plant or plant cell is grown under nitrogen starvation conditions, oleogenic conditions, or a combination thereof.
- In another embodiment, the invention further provides an engineered organism, such as a transgenic plant. In another embodiment, the invention further provides an engineered organism, such as a transgenic seed. In another embodiment, the invention further provides an engineered organism, such as a transgenic alga. In another embodiment, the invention further provides an engineered organism, such as a transgenic animal. In another embodiment, an engineered organism is engineered to express a protein as described herein. In another embodiment, an engineered organism is engineered to express a combination of proteins as described herein. In another embodiment, an engineered organism is engineered to express elevated levels of the protein or a combination of proteins. In another embodiment, an engineered plant as described herein is used for manufacturing desired PUFAs such as but not limited to ARA. In another embodiment, an engineered plant as described herein is used for manufacturing desired PUFAs such as ARA at a reduced cost.
- In another embodiment, an engineered organism comprises a synthetic pathway for the production of a protein. In another embodiment, an engineered organism comprising a synthetic pathway for the production of the protein allows greater control over the production of PUFAs by the pathway by an organism. In another embodiment, the pathway includes but is not limited to A′-fatty acid desaturase, and/or A′-fatty acid desaturase.
- In another embodiment, an engineered cell, plant or seed comprises an oligonucleotide as described herein. In another embodiment, an engineered plant or seed produces a protein as described herein and comprises an oligonucleotide as described herein. In another embodiment, an engineered plant or seed produces proteins as described herein and comprises oligonucleotides as described herein.
- In another embodiment, the invention provides a method of producing very long-chain polyunsaturated fatty acid (VLC-PUFA) in a cell, a plant, a plant cell, or an alga, comprising the step of transforming a plant, a plant cell, or an alga with a polynucleotide as described herein, thereby producing a VLC-PUFA in a plant, a plant cell, or an alga. In another embodiment, the invention provides a method of producing very long-chain polyunsaturated fatty acid (VLC-PUFA) in a cell, a plant, a plant cell, or an alga, comprising the step of transforming a plant, a plant cell, or an alga with an exogenous polynucleotide as described herein, thereby producing a VLC-PUFA in a cell, a plant, a plant cell, or an alga. In another embodiment, the invention provides a method of producing very long-chain polyunsaturated fatty acid (VLC-PUFA) in a cell, a plant, a plant cell, or an alga, comprising the step of transforming a plant, a plant cell, or an alga with a vector comprising an exogenous polynucleotide as described herein, thereby producing a VLC-PUFA in a cell; a plant, a plant cell, or an alga. In another embodiment, the invention provides a method of producing very long-chain polyunsaturated fatty acid (VLC-PUFA) in a cell, a plant, a plant cell, or an alga, comprising the step of transforming a plant, a plant cell, or an alga with a combination of vectors comprising a combination of exogenous polynucleotides as described herein, thereby producing a VLC-PUFA in a cell, a plant, a plant cell, or an alga. In another embodiment, the invention provides a method of producing very long-chain polyunsaturated fatty acid (VLC-PUFA) in a cell, a plant, a plant cell, or an alga, comprising the step of transforming a cell, a plant, a plant cell, or an alga with a combination of exogenous polynucleotides as described herein, thereby producing a VLC-PUFA in a cell, a plant, a plant cell, or an alga.
- In another embodiment, the invention provides that a plant, a cell, a plant cell, or an alga as described herein is treated or supplemented with linoleic acid (LA; 18:2ω6), α-linolenic acid (ALA; 18:3ω3), oleic acid (18:1), dihomo-gamma-linolenic acid (20:3ω6), phosphatidylcholine (PC), diacylglyceroltrimethylhomoserine (DGTS), phosphatidylethanolamine (PE), or any combination thereof, before transformation, after transformation, during transformation or a combination thereof.
- In another embodiment, the invention provides that the VLC-PUFA is eicosapentaenoic acid (EPA, 20:5ω3). In another embodiment, the invention provides that the VLC-PUFA is docosahexaenoic acid (DHA, 22:6ω3). In another embodiment, the invention provides that the VLC-PUFA is arachidonic acid (ARA, 20:4ω6). In another embodiment, the invention provides that a cell, a plant, or an alga transformed by a polynucleotide or a combination of polynucleotides as described herein, is grown under oleogenic conditions. In another embodiment, the invention provides that a cell, a plant, or an alga transformed by a polynucleotide or a combination of polynucleotides as described herein, is grown under nitrogen starvation conditions.
- In another embodiment, the invention provides that producing very long-chain polyunsaturated fatty acid (VLC-PUFA) is enhancing oil storage, arachidonic acid accumulation, eicosapentaenoic acid accumulation, docosahexaenoic acid accumulation, or a combination thereof that a cell, a plant, or an alga transformed by a polynucleotide or a combination of polynucleotides as described herein
- In another embodiment, a PUFA is di-homo-gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid, docosatrienoic acid, docosatetraenoic acid, docosapentaenoic acid or docosahexaenoic acid. In another embodiment, a PUFA is a 24 carbon fatty acid with at least 4 double bonds.
- In another embodiment, expression of the protein/s of the invention in plants or seed requires subcloning an ORF/s sequence encoding the protein/s into a plant expression vector, which may comprise a viral 35S promoter, and a Nos terminator. In another embodiment, a cassette or promoter/coding sequence/terminator is then be subcloned into the plant binary transformation vector, and the resulting plasmid introduced into Agrobacterium. In another embodiment, the Agrobacterium strain transforms the plant. In another embodiment, the. Agrobacterium strain transforms the plant by the vacuum-infiltration of inflorescences, and the seeds harvested and plated onto selective media containing an antibiotic. In another embodiment, the plasmid confers resistance to an antibiotic, thus only transformed plant material will grow in the presence of an antibiotic. In another embodiment, resistant lines are identified and self-fertilized to produce homozygous material. In another embodiment, leaf material is analyzed for expression of the protein comprising desaturase activity. In another embodiment, leaf material is analyzed for expression of a combination of protein comprising desaturase and elongase activities.
- In some embodiments, the terms “protein”, “desaturase”, or “polypeptide” are used interchangeably. In some embodiments, “protein”, “desaturase”, or “polypeptide” as used herein encompasses native polypeptides (either degradation products, synthetically synthesized polypeptides or recombinant polypeptides) and peptidomimetics (typically, synthetically synthesized polypeptides), as well as peptoids and semipeptoids which are polypeptide analogs, which have, in some embodiments, modifications rendering the polypeptides/proteins even more stable while in a body or more capable of penetrating into cells.
- In some embodiments, modifications include, but are not limited to N terminus modification, C terminus modification, polypeptide bond modification, including, but not limited to, CH2—NH, CH2—S, CH2—S═O, O═C—NH, CH2—O, CH2—CH2, S═C—NH, CH═CH or CF═CH, backbone modifications, and residue modification. Methods for preparing peptidomimetic compounds are well known in the art and are specified, for example, in Quantitative Drug Design, C. A. Ramsden Gd., Chapter 17.2, F. Choplin Pergamon Press (1992), which is incorporated by reference as if fully set forth herein. Further details in this respect are provided hereinunder.
- In some embodiments, polypeptide bonds (—CO—NH—) within the polypeptide are substituted. In some embodiments, the polypeptide bonds are substituted by N-methylated bonds (—N(CH3)—CO—). In some embodiments, the polypeptide bonds are substituted by ester bonds (—C(R)H—C—O—O—C(R)—N—). In some embodiments, the polypeptide bonds are substituted by ketomethylene bonds (—CO—CH2—). In some embodiments, the polypeptide bonds are substituted by α-aza bonds (—NH—N(R)—CO—), wherein R is any alkyl, e.g., methyl, carbo bonds (—CH2—NH—). In some embodiments, the polypeptide bonds are substituted by hydroxyethylene bonds (—CH(OH)—CH2—). In some embodiments, the polypeptide bonds are substituted by thioamide bonds (—CS—NH—). In some embodiments, the polypeptide bonds are substituted by olefmic double bonds (—CH=CH—). In some embodiments, the polypeptide bonds are substituted by retro amide bonds (—NH—CO—). In some embodiments, the polypeptide bonds are substituted by polypeptide derivatives (—N(R)—CH2—CO—), wherein R is the “normal” side chain, naturally presented on the carbon atom. In some embodiments, these modifications occur at any of the bonds along the polypeptide chain and even at several (2-3 bonds) at the same time.
- In some embodiments, natural aromatic amino acids of the polypeptide such as Trp, Tyr and Phe, be substituted for synthetic non-natural acid such as Phenylglycine, TIC, naphthylelanine (Nol), ring-methylated derivatives of Phe, halogenated derivatives of Phe or o-methyl-Tyr. In some embodiments, the polypeptides of the present invention include one or more modified amino acid or one or more non-amino acid monomers (e.g., fatty acid, complex carbohydrates, etc.).
- In one embodiment, “amino acid” or “amino acids” is understood to include the 20 naturally occurring amino acid; those amino acid often modified post-translationally in vivo, including, for example, hydroxyproline, phosphoserine and phosphothreonine; and other unusual amino acid including, but not limited to, 2-aminoadipic acid, hydroxylysine, isodesmosine, nor-valine, nor-leucine and ornithine. In one embodiment, “amino acid” includes both D- and L-amino acid.
- In some embodiments, the polypeptides or proteins of the present invention are utilized in a soluble form. In some embodiments, the polypeptides or proteins of the present invention include one or more non-natural or natural polar amino acid, including but not limited to serine and threonine which are capable of increasing polypeptide or protein solubility due to their hydroxyl-containing side chain.
- In some embodiments, the polypeptides or proteins of the present invention are utilized in a linear form, although it will be appreciated by one skilled in the art that in cases where cyclization does not severely interfere with polypeptide characteristics, cyclic forms of the polypeptide can also be utilized.
- In some embodiments, the polypeptides or proteins of present invention are biochemically synthesized such as by using standard solid phase techniques. In some embodiments, these biochemical methods include exclusive solid phase synthesis, partial solid phase synthesis, fragment condensation, or classical solution synthesis. In some embodiments, these methods are used when the polypeptide is relatively short (about 5-15 kDa) and/or when it cannot be produced by recombinant techniques (i.e., not encoded by a nucleic acid sequence) and therefore involves different chemistry.
- In some embodiments, solid phase polypeptide or protein synthesis procedures are well known to one skilled in the art and further described by John Morrow Stewart and Janis Dillaha Young, Solid Phase Polypeptide Syntheses (2nd Ed., Pierce Chemical Company, 1984). In some embodiments, synthetic polypeptides or proteins are purified by preparative high performance liquid chromatography [Creighton T. (1983) Proteins, structures and molecular principles. WH Freeman and Co. N.Y.], and the composition of which can be confirmed via amino acid sequencing by methods known to one skilled in the art.
- In some embodiments, recombinant protein techniques are used to generate the polypeptides of the present invention. In some embodiments, recombinant protein techniques are used for generation of relatively long polypeptides (e.g., longer than 18-25 amino acid). In some embodiments, recombinant protein techniques are used for the generation of large amounts of the polypeptide of the present invention. In some embodiments, recombinant techniques are described by Bitter et al., (1987) Methods in Enzymol. 153:516-544, Studier et al. (1990) Methods in Enzymol. 185:60-89, Brisson et al. (1984) Nature 310:511-514, Takamatsu et al. (1987) EMBO J. 6:307-311, Coruzzi et al. (1984) EMBO J. 3:1671-1680 and Brogli et al, (1984) Science 224:838-843, Gurley et al. (1986) Mol. Cell. Biol. 6:559-565 and Weissbach & Weissbach, 1988, Methods for Plant Molecular Biology, Academic Press, NY, Section VIII, pp 421-463.
- In one embodiment, a polypeptide or protein of the present invention is synthesized using a polynucleotide encoding a polypeptide or protein of the present invention. In some embodiments, the polynucleotide encoding a polypeptide of the present invention is ligated into an expression vector, comprising a transcriptional control of a cis-regulatory sequence (e.g., promoter sequence). In some embodiments, the cis-regulatory sequence is suitable for directing constitutive expression of the polypeptide of the present invention. In some embodiments, the cis-regulatory sequence is suitable for directing tissue specific expression of the polypeptide of the present invention. In some embodiments, the cis-regulatory sequence is suitable for directing inducible expression of the polypeptide of the present invention. In another embodiment, a polypeptide is a protein comprising a desaturase as described herein.
- In another embodiment, the polynucleotide comprises a genomic polynucleotide sequence. In another embodiment, the polynucleotide comprises a composite polynucleotide sequence.
- In one embodiment, the phrase “a polynucleotide” refers to a single or double stranded nucleic acid sequence which be isolated and provided in the form of an RNA sequence, a complementary polynucleotide sequence (cDNA), a genomic polynucleotide sequence and/or a composite polynucleotide sequences (e.g., a combination of the above).
- In one embodiment, “genomic polynucleotide sequence” refers to a sequence derived (isolated) from a chromosome and thus it represents a contiguous portion of a chromosome.
- In one embodiment, “composite polynucleotide sequence” refers to a sequence, which is at least partially complementary and at least partially genomic. In one embodiment, a composite sequence can include some exonal sequences required to encode the polypeptide of the present invention, as well as some intronic sequences interposing there between. In one embodiment, the intronic sequences can be of any source, including of other genes, and typically will include conserved splicing signal sequences. In one embodiment, intronic sequences include cis acting expression regulatory elements.
- In one embodiment, the polynucleotides of the present invention further comprise a signal sequence encoding a signal peptide for the secretion of the polypeptides of the present invention. In one embodiment, following expression, the signal peptides are cleaved from the precursor proteins resulting in the mature proteins.
- In some embodiments, polynucleotides of the present invention are prepared using PCR techniques or any other method or procedure known to one skilled in the art. In some embodiments, the procedure involves the legation of two different DNA sequences (See, for example, “Current Protocols in Molecular Biology”, eds. Ausubel et al., John Wiley & Sons, 1992).
- In one embodiment, polynucleotides of the present invention are inserted into expression vectors (i.e., a nucleic acid construct) to enable expression of the recombinant polypeptide. In one embodiment, the expression vector of the present invention includes additional sequences which render this vector suitable for replication and integration in prokaryotes. In one embodiment, the expression vector of the present invention includes additional sequences which render this vector suitable for replication and integration in eukaryotes. In one embodiment, the expression vector of the present invention includes a shuttle vector which renders this vector suitable for replication and integration in both prokaryotes and eukaryotes. In some embodiments, cloning vectors comprise transcription and translation initiation sequences (e.g., promoters, enhancers) and transcription and translation terminators (e.g., polyadenylation signals).
- In one embodiment, a variety of prokaryotic or eukaryotic cells can be used as host-expression systems to express the polypeptides of the present invention. In some embodiments, these include, but are not limited to, microorganisms, such as bacteria transformed with a recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vector containing the polypeptide coding sequence; yeast transformed with recombinant yeast expression vectors containing the polypeptide coding sequence; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors, such as Ti plasmid, containing the polypeptide coding sequence.
- In some embodiments, non-bacterial expression systems are used (e.g., plant expression systems) to express the polypeptide of the present invention.
- In one embodiment, yeast expression systems are used. In one embodiment, algae expression systems are used. In one embodiment, plant expression systems are used. In one embodiment, a number of vectors containing constitutive or inducible promoters can be used in yeast as disclosed in U.S. Pat. No. 5,932,447 which is hereby incorporated in its entirety by reference. In another embodiment, vectors which promote integration of foreign DNA sequences into the yeast chromosome are used.
- In another embodiment, expression in a host cell can be accomplished in a transient or a stable fashion. In another embodiment, a host cell is a cell as described herein. In another embodiment, transient expression is from introduced constructs which contain expression signals functional in the host cell, but which constructs do not replicate and rarely integrate in the host cell, or where the host cell is not proliferating. In another embodiment, transient expression also can be accomplished by inducing the activity of a regulatable promoter operably linked to the gene of interest.
- In another embodiment, stable expression is achieved by introduction of a construct that integrates into the host genome. In another embodiment, stable expression comprises autonomously replication within the host cell. In another embodiment, stable expression of the polynucleotide of the invention is selected for through the use of a selectable marker located on or transfected with the expression construct, followed by selection for cells expressing the marker. In another embodiment, stable expression results from integration, the site of the construct's integration can occur randomly within the host genome or can be targeted through the use constructs containing regions of homology with the host genome sufficient to target recombination with the host locus. In another embodiment, constructs are targeted to an endogenous locus, all or some of the transcriptional and translational regulatory regions can be provided by the endogenous locus.
- In another embodiment, an expression of a protein as described herein comprising desaturase activity includes functional transcriptional and translational initiation and termination regions that are operably, linked to the DNA encoding the protein comprising a desaturase activity. In another embodiment, an expression of proteins as described herein comprising various desaturase activities includes functional transcriptional and translational initiation and termination regions that are operably linked to the DNA encoding the proteins comprising desaturase activity. In another embodiment, an expression of proteins as described herein comprising desaturase and elongase activities includes functional transcriptional and translational initiation and termination regions that are operably linked to the DNA encoding each protein comprising a desaturase or elongase activity. In another embodiment, transcriptional and translational initiation and termination regions are derived from a variety of nonexclusive sources, including the DNA to be expressed, genes known or suspected to be capable of expression in the desired system, expression vectors, chemical synthesis, or from an endogenous locus in a host cell. hi another embodiment, expression in a plant tissue and/or plant part presents certain efficiencies, particularly where the tissue or part is one which is harvested early, such as seed, leaves, fruits, flowers, roots, etc. In another embodiment, expression can be targeted to that location in a plant by utilizing specific regulatory sequences that are lcnown to one of skill in the art. In another embodiment, the expressed protein is an enzyme which produces a product which may be incorporated, either directly or upon further modifications, into a fluid fraction from the host plant. In another embodiment, expression of a protein of the invention, or antisense thereof, alters the levels of specific PUFAs, or derivatives thereof, found in plant parts and/or plant tissues. The desaturase coding region, in some embodiments, may be expressed either by itself or with other genes such as but not limited to elongase, in order to produce cells, tissues, algae, and/or plant parts containing higher proportions of desired PUFAs or in which the PUFA composition more closely resembles that of human breast milk. In another embodiment, the termination region is derived from the 3′ region of the gene from which the initiation region was obtained or from a different gene. In another embodiment, the termination region usually is selected as a matter of convenience rather than because of any particular property.
- In another embodiment, a plant or plant tissue is utilized as a host or host cell, respectively, for expression of the protein of the invention which may, in turn, be utilized in the production of polyunsaturated fatty acids. In another embodiment, desired PUFAS are expressed in seed. In another embodiment, methods of isolating seed oils are known in the art. In another embodiment, seed oil components are manipulated through the expression of the protein of the invention in order to provide seed oils that can be added to nutritional compositions, pharmaceutical compositions, animal feeds and cosmetics. In another embodiment, a vector which comprises a DNA sequence encoding the protein as described herein is linked to a promoter, and is introduced into the plant tissue or plant for a time and under conditions sufficient for expression of the protein.
- In another embodiment, a vector as described herein comprises additional genes that encode other enzymes, for example, elongase, Δ4-desaturase, a different Δ5-desaturase, a different Δ6-desaturase, Δ10-desaturase, a different Δ12-desaturase, Δ15-desaturase, Δ17-desaturase, Δ19-desaturase, or any combination thereof. In another embodiment, the plant tissue or plant produces the relevant substrate upon which the enzymes act or a vector encoding enzymes which produce such substrates may be introduced into the plant tissue, plant cell or plant. In another embodiment, a substrate is sprayed on plant tissues expressing the appropriate enzymes. In another embodiment, the invention is directed to a transgenic plant comprising the above-described vector, wherein expression of the nucleotide sequence of the vector results in production of a polyunsaturated fatty acid in, for example, the seeds of the transgenic plant.
- In another embodiment, the regeneration, development, and cultivation of plants from single plant protoplast transformants or from various transformed explants is well known in the art (for example: Weissbach and Weissbach, In: Methods for Plant Molecular Biology, (Eds.),
- Academic Press, Inc. San Diego, Calif., (1988)). In another embodiment, regeneration and growth process comprises the steps of selection of transformed cells, culturing those individualized cells through the usual stages of embryonic development through the rooted plantlet stage. In another embodiment, transgenic embryos and seeds are similarly regenerated. In another embodiment, resulting transgenic rooted shoots are thereafter planted in an appropriate plant growth medium such as soil. In another embodiment, regeneration and growth process of algae are known to one of skill in the art. In another embodiment, identification, selection, of transgenic algae are known to one of skill in the art.
- In another embodiment, development or regeneration of plants containing an exogenous polynucleotide as described herein encodes a protein as described herein and is well known in the art. In another embodiment, development or regeneration of algae containing an exogenous polynucleotide as described herein encodes a protein as described herein and is well known in the art. In another embodiment, the regenerated plants are self-pollinated to provide homozygous transgenic plants. In another embodiment, pollen obtained from the regenerated plants is crossed to seed-grown plants of agronomically important lines. In another embodiment, pollen from plants of these important lines is used to pollinate regenerated plants. In another embodiment, a transgenic plant of the present invention containing a desired polypeptide is cultivated using methods well known to one skilled in the art.
- In another embodiment, a variety of methods can be utilized for the regeneration of plants from plant tissue. In another embodiment, the method of regeneration will depend on the starting plant tissue and the particular plant species to be regenerated. In another embodiment, methods for transforming dicots, primarily by use of Agrobacterium tumefaciens, and obtaining transgenic plants are known in the art McCabe et al., Biol. Technology 6:923 (1988), Christou et al., Plant Physiol. 87:671-674 (1988)); Cheng et al., Plant Cell Rep. 15:653657 (1996), McKently et al., Plant Cell Rep. 14:699-703 (1995)); Grant et al., Plant Cell Rep. 15:254-258, (1995).
- In another embodiment, transformation of monocotyledons using electroporation, particle bombardment, and Agrobacterium are known. In another embodiment, transformation and plant regeneration are well established in the art. In another embodiment, assays for gene expression based on the transient expression of cloned nucleic acid constructs have been developed by introducing the nucleic acid molecules into plant cells by polyethylene glycol treatment, electroporation, or particle bombardment (Marcotte et al., Nature 335:454-457 (1988); Marcotte et al., Plant Cell 1:523-532 (1989); McCarty et al., Cell 66:895-905 (1991); Hattori et al., Genes Dev. 6:609-618 (1992); Goff et al., EMBO J. 9:2517-2522 (1990)).
- In another embodiment, transient expression systems are used to functionally dissect the oligonucleotides constructs. In another embodiment, practitioners are familiar with the standard resource materials which describe specific conditions and procedures for the construction, manipulation and isolation of macromolecules (e.g., DNA molecules, plasmids, etc.), generation of recombinant organisms and the screening and isolating of clones, (see for example,: Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press (1989); Maliga et al., Methods in Plant Molecular Biology, Cold Spring Harbor Press (1995); Birren et al., Genome Analysis: Detecting Genes, 1, Cold Spring Harbor, N.Y. (1998); Birren et al., Genome Analysis: Analyzing DNA, 2, Cold Spring Harbor, N.Y. (1998); Plant Molecular Biology: A Laboratory Manual, eds. Clark, Springer, N.Y. (1997)).
- In one embodiment, the expression vector of the present invention can further include additional polynucleotide sequences that allow, for example, the translation of several proteins from a single mRNA such as an internal ribosome entry site (IBES) and sequences for genomic integration of the promoter-chimeric polypeptide.
- In some embodiments, expression vectors containing regulatory elements from eukaryotic viruses such as retroviruses are used by the present invention. In some embodiments, recombinant viral vectors are useful for in vivo expression of the polypeptides of the present invention since they offer advantages such as lateral infection and targeting specificity. In one embodiment, lateral infection is inherent in the life cycle of, for example, retrovirus, and is the process by which a single infected cell produces many progeny virions that bud off and infect neighboring cells. In one embodiment, the result is that a large area becomes rapidly infected, most of which was not initially infected by the original viral particles. In one embodiment, viral vectors are produced that are unable to spread laterally. In one embodiment, this characteristic can be useful if the desired purpose is to introduce a specified gene into only a localized number of targeted cells.
- In one embodiment, various methods can be used to introduce the expression vector of the present invention into cells. Such methods are generally described in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Springs Harbor Laboratory, New York (1989, 1992), in Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, Md. (1989), Chang et al., Somatic Gene Therapy, CRC Press, Ann Arbor, Mich. (1995), Vega et al., Gene Targeting, CRC Press, Ann Arbor Mich. (1995), Vectors: A Survey of Molecular Cloning Vectors and Their Uses, Butterworths, Boston Mass. (1988) and Gilboa et al. [Biotechniques 4 (6): 504-512, 1986] and include, for example, stable or transient transfection, lipofection, electroporation and infection with recombinant viral vectors. In addition, see U.S. Pat. Nos. 5,464,764 and 5,487,992 for positive-negative selection methods.
- In one embodiment, plant expression vectors are used. In one embodiment, the expression of a polypeptide coding sequence is driven by a number of promoters. In some embodiments, viral promoters such as the 35S RNA and 19S RNA promoters of CaMV [Brisson et al., Nature 310:511-514 (1984)], or the coat protein promoter to TMV [Takamatsu et al., EMBO J. 6:307-311 (1987)] are used. In another embodiment, plant promoters are used such as, for example, the small subunit of RUBISCO [Coruzzi et al., EMBO J. 3:1671-1680 (1984); and Brogli et al., Science 224:838-843 (1984)] or heat shock promoters, e.g., soybean hsp17.5-E or hsp17.3-B [Gurley et al., Mol. Cell. Biol. 6:559-565 (1986)]. In one embodiment, constructs are introduced into plant cells using Ti plasmid, Ri plasmid, plant viral vectors, direct DNA transformation, microinjection, electroporation and other techniques well known to the skilled artisan. See, for example, Weissbach & Weissbach [Methods for Plant Molecular Biology, Academic Press, NY, Section VIII, pp 421-463(1988)]. Other expression systems such as insects and mammalian host cell systems, which are well known in the art, can also be used by the present invention.
- It will be appreciated that other than containing the necessary elements for the transcription and translation of the inserted coding sequence (encoding the polypeptide or protein), the expression construct of the present invention can also include sequences engineered to optimize stability, production, purification, yield or activity of the expressed polypeptide or protein.
- In some embodiments, transformed cells are cultured under effective conditions, which allow for the expression of high amounts of recombinant polypeptide or protein. In some embodiments, effective culture conditions include, but are not limited to, effective media, bioreactor, temperature, pH and oxygen conditions that permit protein production. In one embodiment, an effective medium refers to any medium in which a cell is cultured to produce the recombinant polypeptide or protein of the present invention. In some embodiments, a medium typically includes an aqueous solution having assimilable carbon, nitrogen and phosphate sources, and appropriate salts, minerals, metals and other nutrients, such as vitamins. In some embodiments, cells of the present invention can be cultured in conventional fermentation bioreactors, shake flasks, test tubes, microtiter dishes and petri plates. In some embodiments, culturing is carried out at a temperature, pH and oxygen content appropriate for a recombinant cell. In some embodiments, culturing conditions are within the expertise of one of ordinary skill in the art.
- In some embodiments, depending on the vector and host system used for production, resultant polypeptides or proteins of the present invention either remain within the recombinant cell, secreted into the fermentation medium, secreted into a space between two cellular membranes, or retained on the outer surface of a cell or viral membrane.
- In one embodiment, following a predetermined time in culture, recovery of the recombinant polypeptide or protein is effected.
- In one embodiment, the phrase “recovering the recombinant polypeptide or protein” used herein refers to collecting the whole fermentation medium containing the polypeptide or protein and need not imply additional steps of separation or purification.
- In one embodiment, polypeptides or proteins of the present invention are purified using a variety of standard protein purification techniques, such as, but not limited to, affinity chromatography, ion exchange chromatography, filtration, electrophoresis, hydrophobic interaction chromatography, gel filtration chromatography, reverse phase chromatography, concanavalin A chromatography, chromatofocusing and differential solubilization.
- In one embodiment, to facilitate recovery, the expressed coding sequence can be engineered to encode the polypeptide or proteins of the present invention and fused cleavable moiety. In one embodiment, a fusion protein can be designed so that the polypeptide or protein can be readily isolated by affinity chromatography; e.g., by immobilization on a column specific for the cleavable moiety. In one embodiment, a cleavage site is engineered between the polypeptide or protein and the cleavable moiety and the polypeptide or protein can be released from the chromatographic column by treatment with an appropriate enzyme or agent that specifically cleaves the fusion protein at this site [e.g., see Booth et al., Immunol. Lett. 19:65-70 (1988); and Gardella et al., J. Biol. Chem. 265:15854-15859 (1990)].
- In one embodiment, the polypeptide or protein of the present invention is retrieved in “substantially pure” form.
- In one embodiment, the phrase “substantially pure” refers to a purity that allows for the effective use of the protein in the applications described herein.
- In one embodiment, the polypeptide or protein of the present invention can also be synthesized using in vitro expression systems. In one embodiment, in vitro synthesis methods are well known in the art and the components of the system are commercially available.
- In another embodiment, the invention comprises a process for making a very long-chain polyunsaturated fatty acid produced by the protein or combination of proteins of the invention in a cell as described herein. In another embodiment, the resulting very long-chain polyunsaturated fatty acid produced by the transgenic cell or organism as described herein is utilized as a food additive. In another embodiment, a very long-chain polyunsaturated fatty acid produced by the transgenic cell or organism as described herein is utilized as a supplement. In another embodiment, a very long-chain polyunsaturated fatty acid produced by the transgenic cell or organism as described herein is administered to a human subject. In another embodiment, a very long-chain polyunsaturated fatty acid produced by the transgenic cell or organism as described herein is administered to a baby. In another embodiment, a very long-chain polyunsaturated fatty acid produced by the transgenic cell or organism as described herein is administered to an infant. In another embodiment, a very long-chain polyunsaturated fatty acid produced by the transgenic cell or organism as described herein is administered to an animal. In another embodiment, a very long-chain polyunsaturated fatty acid produced by the transgenic cell or organism as described herein is administered to a mammal. In another embodiment, a very long-chain polyunsaturated fatty acid produced by the transgenic cell or organism as described herein is administered to a farm animal, a rodent, a pet, or a lab animal.
- In another embodiment, the described pharmaceutical and nutritional compositions are utilized in connection with animals (i.e., domestic or non-domestic), as well as humans, as animals experience many of the same needs and conditions as humans. For example, the oil or acids of the present invention may be utilized in animal or aquaculture feed supplements, animal feed substitutes, animal vitamins or in animal topical ointments.
- In another embodiment, a very long-chain polyunsaturated fatty acid produced by a protein or a combination of proteins of the invention is utilized in an infant formula. In another embodiment, a very long-chain polyunsaturated fatty acid produced by a protein or a combination of proteins of the invention is administered to a subject having a deficiency in very long-chain polyunsaturated fatty acid. In another embodiment, a very long-chain polyunsaturated fatty acid is a polyunsaturated C20 fatty acid.
- In another embodiment, the isolated protein comprising desaturase activity is used indirectly or directly in the production of polyunsaturated fatty acids. In another embodiment, the isolated protein or a combination of isolated proteins comprising desaturase and/or desaturase/elongase activities are used indirectly or directly in the production of polyunsaturated fatty acids. In another embodiment, “Directly” is meant to encompass the situation where the enzyme directly desaturates the acid. In another embodiment, the latter of which is utilized in a composition. In another embodiment, “Indirectly” is meant to encompass the situation where an acid is converted to another acid (i.e., a pathway intermediate) by the enzyme and then the latter acid is converted to another acid by use of a non-desaturase enzyme. In another embodiment, a very long-chain polyunsaturated fatty acid produced either directly or indirectly is added to a nutritional composition, pharmaceutical compositions, cosmetics, and animal feeds, all of which are encompassed by the present invention.
- In another embodiment, nutritional compositions include any food or preparation for human or animal consumption including for enteral or parenteral consumption, which when taken into the body (a) serve to nourish or build up tissues or supply energy and/or (b) maintain, restore or support adequate nutritional status or metabolic functions. In another embodiment, the nutritional composition of the present invention comprises at least one oil or acid produced directly or indirectly by use of the protein of the invention and may either be in a solid or liquid form. In another embodiment, the composition includes edible macronutrients, vitamins and minerals in amounts desired for a particular use. In another embodiment, the amount of such ingredients will vary depending on whether the composition is intended for use with normal, healthy infants, children or adults having specialized needs such as those which accompany certain metabolic conditions (e.g., metabolic disorders).
- In another embodiment, the macronutrients include edible fats, carbohydrates and proteins. In another embodiment, edible fats include but are not limited to coconut oil, soy oil, and mono- and diglycerides. In another embodiment, carbohydrates include but are not limited to glucose, edible lactose and hydrolyzed search. In another embodiment, proteins which are utilized in the nutritional composition of the invention include but are not limited to soy proteins, electrodialysed whey, electrodialysed skim milk, milk whey, or the hydrolysates of these proteins.
- In another embodiment, vitamins and minerals are added to the nutritional compositions of the present invention and include but are not limited to: calcium, phosphorus, potassium, sodium, chloride, magnesium, manganese, iron, copper, zinc, selenium, iodine, and Vitamins A, E, D, C, and the B complex. Other such vitamins and minerals may also be added.
- In another embodiment, components utilized in the nutritional compositions of the present invention will be of semi-purified or purified origin. By semi-purified or purified is meant a material which has been prepared by purification of a natural material or by synthesis. In another embodiment, nutritional compositions of the present invention include but are not limited to infant formulas, dietary supplements, dietary substitutes, and rehydration compositions. In another embodiment, a nutritional composition of the present invention may also be added to food even when supplementation of the diet is not required. In another embodiment, a composition is added to food of any type including but not limited to margarines, modified butters, cheeses, milk, yogurt, chocolate, candy, snacks, salad oils, cooking oils, cooking fats, meats, fish and beverages.
- In another embodiment, a nutritional composition is an enteral nutritional product. In another embodiment, a nutritional composition is an adult or pediatric enteral nutritional product. In another embodiment, a composition is administered to adults or children experiencing stress or having specialized needs due to chronic or acute disease states. In another embodiment, a composition comprises, in addition to polyunsaturated fatty acids produced in accordance with the present invention, macronutrients, vitamins and minerals as described above. In another embodiment, the macronutrients may be present in amounts equivalent to those present in human milk or on an energy basis, i.e., on a per calorie basis.
- In another embodiment, the present invention includes an enteral formula comprising polyunsaturated fatty acids produced in accordance with the present invention. In another embodiment, an enteral formula is sterilized and subsequently utilized on a ready-to-feed basis or stored in a concentrated liquid or powder. In another embodiment, a powder is prepared by spray drying the formula prepared as indicated above, and reconstituting it by rehydrating the concentrate. In another embodiment, the present invention includes an adult and pediatric nutritional formulas. In another embodiment, adult and pediatric nutritional formulas are known in the art and are commercially available (e.g., Similac®, Ensure®, Jevity® and Alimentum® from Ross Products Division, Abbott Laboratories). In another embodiment, an oil or acid produce in accordance with the present invention may be add to any of these formulas.
- In another embodiment, a nutritional formula comprises macronutrients, vitamins, and minerals, as provided herein, in addition to the PUFAs produced in accordance with the present invention. In another embodiment, the presence of additional components helps the individual ingest the minimum daily requirements of these elements. In another embodiment, an adult and pediatric nutritional formulas comprises the PUFAs as described herein and zinc, copper, folic acid and antioxidants, or any combination thereof. In another embodiment, PUFAs produced in accordance with the present invention, or derivatives thereof, are added to a dietary substitute or supplement, particularly an infant formula, for patients undergoing intravenous feeding or for preventing or treating malnutrition or other conditions or disease states. In another embodiment, PUFAs produced in accordance with the present invention are used to alter, the composition of infant formulas in order to better replicate the PUFA content of human breast milk or to alter the presence of PUFAs normally found in a non-human mammal's milk.
- In another embodiment, parenteral nutritional compositions comprising from about 2 to about 30 weight percent fatty acids calculated as triglycerides are encompassed by the present invention. In another embodiment, other vitamins, particularly fat-soluble vitamins such as vitamin A, D, E and L-carnitine are also included. In another embodiment, a preservative such as alpha-tocopherol is added in an amount of about 0.05-0.5% by weight.
- In another embodiment, the present invention includes a PUFA produced in accordance with the present invention or host cells containing them, used as animal food supplements to alter an animal's tissue or milk fatty acid composition to one more desirable for human or animal consumption.
- In one embodiment, the polypeptides or protein of the present invention can be provided to the individual per se. In one embodiment, the polypeptides or proteins of the present invention can be provided to the individual as part of a pharmaceutical composition where it is mixed with a pharmaceutically acceptable carrier.
- In one embodiment, a “pharmaceutical composition” refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism. In one embodiment, “active ingredient” refers to the polypeptide or protein sequence of interest.
- In one embodiment, the present invention provides combined preparations. In one embodiment, “a combined preparation” defines especially a “kit of parts” in the sense that the combination partners as defined above can be dosed independently or by use of different fixed combinations with distinguished amounts of the combination partners i.e., simultaneously, concurrently, separately or sequentially. In some embodiments, the parts of the kit of parts can then, e.g., be administered simultaneously or chronologically staggered, that is at different time points and with equal or different time intervals for any part of the kit of parts. The ratio of the total amounts of the combination partners, in some embodiments, can be administered in the combined preparation. In one embodiment, the combined preparation can be varied, e.g., in order to cope with the needs of a patient subpopulation to be treated or the needs of the single patient which different needs can be due to a particular disease, severity of a disease, age, sex, or body weight as can be readily made by a person skilled in the art.
- In one embodiment, the phrase “physiologically acceptable carrier” refers to a carrier or a diluent that does not cause significant irritation to a tissue such as a plant tissue or a cell such as a plant cell; and does not abrogate the biological activity and properties of the protein or polynucleotide of the invention. An adjuvant is included under these phrases. In one embodiment, one of the ingredients included in the physiologically acceptable carrier can be for example polyethylene glycol (PEG), a biocompatible polymer with a wide range of solubility in both organic and aqueous media (Mutter et al. (1979).
- In one embodiment, “excipient” refers to an inert substance added to the composition to further facilitate administration of an active ingredient. In one embodiment, excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.
- Techniques for formulation and administration of peptide to plants or in-vitro are known to one of skill in the art.
- In one embodiment, compositions of the present invention are manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, or lyophilizing processes.
- In one embodiment, compositions for use in accordance with the present invention is formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the proteins/polynucleotides into preparations. In one embodiment, formulation is dependent upon the method of administration chosen.
- The compositions also comprise, in some embodiments, preservatives, such as benzalkonium chloride and thimerosal and the like; chelating agents, such as edetate sodium and others; buffers such as phosphate, citrate and acetate; tonicity agents such as sodium chloride, potassium chloride, glycerin, mannitol and others; antioxidants such as ascorbic acid, acetylcystine, sodium metabisulfote and others; aromatic agents; viscosity adjustors, such as polymers, including cellulose and derivatives thereof; and polyvinyl alcohol and acid and bases to adjust the pH of these aqueous compositions as needed. The compositions also comprise, in some embodiments, local anesthetics or other actives. The compositions can be used as sprays, mists, drops, and the like.
- Additionally, suspensions of the active ingredients, in some embodiments, are prepared as appropriate oily or water based suspensions. Suitable lipophilic solvents or vehicles include, in some embodiments, fatty oils such as sesame oil, or synthetic fatty acid esters such as ethyl oleate, triglycerides or liposomes. Aqueous injection suspensions contain, in some embodiments, substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol or dextran. In another embodiment, the suspension also contains suitable stabilizers or agents, which increase the solubility of the active ingredients to allow for the preparation of highly concentrated solutions.
- In another embodiment, the proteins as described herein can be delivered in a vesicle, in particular a liposome (see Langer, Science 249:1527-1533 (1990); Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, N.Y., pp. 353-365 (1989); Lopez-Berestein, ibid., pp. 317-327; see generally ibid).
- In some embodiments, the protein as described herein is in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water based solution, before use. In another embodiment, compositions are contained in a container with attached atomizing means.
- In some embodiments, compositions suitable for use in context of the present invention include compositions wherein the proteins or oligonucleotides are contained in an amount effective to achieve the intended purpose. In one embodiment, determination of the effective amount is well within the capability of those skilled in the art.
- Some examples of substances which can serve as carriers or components thereof are sugars, such as lactose, glucose and sucrose; starches, such as com starch and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and methyl cellulose; powdered tragacanth; malt; gelatin; talc; solid lubricants, such as stearic acid and magnesium stearate; calcium sulfate; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and oil of theobroma; polyols such as propylene glycol, glycerine, sorbitol, mannitol, and polyethylene glycol; alginic acid; emulsifiers, such as the Tween brand emulsifiers; wetting agents, such sodium lauryl sulfate; coloring agents; flavoring agents; tableting agents, stabilizers; antioxidants; preservatives; pyrogen-free water, isotonic saline; and phosphate buffer solutions. The choice of a pharmaceutically-acceptable carrier to be used in conjunction with the compound is basically determined by the way the compound is to be administered. If the subject compound is to be injected, in one embodiment, the pharmaceutically-acceptable carrier is sterile, physiological saline, with a blood-compatible suspending agent, the pH of which has been adjusted to about 7.4.
- In addition, the compositions further comprise binders (e.g., acacia, cornstarch, gelatin, carbomer, ethyl cellulose, guar gum, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, povidone), disintegrating agents (e.g., cornstarch, potato starch, alginic acid, silicon dioxide, croscarmelose sodium, crospovidone, guar gum, sodium starch glycolate), buffers (e.g., Tris-HCl, acetate, phosphate) of various pH and ionic strength, additives such as albumin or gelatin to prevent absorption to surfaces, detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile acid salts), protease inhibitors, surfactants (e.g., sodium lauryl sulfate), permeation enhancers, solubilizing agents (e.g., glycerol, polyethylene glycerol), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite, butylated hydroxyanisole), stabilizers (e.g., hydroxypropyl cellulose, hyroxypropylmethyl cellulose), viscosity increasing agents(e.g., carbomer, colloidal silicon dioxide, ethyl cellulose, guar gum), sweeteners (e.g., aspartame, citric acid), preservatives (e.g., Thimerosal, benzyl alcohol, parabens), lubricants (e.g., stearic acid, magnesium stearate, polyethylene glycol, sodium lauryl sulfate), flow-aids (e.g., colloidal silicon dioxide), plasticizers (e.g., diethyl phthalate, triethyl citrate), emulsifiers (e.g., carbomer, hydroxypropyl cellulose, sodium lauryl sulfate), polymer coatings (e.g., poloxamers or poloxamines), coating and film forming agents (e.g., ethyl cellulose, acrylates, polymethacrylates) and/or adjuvants.
- The compositions also include incorporation of the proteins or oligonucleotides of the invention into or onto particulate preparations of polymeric compounds such as polylactic acid, polglycolic acid, hydrogels, etc., or onto liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts, or spheroplasts.) Such compositions will influence the physical state, solubility, stability, rate of in vivo release, and rate of in vivo clearance.
- Also comprehended by the invention are particulate compositions coated with polymers (e.g. poloxamers or poloxamines) and the proteins or oligonucleotides of the invention coupled to antibodies directed against tissue-specific receptors, ligands or antigens or coupled to ligands of tissue-specific receptors.
- In some embodiments, the proteins or oligonucleotides of the invention modified by the covalent attachment of water-soluble polymers such as polyethylene glycol, copolymers of polyethylene, glycol and polypropylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone or polyproline. In another embodiment, the modified proteins or oligonucleotides of the invention exhibit substantially longer half-lives in blood following intravenous injection than do the corresponding unmodified compounds. In one embodiment, modifications also increase the proteins or oligonucleotides solubility in aqueous solution, eliminate aggregation, enhance the physical and chemical stability of the compound, and greatly reduce the immunogenicity and reactivity of the compound. In another embodiment, the desired in vivo biological activity is achieved by the administration of such polymer-compound abducts less frequently or in lower doses than with the unmodified compound.
- Additional objects, advantages, and novel features of the present invention will become apparent to one ordinarily skilled in the art upon examination of the following examples, which are not intended to be limiting. Additionally, each of the various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below finds experimental support in the following examples.
- Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are thoroughly explained in the literature. See, for example, “Molecular Cloning: A laboratory Manual” Sambrook et al., (1989); “Current Protocols in Molecular Biology” Volumes I-III Ausubel, R. M., ed. (1994); Ausubel et al., “Current Protocols in Molecular Biology”, John Wiley and Sons, Baltimore, Maryland (1989); Perbal, “A Practical Guide to Molecular Cloning”, John Wiley & Sons, New York (1988); Watson et al., “Recombinant DNA”, Scientific American Books, New York; Birren et al. (eds) “Genome Analysis: A Laboratory Manual Series”, Vols. 1-4, Cold Spring Harbor Laboratory Press, New York (1998); methodologies as set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057; “Cell Biology: A Laboratory Handbook”, Volumes I-III Cellis, J. E., ed. (1994); “Culture of Animal Cells—A Manual of Basic Technique” by Freshney, Wiley-Liss, N.Y. (1994), Third Edition; “Current Protocols in Immunology” Volumes I-III Coligan J. E., ed. (1994); Stites et al. (eds), “Basic and Clinical Immunology” (8th Edition), Appleton & Lange, Norwalk, Conn. (1994); Mishell and Shiigi (eds), “Selected Methods in Cellular Immunology”, W. H. Freeman and Co., New York (1980); available immunoassays are extensively described in the patent'and scientific literature, see, for example, U.S. Pat. Nos. 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771 and 5,281,521; “Oligonucleotide Synthesis” Gait, M. J., ed. (1984); “Nucleic Acid Hybridization” Hames, B. D., and Higgins S. J., eds. (1985); “Transcription and Translation” Hames, B. D., and Higgins S. J., eds. (1984); “Animal Cell Culture” Freshney, R. I., ed. (1986); “Immobilized Cells and Enzymes” IRL Press, (1986); “A Practical Guide to Molecular Cloning” Perbal, B., (1984) and “Methods in Enzymology” Vol. 1-317, Academic Press; “PCR Protocols: A Guide To Methods And Applications”, Academic Press, San Diego, Calif. (1990); Marshak et al., “Strategies for Protein Purification and Characterization—A Laboratory Course Manual” CSHL Press (1996); all of which are incorporated by reference. Other general references are provided throughout this document.
- Axenic cultures of P. incisa were cultivated on BG-11 nutrient medium in 250 ml Erlenmeyer glass flasks in an incubator shaker at controlled temperature (25° C.) and illumination (115 μmol quanta m−2 S−1) under an air/CO2 atmosphere (99:1, v/v) and a speed of 170 rpm. For N-starvation experiments, cells of daily-diluted cultures were collected by centrifugation, washed three times in sterile DDW and resuspended in N-free BG11 medium. To prepare N-free BG-11 medium, sodium nitrate was omitted and ferric ammonium citrate was substituted with ferric citrate. Biomass was sampled at
time 0, and in 1.5, 3, 7 and 14 days from the onset of N-starvation for determination of growth parameters, and was further used for fatty acid analysis and RNA isolation. Duplicate samples were collected from 3 separate flasks for each time point and measurement. - Dry weight and chlorophyll contents were determined as previously described in A. E. Solovchenko, I. Khozin-Goldberg, Z. Cohen, M. N. Merzlyak, Carotenoid-to-chlorophyll ratio as a proxy for assay of total fatty acids and arachidonic acid content in the green micro-alga, Parietochloris incisa, J. Appl. Phycol. (2008) 361-366.
- Aliquots of the cultures were filtered through a glass fiber filter (GF-52, Schleicher & Schuell, Germany); cells were collected by scraping and immediately flash-frozen in liquid nitrogen and stored at −80° C. for further use. Total RNA was isolated by the procedure described by Bekesiova et al. (I. Bekesiova, J. P. Nap, L. Mlynarova, Isolation of high quality DNA and RNA from leaves of the carnivorous plant Drosera rotundifolia, Plant. Mol. Biol. Rep. 17 (1999) 269-277), with minor modifications. Three independent RNA isolations were conducted for each time point. The total RNA samples were treated with RNAase-free Baseline-ZERO™ DNAase (Epicentre Technologies, Madison, Wis., USA) before being used in cDNA synthesis for real-time PCR experiments.
- Partial sequences of the Δ12, Δ6, Δ5 desaturase and actin genes were obtained by PCR (ReddyMix PCR Master Mix, Thermo Scientific, Surrey, UK) using the degenerated primers listed in the Table 1. To generate the full-length cDNAs, 3′- and 5′-rapid amplification of the cDNA ends (RACE) was performed using a BD Smart™ RACE cDNA Amplification Kit (BD Biosciences Clontech, Foster City, Calif., USA). Gene specific primers were designed (Table 1) and RACE PCR reactions were conducted using 5′ and 3′-RACE-Ready cDNAs made from 1 μg total RNA of N-starved cells with 50×
BD Advantage 2 polymerase mix (Clontech Laboratories Inc., Mountain View, Calif., USA). The PCR products of the expected sizes were excised, purified from the gel (Nucleo Spin Extract II purification kit, Machery-Nagel, Duren, Germany) and ligated into a pGEM T-Easy vector (Promega, Madison, Wis., USA). The full-length cDNAs were assembled based on the sequences of the 5′ and 3′ RACE fragments. -
TABLE 1 Primers used for obtaining partial, 5′ and 3′ end fragments of actin, Δ12, A6 and A5 desaturase genes of P. incisa followed by full-length assembly SEQ ID Gene Forward/Reverse primer (Sequence 5′ to 3′) NO: Primers used for partial sequence DesΔ12 CAC MYC VTS THC VWG CTG CTG VWB CCC CAC (FWD) 9 CTG CCC GAA GTT GAC CGC GGC GTG CTG (REV) 10 DesΔ6 TGG TGG AAR CAY AAR CAY AAY (FWD) 11 GCG AGG GAT CCA AGG RAA NAR RTG RTG YTC (REV) 12 DesΔ5 ATH RAI GRI AAR GTI TAY GAY GT (FWD) 13 GGI AYI KWI TSD ATR TCI GGR TC (REV) 14 Actin AGA TCT GGC ACC ACA CCT TCT TCA (FWD) 15 TGT TGT TGT AGA GGT CCT TGC GGA (REV) 16 Primers used for 5′ and 3′ RACE amplification DesΔ12 CCACATAGCGGCACAGGCTGAAATC (FWD) 17 GCTCTGGGAGGATTTCAGCCTGTGC (REV) 18 DesΔ6 GACACAATCTGGGCCGTCACAAAGTC (FWD) 19 GGACTTTGTGACGGCCCAGATTGTGTC (REV) 20 DesΔ5 ACTGACCCTCCTCTGTGTCCTCTTCG (FWD) 21 TGTACGCCAAGTCGCTGACCATCC (REV) 22 Restriction sites*/ SEQ ID Primers used for full-length cloning and yeast transformations NO: DesΔ12 TGGAATTC AAAATGGGGAAAGGAGGCTG (FWD) EcoRI/23 CTGTCTAGA TCAAGCGCGGAACCACAGG Xba I/24 DesΔ6 TCGAATTCAAAATGTGCCAGGGACAGG (FWD) EcoRI/25 GGCTCTAGA CTAGGCCTCAGCTGCCACG XbaI/26 DesΔ5 CCAAAGCTTAAAATGATGGCTGTAACAGA (FWD) HindIII/27 GCTCTAGA CTATCCCACGGTGGCCA XbaI/28 - The open reading frames (ORFs) encoding for the Δ2, Δ6, and Δ5 desaturases were amplified using PfuUltra II fusion HS DNA polymerase (Stratagene, La Jolla, Calif., USA) with the respective primer pairs (Table 1). The forward primers contained a restriction site (underlined) and a yeast translation consensus (double underlined) followed by ATG. The reverse primers contained a restriction site (underlined) and a stop codon (double underlined). Following restriction and ligation to the pYES2 vector (Invitrogen, Carlsbad, Calif., USA), the constructs were used to transform S. cerevisiae strain W303 by the PEG/lithium acetate method [R. D. Gietz, R. A. Woods, Yeast Transformation by the LiAc/SS Carrier DNA/PEG Method, in: W. Xiao (Ed.), Yeast Protocols, Second Edition, vol. 313, Methods in Molecular Biology, Humana Press Inc, Totowa, N.J., 2006, pp.107-120]. The yeast cells harboring the empty pYES2 vector were used as control. Transformants were selected by uracil prototrophy on yeast synthetic medium (YSM) lacking uracil (Invitrogen, Carlsbad, Calif., USA). For functional expression, a minimal selection medium containing 2% (w/v) raffinose was inoculated with the pYPiDesΔ12, pYPiDesΔ6 or pYPiDesΔ5 transformants and grown at 27° C. for 24 h in a water bath shaker. Five ml of sterile YSM, containing 1% (w/v) Tergitol-40 and 250 μM of the appropriate fatty acid substrate was inoculated with raffinose-grown cultures to obtain an OD of 0.2 at 600 nm. Expression was induced by adding galactose to a final concentration of 2% (w/v) and cultures were further grown at 27° C. for 48 h. Cells were harvested by centrifugation, washed twice with 0.1% NaHCO3, freeze-dried and used for fatty acid analysis.
- To generate the full-length cDNA of the putative PUFA elongase, 3′-and 5′-rapid amplification of the cDNA ends (RACE) was performed using a BD smart™ RACE cDNA Amplification Kit (BD Biosciences Clontech, Foster City, Calif.) according to the manufacturer's manual. To amplify the 5′-end, the reverse gene-specific primers (GSP) 5′-CCCGGCTGCTGCCATGCTTCTGTG (EL5R1) (SEQ ID NO: 29) 5′-TGGGGTAGGGAGAGTAGGCCCAAGT (EL5RN) (SEQ ID NO: 30) were designed using the Primer3 online software (http://frodo.wi.mit.edu). Based on the nucleotide sequence of the obtained 5′-end fragment, two forward GSPs, 5′-GCCTACATGTCCTCTGCCGCCTGCTA (EL3R1) (SEQ ID NO: 31) and the nested, 5′-GCGGGACATGGGAGGGCTCATCTATACC (EL3R2) (SEQ ID NO: 32), were constructed to amplify the 3′-end of the target gene. RACE PCR reactions were conducted using 5′ and 3′-RACE-Ready cDNAs made from lug total RNA of N-starved cells with 50×
BD Advantage 2 polymerase mix (Clontech Laboratories Inc., Mountain View, Calif.). The PCR products of the expected size were excised and purified from the gel (NucleoSpin Extract II purification kit, Machery-Nagel, Duren, Germany) and ligated into a pGEM T-Easy vector (Promega, Madison, Wis.). The full length cDNA corresponding to the P. incisa putative PUFA elongase (designated PiELO1) was assembled from the 5′ and 3′ RACE fragments and its ORF was further subcloned into a pYES2 vector (Invitrogen, Carlsbad, Calif.). - The ORF encoding for PiELO1 was amplified using PfuUltra II fusion HS DNA polymerase (Stratagene, La Jolla, Calif.) with the forward primer, 5′-AGGAATTCAAAATGGCATTGACGGCGGCCT (PUFAEL5RES1) (SEQ ID NO: 33), containing a restriction site (underlined) and a yeast translation consensus followed by ATG (double underlined) and the
reverse primer 5′-CATTCTAGATTACTGCAGCTTTTGCTTGGCTGC (PUFAEL3RES2) (SEQ ID NO: 34) containing a restriction site (underlined) and a stop codon (double underlined). The amplified sequence was then restricted with EcoRI and XbaI (NEB, Ipswich, Mass.). The expected bands were gel-purified with NucleoSpin Extract II purification kit (Machery-Nagel GmbH, Duren, Germany) and ligated into a EcoRI-Xbal cut pYES2 vector, yielding YpPiELO1. Saccharomyces cerevisiae strain W303 was transformed with YpPiELO1 by the PEG/lithium acetate method. The yeast cells harboring the empty pYES2 vector were used as control. Transformants were selected by uracil prototrophy on yeast synthetic medium (YSM) lacking uracil (Invitrogen, Carlsbad, Calif.). For functional expression, a minimal selection medium containing 2% (w/v) raffinose was inoculated with the YpPiELO1-transformants and grown at 27° C. for 24 h in a water bath shaker. Five ml of sterile YSM, containing 1% (w/v) Tergitol-40 and 250 μM of the appropriate fatty acid was inoculated with raffinose-grown cultures to obtain an OD of 0.2 at 600 nm. Expression was induced by adding galactose to a final concentration of 2% (w/v) and cultures were further grown at 27° C. for 48 h. Cells were harvested by centrifugation, washed twice with 0.1% NaHCO3, freeze-dried and used for fatty acid analysis. - Real-Time Quantitative PCR primer pairs were designed for the PiELOJ and the house keeping gene 18S SSU rRNA using the PrimerQuest tool (http://test.idtdna.com/Scitools/Applications/Primerquest/). Parameters were set for a primer length of 19 to 26 bp, primer melting temperature of 60.0±1.0° C., and amplicon length of 90 to 150 bases. Primer pairs were validated using seven serial fifty-fold dilutions of cDNA samples and standard curves were plotted to test for linearity of the response. The primer pairs and primer concentrations with reaction efficiencies of 100±10% were chosen for quantitative RT-PCR analysis of relative gene expression. The nucleotide sequences and characteristics of primers used for quantitative RT-PCR analysis are presented in Table 2.
-
TABLE 2 Parameters of the primers used in RTQPCR reactions Amplicon PCR Forward primer size efficiency Gene Reverse primer (bp) (%) PiELO1 AAGCTGTACGAGTTTGTGGATACGCT (SEQ ID NO: 35) (FWD) 95 92.3 GGATATGGAAGCGTGGTGGTAGA (SEQ ID NO: 36) (REV) 18S TGAAAGACGAACTTCTGCGAAAGCA (SEQ ID NO: 37) (FWD) 120 96.8 SSU AGTCGGCATCGTTTATGGTTGAGA (SEQ ID NO: 38) (REV) rRNA - The mean fold changes in gene expression were calculated according to the 2-ΔΔCt method using the average of threshold cycle (Ct) values from triplicate cDNA-primer samples. The ACt followed by the AACt was calculated from the average Ct values of the target and the endogenous genes. The transcript abundance of the PiELO1 gene was normalized to the endogenous control 18S SSU rRNA gene. The fold-change in gene expression was calculated using 2-ΔΔCt to find the expression level of the target gene which was normalized to the endogenous gene, relative to the expression of the target gene at
time 0. - Fatty acid methyl esters (FAMES) were obtained by transmethylation of the freeze-dried P. incisa or yeast biomass, with dry methanol containing 2% H2SO4 (v/v) and heating at 80° C. for 1.5 h while stirring under an argon atmosphere. Gas chromatographic analysis of FAMEs was performed on a Thermo Ultra Gas chromatograph (Thermo Scientific, Italy) equipped with PTV injector, FID detector and a fused silica capillary column (30 m×0.32 mm; ZB WAXplus, Phenomenex). FAMEs were identified by co-chromatography with authentic standards (Sigma Chemical Co., St. Louis, Mo.; Larodan Fine Chemicals, Malmö, Sweden) and FAME of fish oil (Larodan Fine Chemicals). Each sample was analyzed in duplicates of three independent experiments. The structures of fatty acids were confirmed by GC-MS of their pyrrolidine derivatives [W.W. Christie, The analysis of fatty acids in: W.W. Christie (Ed.), Lipid analysis Isolation, separation, identification and structural analysis of lipids, vol. 15, Third edition, The Oily Press, Bridgewater, England, 2003, pp. 205-225] on HP 5890 equipped with a mass selective detector (HP 5971A) utilizing a HP-5 capillary column and a linear temperature gradient from 120 to 300° C.
- The biomass of S. cerevisiae was heated with isopropanol at 80° C. for 10 min and lipids were extracted by the method of Bligh-Dyer (1959) [E. G. Bligh, W. J. Dyer, A rapid method of total lipid extraction and purification, Can. J. Biochem. Physiol. 37 (1959) 911-917]. Total lipid extract was separated into neutral and polar lipids by silica Bond-Elute cartridges (Varian, Calif.) using 1% of ethanol in chloroform (v/v) and methanol to elute neutral and polar lipids, respectively [Z. Cohen, S. Didi, Y. M. Heimer, Overproduction of γ-linolenic and eicosapentaenoic acids by algae, Plant Physiol. 98 (1992) 569-572].
- Polar lipids were separated into individual lipids by two dimensional TLC on
Silica Gel 60 glass plates (10×10 cm, 0.25 mm thickness (Merck, Darmstadt, Germany) according to Khozin et al. [I. Khozin, D. Adlerstein, C. Bigogno, Y. M. Heimer, Z. Cohen, Elucidation of the Biosynthesis of Eicosapentaenoic Acid in the Microalga Porphyridium cruentum (II. Studies with Radiolabeled Precursors), Plant Physiol. 114 (1997) 223-230]. Neutral lipids were resolved with petroleum ether:diethyl ether:acetic acid (70:30:1, v/v/v). Lipids on TLC plates were visualized by brief exposure to iodine vapors, scraped from the plates and were transmethylated for the fatty acid analysis as previously described. - Template cDNA for real-time quantitative PCR (RTQPCR) was synthesized using 1 μg of total RNA in a total volume of 20-μl, using oligo dT primer (Reverse-
iT TM 1st Strand Synthesis Kit, ABgene, Surrey, UK). Each 20-μL cDNA reaction was then diluted 3-fold with PCR grade water. - Real-Time Quantitative PCR (RTQPCR) primer pairs were designed for the PiDes12, PiDes6, and PiDes5 genes and the house keeping gene actin, PiAct using the PrimerQuest tool (http://test.idtdna.com/Scitools/Applications/Primerquest/). Primer pairs were validated as described by Iskandarov et al. [U. Iskandarov, I. Khozin-Goldberg, R. Ofir, Z. Cohen, Cloning and Characterization of the Δ6 Polyunsaturated Fatty Acid Elongase from the Green Microalga Parietochloris incisa, Lipids 44 (2009) 545-554]. The nucleotide sequences of primer pairs and the amplicon sizes are presented in Table 3.
-
TABLE 3 Primers used in RTQPCR experiments Forward primer/ Amplicon Gene Reverse primer size (bp) PiDes12 5′-GAAGCACCACCAAGGATGAGGT (SEQ ID NO: 39) (FWD) 112 5′-AGCGAGACGAAGATGACCAGGAA (SEQ BD NO: 40) (REV) PiDes6 5′-ACTTCCTGCACCACCAGGTCTTC (SEQ ID NO: 41) (FWD) 112 5′-TCGTGCTTGCTCTTCCACCAGT (SEQ ID NO: 42) (REV) PiDes5 5′-TAAGTGCCAGGGCTGTGCTAGA (SEQ ID NO: 43) (FWD) 110 5′-GAACTGACCCTCCTCTGTGTCCT (SEQ ID NO: 44) (REV) PiAct 5′-CGTCCAGCTCCACGATTGAGAAGA (SEQ ID NO: 45) (FWD) 154 5′-ATGGAGTTGAAGGCGGTCTCGT (SEQ ID NO: 46) (REV) - The partial sequences of the Δ12, Δ6 and Δ5 desaturase gene homologues were isolated using degenerate oligonucleotides (Table 1) targeting conserved amino acid motifs identified in algae, lower plants and fungi. A partial sequence of the actin gene was amplified to be used as a house keeping gene in RTQPCR experiments.
- Partial sequences of 503, 558 and 636 bp, corresponding to the Δ12, Δ6, and Δ5 desaturase genes, respectively, were used for designing gene specific primers that were used to amplify the 5′- and 3′-ends of the expected genes. Assembling the 5′ and 3′ RACE PCR product sequences resulted in the identification of three cDNA clones with sequence homologies to known Δ12, Δ6, and Δ5 desaturase genes. The full-length cDNAs corresponding to Δ12, Δ6, and Δ5 desaturase genes were thus designated PiDes12, PiDes6, and PiDes5. The ORFs for PiDes12, PiDes6 and PiDes5 genes were 1140, 1443, and 1446 by in length, respectively, coding for the corresponding predicted proteins of 380, 481 and 482 amino acids. The predicted amino acid sequence of PiDes12 is 64% and 62% identical to that of Chlorella vulgaris (BAB78716) and Chlamydomonas reinhardtii (XP—001691669), respectively, while it shares more than 50% identity with those of higher plants. It contains three conserved histidine motifs HxxxH, HxxHII and HxxHH. The deduced amino acid sequence of PiDes6 is 52% and 51% identical to those of the Δ6 desaturases from the liverwort M. polymorpha (AAT85661) and the moss Ceratodon purpureus, respectively (CAB94993). It is also 45% identical to the M. alpina Δ6 desaturase (ABN69090). PiDes5 shares 55 and 51% identity with the Δ5 desaturase from the microalgae M. squamata (CAQ30478), and O. tauri (CAL57370), respectively, and 54% with that from M. polymorpha (AAT85663) but is only 36% identical to the M. alpina Δ5 desaturase (AAC72755). Both PiDes6 and PiDes5 contain N-terminal fused cytochrome b5 domain including the HPGG motif and the three histidine boxes found to be conserved in front-end desaturases. The three characteristically conserved histidine-rich motifs with amino acid patterns of HD(E)xxH, HxxHH,, QxxHH in Δ6 desaturases, and HDxxH, QHxxxHH, QxxHH in Δ5 desaturases are also present in PiDes6 and PiDes5, respectively (
FIG. 1 ). - An unrooted phylogenetic tree (
FIG. 2 ) of PiDes12, PiDes6, PiDes5 and several functionally characterized desaturases from all three groups were constructed to identify their functional and phylogenetic relationships by the neighbor-joining program in MEGA4 [K. Tamura, J. Dudley, M. Nei, S. Kumar, MEGA4: Molecular evolutionary genetics analysis (MEGA) software version 4.0, Mol. Biol. Evol. 24 (2007) 1596-1599]. The deduced amino acid sequence of PiDes12 is closely related to Δ12 desaturases of green algae and very similar to those of higher plants. The sequences of PiDes6 and PiDes5 cluster with Δ6 and Δ5 desaturases, respectively, from algae, moss and fungi. PiDes6 is highly similar to the M. polymorpha (MpDEs6) and P. tricornutum (PtD6p) Δ6 desaturases, while PiDes5 appears to be closely related to the Δ5 desaturase from the moss M. polymorpha and shares more sequence similarity with the Δ5 desaturase from the chlorophytes M. squamata and O. tauri than with those of fungal origin. However, both Δ6 or Δ5 desaturases from M. squamata and O. tauri appear to be structurally more similar to each other than to any of the known desaturases from either group. - The functional activities of the proteins encoded by PiDes12, PiDes6 and PiDes5 were examined by heterologous expression in S. cerevisiae. To this aim, the pYES2 constructs pYPiDes12, pYPiDes6 and pYPiDes5 containing the ORFs for PiDes12, PiDes6, and PiDes5, respectively, were transformed into S. cerevisiae. GC analysis of the FAMEs of the yeast transformed with pYPiDes12, revealed an appearance of a small peak corresponding to 18:2 (0.3% of TFA; not shown). An attempt to improve the expression of the recombinant protein and to increase the activity by the modification of yeast translation consensus was not successful. The yeast cells harboring the empty vector, pYES2 (control) did not demonstrate desaturation activity on the added substrates (
FIG. 3 ). - PiDes6 and PiDes5 expressions were induced in the presence of the main ω6 substrates for Δ6 or Δ5 fatty acid desaturases, 18:2ω6 and 20:3ω6, respectively. New peaks corresponding to 18:3ω6 and 20:4ω6, respectively, were detected, confirming the predicted function of PiDes6 and PiDes5. The expression of PiDes6 in the presence of 18:3ω3 resulted in the appearance of the corresponding Δ6 desaturation product 18:4ω3 (
FIG. 3 ). PiDes6 desaturase was neither active on endogenous yeast fatty acids nor on external 18:1. PiDes6 was not active on 20:36ω3 either, whereas PiDes5 desaturated it to the non-methylene-interrupted 20:4Δ5,11,14,17. PiDes5 converted 20:4ω3 into the respective Δ5 product, 20:5ω3 (EPA) as well as the added 18:1 into the non-methylene-interrupted 18:2Δ5,9 (FIG. 3 ). The Δ5 position on 18:2Δ5,9 was determined by a characteristic peak of m/z=180 on the GC-MS spectra of its pyrrolidine derivative (not shown). The presence of 18:2Δ5,9 was also observed in the chromatograms of the PiDes5 transformant supplied with C20 fatty acids. In addition, a tiny peak, tentatively identified as 18:4Δ5,9,12,15 was present on the chromatogram of the PiDes5 transformant fed with 18:30 (Table 4). -
TABLE 4 Conversion percent of the supplied fatty acids by PiDes6 and PiDes5 in S. cerevisiae Fatty acid Desaturase product and conversion (%)* substrate PiDesΔ6 PiDesΔ5 18:1Δ9 — 18:2Δ5, 9 (4.2) 18:2Δ9, 12 18:2Δ6, 9, 12 (5.1) — 18:3Δ9, 12, 15 18:4Δ6, 9, 12, 15 (4.5) 18:4Δ5, 9, 12, 15** (1.4) 18:3Δ6, 9, 12 — 20:3Δ11, 14, 17 — 20:4Δ5, 11, 14, 17 (10.0) 20:3Δ8, 11, 14 — 20:4Δ5, 8, 11, 14 (16.4) 20:4Δ8, 11, 14, 17 20:5Δ5, 8, 11, 14, 17 (17.1) *calculated as the ratio of product/(substrate + product) **tentative identification - A kinetic analysis of ARA emergence was conducted in total fatty acids of the PiDes5 transfomiant during 24 h following the addition of DGLA. Results showed that ARA peak was evident already after 3 h (corresponding to 10.9% substrate conversion) with a gradual but slow increase (up to 15.1% conversion) after 24 h. Fatty acid analysis of the major polar and neutral lipids of the yeast transformed with pYPiDes5 was performed 24 h after feeding with 20:3ω6 to study the pattern of distribution of ARA within individual lipids. In the transformed yeast, ARA appeared in all major phospholipids (Table 4), with the highest proportion detected in PC. It was also present in the neutral lipids, TAG, free fatty acids (FFA), diacylglycerol (DAG) and sterol esters (SE). Taking into account that PC, a major phospholipid of S. cerevisiae, constituted for about 16% of total lipids (Table 5), it is obvious that PC allocated the main part of ARA attached to phospholipids.
-
TABLE 5 Fatty acid composition and distribution of individual lipid classes of S. cerevisiae expressing the PiDes5 ORF. Fatty acid composition (% of total fatty acids) % % 20:4ω6 Lipid 16:0 16:1 18:0 18:1ω9 18:2Δ5, 9 20:3ω6 20:4ω6 conversion of TL* % TL TAG 17.4 27.6 9.6 23.0 0.4 19.6 2.0 9.3 61.3 55.2 SE 10.5 38.5 7.1 30.4 0.0 12.2 1.1 8.4 3.6 1.8 DAG 27.9 16.3 21.9 24.3 0.1 7.2 2.0 24.0 1.6 1.4 FFA 26.1 20.3 23.5 8.9 0.2 17.2 3.6 17.2 5.5 9.1 PC 19.7 30.1 9.3 24.3 0.7 11.6 3.6 24.2 15.7 25.7 PE 21.7 34.9 2.8 32.8 0.5 5.0 1.6 24.6 3.2 2.3 PI + PS 34.0 20.8 12.4 26.5 0.2 4.6 1.1 18.1 9.0 4.4 *TL—total lipids - To use actin as a house-keeping gene in quantitative real-time PCR experiments, a partial fragment (503 bp) of the P. incisa actin gene was amplified using the primers whose design was based on the C. reinhardtii actin cDNA (XM—001699016). Indeed, the expression level of the actin gene did not significantly change throughout the nitrogen starvation. PiDes12, PiDes6, and PiDes5 were upregulated following the transfer to Nitrogen starvation, reaching the highest expression level on
day 3 and decreasing thereafter to a level about 15 to 20 fold higher than that at time 0 (FIG. 4 ). Both the PiDes12 and PiDes5 genes were expressed at levels approximately 65 to 70 fold higher onday 3 than attime 0, while the PiDes6 transcript was about 45 fold higher (FIG. 4 ). The expression patterns of PiDes12, PiDes6, and PiDes5 correlated with the enhanced biosynthesis of ARA in P. incisa cells (Table 6). -
TABLE 6 Major fatty acid composition of P. incisa cells grown under N-starvation Time Fatty acid composition (% of total fatty acids) TFA (d) 16:0 16:1 16:2 16:3 18:0 18:1 18:2 18:3ω6 18:3ω3 20:3ω6 20:4ω6 20:5ω3 (% DW) 0 19.1 5.6 4.1 2.9 3.1 9.1 20.1 1.2 6.0 0.5 23.0 0.7 6.4 1.5 15.9 3.1 2.3 2.1 3.8 15.6 15.6 2.1 2.9 1.0 30.3 0.6 8.7 3 12.7 2.3 1.5 1.9 3.8 15.2 13.5 1.6 2.0 0.9 39.7 0.6 11.0 7 10.7 1.0 0.6 1.1 3.5 14.9 10.0 1.1 0.9 1.0 50.0 0.5 21.2 14 9.0 0.2 0.3 0.8 3.1 13.4 8.8 0.9 0.6 0.9 56.9 0.6 29.0 - The BLASTX analysis (http://www.ncbi.nlm.nih.gov/blast) of clones obtained through subtractive hybridization revealed a clone of 141 bp whose putative amino acid sequence was highly homological to the C-terminal region of PUFA elongases. Using GSP primers, the 870 by 5′-end fragment was amplified and the sequence information was used to obtain the 3′ end fragment from the 3′ RACE Ready cDNA. Alignment of the 800 by 3′-end sequence with that of the 5′-end fragment provided an overlapping nucleotide sequence and included the partial 141 bp sequence, thus confirming the amplification of both ends of the expected gene. The assembled complete 867 by cDNA sequence, designated as PiELO1, preceded and followed by 22 and 150 by nucleotides at 5′ and 3′ UTR, respectively. PiELO1 contained an ORF of 289 predicted amino acid residues consistent with functionally characterized PUFA elongase ORFs from fungi, lower plants and algae (
FIG. 5 ). The deduced amino acid sequence of the PiELO1 was 50% identical to O. tauri and M. polymorpha Δ6 PUFA elongase, while sharing 48 and 44% identity with P. patens Δ6 elongase and M. polymorpha Δ5 elongase, respectively. The PiELO1 is also similar, yet with a lower score, to Δ6 elongases of fungal origin. It shares 40 and 36% identity with the Δ6 PUFA elongases of Thraustochytrium and M. alpina (not included in the alignment), respectively. - The predicted amino acid sequence of the PiELO1 contained four conserved motifs that are characteristic for PUFA elongases (
FIG. 5 , highlighted). The hydropathy plot of the PiELO1 deduced amino acid sequences was obtained using the algorithm available in the DAS transmembrane prediction server (http://www.sbc.su.se/˜miklos/DAS/). The two strictly hydrophobic transmembrane domains were found about 50 amino acids downstream and upstream from the N and C termini, respectively, while the two less hydrophobic domains were located about 100 amino acids downstream and upstream from the N and C termini, respectively (FIG. 6 ). - An unrooted phylogenetic tree of the PiELO1 and several functionally characterized PUFA elongases was constructed to identify their functional and phylogenetic relationships by the neighbor-joining program in MEGA4. According to
FIG. 7 one can see that PiELO1 falls into a group of PUFA elongases of lower eukaryotes. Although the group contains mostly PUFA elongases with Δ6 activity, some Δ5 elongases, e.g., that of M. polymorpha and Leishmania infantum, are more related to Δ6 elongases of lower eukaryotes than to Δ5 elongases of higher eukaryotes. PiELO1 makes a closely related subgroup with OtELO1, MpELO1, MpELO2 and PpELO1, the OtELO1 being the closest one. - To characterize the enzymatic activity of PiELO1, the pYES2 plasmid containing the PiELO1 ORF downstream of the GAL1 promoter was transformed into S. cerevisiae. The PiELO1 was expressed in the presence of the Δ6 PUFA elongase substrates, 18:3ω6 (γ-linolenic acid, GLA) and 18:4ω3 (stearidonic acid, STA). GC analysis of the FAMEs of transformed yeast cells showed that PiELO1 elongated GLA and STA, converting them into dihomo-γ-linoleic acid (DGLA, 20:3ω6) and eicosatetraenoic acid (20:4ω3), respectively (
FIG. 8 ). The yeast cells harboring the empty vector alone did not demonstrate any elongation activity on the added substrates, confirming that the PiELO1 encoded enzyme has a Δ6 PUFA elongase activity. Feeding the PiELO1 transformants with the ω6 fatty acids, LA and ARA, did not result in their elongation (not shown). - Real-time quantitative PCR was performed to quantitate the alterations in expression levels of the Δ6 PiELO1 in P. incisa cells under nitrogen starvation. The expression levels of the genes under nitrogen starvation were measured and normalized to the expression level of the endogenous control gene 18S SSU rRNA. The fold change in the expression level of the target genes in P. incisa cells grown for 3, 7 and 14 d on N-free medium was calculated relative to the expression level of the target genes in the log phase (time 0). The results showed that during nitrogen starvation the mRNA of the PiELO1 gene was induced to its highest level at day 3 (14 fold increase over time 0), decreasing thereafter to a level still higher than that of day 0 (
FIG. 9 ). After 7 and 14 d, the expression level of the PiELO1 gene was still 7.5 and 4.3 fold higher, respectively. The level of expression of the PiELO1 gene correlated with the increase in the share of ARA and the C20/(C16+C18) elongation ratio (Table 7). The share of the elongation product, DGLA, increased sharply at day 3 (50% increase over time 0) and decreased thereafter. -
TABLE 7 Major fatty acid composition of P. incisa cells grown under N-starvation Time Fatty acid composition (% of total fatty acids) Elo. (days) 16:0 16:1 16:2 16:3 18:0 18:1 18:2 18:3ω6 18:3ω3 20:3ω6 20:4ω6 20: 5ω3 ratio a 0 19.1 5.6 4.1 2.9 3.1 9.1 20.1 1.2 6.0 0.5 23.0 0.7 0.34 3 12.7 2.3 1.5 1.9 3.8 15.2 13.5 1.6 2.0 0.9 39.7 0.6 0.74 7 10.7 1.0 0.6 1.1 3.5 14.9 10.0 1.1 0.9 1.0 50.0 0.5 1.10 14 9.0 0.2 0.3 0.8 3.1 13.4 8.8 0.9 0.6 0.9 56.9 0.6 1.44 aElongation ratio, C20/(C18 + C16) - The capacity of P. incisa to accumulate large quantities of ARA-rich TAG under nitrogen starvation, suggested that it would be of great interest to study its genes and enzymes involved in the accumulation of VLC-PUFA. In the present work, P. incisa Δ12, Δ6, and Δ5 desaturases were cloned and studied, which in conjunction with a recently cloned Δ6 specific PUFA elongase [U. Iskandarov, I. Khozin-Goldberg, R. Ofir, Z. Cohen, Cloning and Characterization of the Δ6 Polyunsaturated Fatty Acid Elongase from the Green Microalga Parietochloris incisa, Lipids 44 (2009) 545-554.], represent a set of P. incisa genes involved in the biosynthesis of ARA. U. Iskandarov et al., 2009 is incorporated by reference as if fully set forth herein.
- The his-boxes of Δ12, Δ6 and Δ5 desaturases including PiDes12, PiDes6, and PiDes5 are detailed in Table 8.
-
TABLE 8 Conserved histidine rich motifs of Δ12, Δ6, and Δ5 desaturases Des Δ12 HECxH HxxHH HxxHH Des Δ6 HD(E)xxH HxxHH QxxHH Des Δ5 HDxxH QHxxxHH QxxHH - Notably, cysteine (C) in the first his-box and the first histidine (H) in the third his-boxes, respectively, are conserved only in Δ12 desaturases. The second residue in the first his-box of the all three types of desaturases is acidic; in Δ6 and Δ5 desaturases it is mostly aspartic acid (D), and in Δ12 desaturases mostly glutamic acid (E). This indicates the importance of an acidic residue at this position for desaturation. Similarly to other Δ6 and Δ5 desaturases glutamine (Q) is found in the third his-box of PiDes6 and PiDes5 (
FIG. 1 ; Table 8) and in the second his-box of Δ5 desaturases. The replacement of the H residue with Q in the third his-box of Δ6 and Δ5 desaturases points to the role of Q in PUFA desaturation. Indeed, replacing this Q with histidine or isoleucine eliminated the enzyme activity of the recombinant Δ6 desaturase in yeast cells. Glutamine was also found to be highly conserved in the third his-box of the Δ4 desaturases Pavlova lutheri (AY332747), Euglena gracilis (AY278558), and Thraustochytrium sp. (AF489589). - Heterologous expression of PiDes6 and PiDes5 in yeast cells confirmed their Δ6 and Δ5 activity by conversion of supplemented fatty acids to the corresponding desaturation products. PiDes12 demonstrated very low desaturation activity, which could not be enhanced by the 5′ modification of the inserted sequence. A similar low activity in yeast was also demonstrated in some cases, such as for Δ5 and Δ12 desaturases of O. tauri and Chlorella vulgaris NJ-7, respectively.
- PiDes6 and PiDes5 desaturated both ω3 and ω6 fatty acids with similar efficiency (
FIG. 3 ; Table 4). Various results concerning ω3/ω6 substrate preference were reported for functionally characterized Δ6 and Δ5 desaturases from different organisms that were expressed in yeast. A front-end PiDes5 desaturated its principal substrate 20:3ω6 as well as 20:4ω3; in addition, non-methylene interrupted fatty acids were also produced as a result of its activity on 20:3ω3, and on both endogenous and exogenous 18:1, but with lower efficiency. PiDes5 produced 18:2Δ5,9 from 18:1 but was more active when 18:1 was exogenously supplied. CrDES did insert Δ5 double bond on both 18:1 and 18:2 producing the non-methylene interrupted 18:2Δ5,9 and 18:3Δ5,9,12, while adding a Δ7 double bond to 20:2ω6 and 20:30ω. Apparently, in addition to the fatty acid chain length, the location and number of double bond, and the form of the substrate (lipid- or CoA bound) are also crucial for Δ5 desaturation. - PiDes6 desaturated neither the yeast major monounsaturated fatty acids nor the exogenously supplied 18:1. PiDes6 did not act on 20:3ω3, indicating that it is specific for Δ9 C18 PUFA. It appears that not only the organisms being transformed, but also the gene origin, determine the substrate specificity of the recombinant Δ6 and Δ5 desaturase. Functional characterization of PiDes6 and PiDes5 confirmed the previously reported substrate specificities of these desaturases which were generally restricted to C18 and C20 substrates, respectively.
- In P. incisa it was shown that PC and DGTS are used for lipid-linked C18 Δ6 desaturation whereas mostly PE is used for C20 Δ5 desaturation. PiDes5 featured higher substrate conversion rate in comparison to PiDes6. A relatively fast emergence of substantial percentage of ARA (10.6% conversion after 3 h of feeding) pursued us to study ARA distribution in individual lipid classes of the transformed yeast (24 h of feeding). ARA was detected in all analyzed phospho- and neutral lipid classes of S. cerevisiae expressing PiDes5 (Table 5). Similar conversion percentages were determined in all analyzed phospholipids, however, ARA distribution showed preference for the major phospholipids, PC, followed by PE. In P. incisa, PE was found to be the main site for lipid-linked Δ5 desaturation [C. Bigogno, I. Khozin-Goldberg, D. Adlerstein, Z. Cohen, Biosynthesis of arachidonic acid in the oleaginous microalga Parietochloris incisa (Chlorophyceae): Radiolabeling studies, Lipids 37 (2002) 209-216], while PC, a major Δ6 acyl lipid desaturation substrate in this organism, was assumed to be utilized for Δ5 desaturation, too.
- The quantitative RT-PCR results revealed that the gene expression levels of PiDes12, PiDes6, and PiDes5 followed a similar pattern during the course of nitrogen starvation. The major transcriptional activation of the all three desaturases occurred on
day 3 coinciding with a sharp rise in the percentage of ARA, which almost doubled (FIG. 4 , Table 6). The same expression pattern featured the P. incisa Δ6 PUFA elongase, however, at lower level. It was shown in radiolabeling and inhibitor studies, that ARA biosynthesis in P. incisa follows the ω6 pathway. The concerted transcriptional activation of the PiDes12, PiDes6, PiDes5 and PiELO1 genes was accompanied by an increase in the percent share of 18:1, a main chloroplast-derived fatty acid exported to ER and substrate of Δ12 desaturase. High expression of ARA biosynthetic genes was accompanied by enhanced Δ5 and Δ6 desaturations (Table 6). - In conclusion, the Δ12, Δ6 and Δ5 fatty acid desaturases involved in ARA biosynthesis in P. incisa were identified and functionally characterized. The corresponding ORFs PiDes12, PiDes6, and PiDes5, expressed in yeast confirmed their favorable enzymatic activity. Nitrogen starvation led to an increased transcription of the cloned genes reaching maximum on
day 3 and enhanced accumulation of ARA thereafter. Understanding the mechanisms underlying gene transcription regulation in metabolic pathways and characteristics of enzymes involved in ARA and lipid biosynthesis in P. incisa is a prerequisite for manipulating algal species to produce sustainable oils of pharmaceutical and neutraceutical values. - A cDNA (PiELO1) of an elongase encoding for a deduced protein was isolated from P. incisa, structurally similar to 46 PUFA elongase gene products from microalgae, lower plants and fungi (
FIG. 5 ). The deduced amino acid sequence of the PiELO1 ORF was about 50% identical to that of 46 elongases from the liverwort M. polymorpha (AAT85662), the green marine microalga O. tauri (AAV67797) and the moss P. patens (AAL84174). In similarity to recently cloned PUFA elongases, the predicted protein is highly hydrophobic and has two strongly hydrophobic transmembrane regions, the first one located about 50 amino acids downstream of the N-terminus and the second one in the vicinity of the C-terminus. The PiELO1 sequence was identified in a C-terminal lysine-rich motif, important for the endoplamic reticulum targeting, as well as four conserved motifs FYxSKxxEFxDT, QxxxLHVYHHxxI, NSxxHVxMYxYY and TxxQxxQF, including a highly conserved histidine box suggested to be functionally important for PUFA elongation (FIG. 5 ). These conserved motifs were not found in other classes of plant microsomal elongases, β ketoacyl CoA synthases and fatty acid elongases (FAE) involved in extraplastidial elongation of saturated and monounsaturated fatty acids. A variant histidine box QAFHH with three replacements in C18-Δ9-PUFA elongase IgASE1 from I. galbana is thought to be important for enzymatic activity rather then for substrate specificity. - PiELO1 is another example of a single step Δ6 PUFA elongases cloned from an algal species. Similarly to GLELO of M. alpina, PiELO1 prefers the Δ6 C18 PUFA substrates, GLA and STA. Only these Δ6 fatty acids were, when exogenously added, elongated to the respective products by S. cerevisiae cells transformed with PiELO1 (
FIG. 8 ). Transformation of a higher plant so as to render it to produce Δ6 PUFA requires that the elongase used will have a high selectivity for Δ6 PUFA, thereby reducing the appearance of side products in the transformed plant. Bifunctional invertebrate PUFA elongases with both Δ6 and Δ5 activities (OmELO, XiELO, and CiELO) are less desirable in plant transformations. - Phylogenetic analysis showed (
FIG. 6 ) that the PUFA elongases are not strictly divided according to their substrate specificity. The Δ6 elongases of algal (OtELO1, TpELO1, PiELO1) and moss (PpELO1) origin are functionally restricted to the elongation of Δ6-C18-PUFAs, however these elongases are placed in separate groups on the phylogenetic tree (FIG. 7 ). PiELO1 is closely related to OtELO1 isolated from a chloropyte and a lower plant rather than to ELO1 genes isolated from a diatom, although both are specific for the elongation of Δ6-C18-PUFAs (FIG. 7 ). PiELO1 is highly similar to and is placed in the same group with both Δ6 and Δ5 elongases of the liverwort M. polymorpha. Kajikawa et al. suggested that MpELO2, a Δ5 elongase, is likely to have originated through gene duplication of the MpELO1 gene. The algal Δ5 PUFA elongases, OtELO2, TpELO2 and the P. salina ELO1 are more likely to share a common branch with the mammalian and animal Δ5 PUFA elongases, OmELO and HsELO2, while they are also similar to bifunctional PUFA elongases such as CiELO1/2. - Quantitative real timd PCR studies revealed that the expression level of the PiELO1 gene was up regulated during the time course of N-starvation (
FIG. 9 ). Nitrogen starvation led to a continuous increase in the share of ARA and the C20/(C16+C18) elongation ratio (Table 7). However, a major transcriptional activation of PiELO1 which occurred on day 3 (14-fold increase in transcript level) coincided with the steep rise in AA accumulation and elongation ratio (Table 7). The increase in PiELO1 transcription level followed by enhanced biosynthesis of ARA may be interpreted as an increase in PiELO1 enzyme level and/or enzymatic activity. The importance of the transcriptional activation of PiELO1 is supported by the fact that PUFA elongase was the only ARA biosynthesis related gene that was obtained from the subtractive library. - The significance of the coordinated transcription and action of desaturases and elongases in ARA biosynthesis in P. incisa is yet to be elucidated. Possibly, the elongation of GLA by PiELO1 could be rate-limiting in ARA biosynthesis as it is in M. alpina. Abbadi et al. (2004) speculated that in transgenic plants modified with VLC-PUFA biosynthesis genes, substrate availability rather than enzymatic activity is rate-limiting in the Δ6 elongation of PUFA.
Claims (42)
1. An isolated protein comprising, an amino acid sequence set forth in SEQ ED NO: 1.
2. A composition comprising the protein of claim 1 .
3. An isolated protein comprising, an amino acid sequence set forth in SEQ ID NO: 2.
4. A composition comprising the protein of claim 3 .
5. An isolated protein comprising, an amino acid sequence set forth in SEQ ID NO: 3.
6. A composition comprising the protein of claim 5 .
7. An isolated polynucleotide comprising a coding portion encoding the protein of claim 1 .
8. The isolated polynucleotide of claim 7 , wherein said coding portion comprises a nucleic acid sequence set forth in SEQ ID NO: 4.
9. An isolated polynucleotide comprising a coding portion encoding the protein of claim 3 .
10. The isolated polynucleotide of claim 9 , wherein said coding portion comprises a nucleic acid sequence set forth in SEQ ID NO: 5.
11. An isolated polynucleotide comprising a coding portion encoding the protein of claim 5 .
12. The isolated polynucleotide of claim 11 , wherein said coding portion comprises a nucleic acid sequence set forth in SEQ ID NO: 6.
13. An expression vector comprising the polynucleotide of claim 7 .
14. An expression vector comprising the polynucleotide of claim 9 .
15. An expression vector comprising the polynucleotide of claim 11 .
16. A cell comprising the expression vector of claim 13 .
17. A cell comprising the expression vector of claim 14 .
18. A cell comprising the expression vector of claim 15 .
19. A transgenic plant, a transgenic seed, or a transgenic alga transformed by a polynucleotide of claim 7 .
20. A transgenic plant, a transgenic seed, or a transgenic alga transformed by a polynucleotide of claim 9 .
21. A transgenic plant, a transgenic seed, or a transgenic alga transformed by a polynucleotide of claim 11 .
22. A transgenic seed, produced by a transgenic plant transformed by a polynucleotide of claim 7 .
23. A transgenic seed, produced by a transgenic plant transformed by a polynucleotide of claim 9 .
24. A transgenic seed, produced by a transgenic plant transformed by a polynucleotide of claim 11 .
25. A method of producing very long-chain polyunsaturated fatty acid (VLC-PUFA) in a plant, a plant cell, or an alga comprising the step of transforming a plant, a plant cell, or an alga with a polynucleotide of claim 7 , thereby producing a VLC-PUFA in a plant, a plant cell, or an alga.
26. A method of producing very long-chain polyunsaturated fatty acid (VLC-PUFA) in a plant, a plant cell, or an alga, comprising the step of transforming a plant, a plant cell, or an alga with a polynucleotide of claim 9 , thereby producing a VLC-PUFA in a plant, a plant cell, or an alga.
27. A method of producing very long-chain polyunsaturated fatty acid (VLC-PUFA) in a plant, a plant cell, or an alga, comprising the step of transforming a plant, a plant cell, or an alga with a polynucleotide of claim 11 , thereby producing a VLC-PUFA in a plant, a plant cell, or an alga.
28. The method of claim 25 , wherein said plant, said plant cell, or said alga comprises linoleic acid (LA; 18:2ω6), α-linolenic acid (ALA; 18:3ω3), oleic acid (18:1), dihomo-gamma-linolenic acid (20:3ω6), phosphatidylcholine (PC), diacylglyceroltrimethylhomoserine (DGTS), phosphatidylethanolamine (PE), or any combination thereof.
29. The method of claim 25 , wherein said VLC-PUFA is eicosapentaenoic acid (EPA, 20:5ω3), docosahexaenoic acid (DHA, 22:6ω3), dihomo-gamma-linolenic acid (DGLA), or arachidonic acid (ARA, 20:4ω6)
30. The method of claim 25 , wherein said plant, said plant cell, or said alga is grown under oleogenic conditions, under nitrogen starvation conditions, or a combination thereof.
31. The method of claim 25 , wherein said producing very long-chain polyunsaturated fatty acid (VLC-PUFA) is enhancing oil storage, arachidonic acid accumulation, eicosapentaenoic acid accumulation, docosahexaenoic acid accumulation, dihomo-gamma-linolenic acid accumulation, or a combination thereof.
32. The method of claim 25 , further comprising the a step of transforming said plant, said plant cell, or said alga with a polynucleotide of claim 9 , a polynucleotide of claim 11 , a polynucleotide encoding a PUFA-specific elongase, or any combination thereof.
33. The method of claim 26 , further comprising the a step of transforming said plant, said plant cell, or said alga with a polynucleotide of claim 7 , a polynucleotide of claim 11 , a polynucleotide encoding a PUFA-specific elongase, or any combination thereof.
34. The method of claim 27 , further comprising the a step of transforming said plant, said plant cell, or said alga with a polynucleotide of claim 7 , a polynucleotide of claim 9 , a polynucleotide encoding a PUFA-specific elongase, or any combination thereof.
35. The method of claim 26 , wherein said plant, said plant cell, or said alga comprises linoleic acid (LA; 18:2ω6), α-linolenic acid (ALA; 18:3ω3), oleic acid (18:1), dihomo-gamma-linolenic acid (20:3ω6), phosphatidylcholine (PC), diacylglyceroltrimethylhomoserine (DGTS), phosphatidylethanolamine (PE), or any combination thereof.
36. The method of claim 26 , wherein said VLC-PUFA is eicosapentaenoic acid (EPA, 20:5ω3), docosahexaenoic acid (DHA, 22:6ω3), dihomo-gamma-linolenic acid (DGLA), or arachidonic acid (ARA, 20:4ω6)
37. The method of claim 26 , wherein said plant, said plant cell, or said alga is grown under oleogenic conditions, under nitrogen starvation conditions, or a combination thereof.
38. The method of claim 26 , wherein said producing very long-chain polyunsaturated fatty acid (VLC-PUFA) is enhancing oil storage, arachidonic acid accumulation, eicosapentaenoic acid accumulation, docosahexaenoic acid accumulation, dihomo-gamma-linolenic acid accumulation, or a combination thereof.
39. The method of claim 27 , wherein said plant, said plant cell, or said alga comprises linoleic acid (LA; 18:2ω6), a-linolenic acid (ALA; 18:3ω3), oleic acid (18:1), dihomo-gamma-linolenic acid (20:3ω6), phosphatidylcholine (PC), diacylglyceroltrimethylhomoserine (DGTS), phosphatidylethanolamine (PE), or any combination thereof.
40. The method of claim 27 , wherein said VLC-PUFA is eicosapentaenoic acid (EPA, 20:5ω3), docosahexaenoic acid (DHA, 22:6ω3), dihomo-gamma-linolenic acid (DGLA), or arachidonic acid (ARA, 20:4ω6)
41. The method of claim 27 , wherein said plant, said plant cell, or said alga is grown under oleogenic conditions, under nitrogen starvation conditions, or a combination thereof.
42. The method of claim 27 , wherein said producing very long-chain polyunsaturated fatty acid (VLC-PUFA) is enhancing oil storage, arachidonic acid accumulation, eicosapentaenoic acid accumulation, docosahexaenoic acid accumulation, dihomo-gamma-linolenic acid accumulation, or a combination thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/520,607 US20130019341A1 (en) | 2010-01-05 | 2011-01-05 | Desaturases of a green microalga and uses thereof |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29218510P | 2010-01-05 | 2010-01-05 | |
PCT/IL2011/000006 WO2011083463A2 (en) | 2010-01-05 | 2011-01-05 | Desaturases of a green microalga and uses thereof |
US13/520,607 US20130019341A1 (en) | 2010-01-05 | 2011-01-05 | Desaturases of a green microalga and uses thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2011/000006 A-371-Of-International WO2011083463A2 (en) | 2010-01-05 | 2011-01-05 | Desaturases of a green microalga and uses thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/804,638 Continuation US9315837B2 (en) | 2010-01-05 | 2015-07-21 | Desaturases of a green microalga and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130019341A1 true US20130019341A1 (en) | 2013-01-17 |
Family
ID=44305891
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/520,607 Abandoned US20130019341A1 (en) | 2010-01-05 | 2011-01-05 | Desaturases of a green microalga and uses thereof |
US14/804,638 Expired - Fee Related US9315837B2 (en) | 2010-01-05 | 2015-07-21 | Desaturases of a green microalga and uses thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/804,638 Expired - Fee Related US9315837B2 (en) | 2010-01-05 | 2015-07-21 | Desaturases of a green microalga and uses thereof |
Country Status (4)
Country | Link |
---|---|
US (2) | US20130019341A1 (en) |
EP (1) | EP2521440A4 (en) |
AU (1) | AU2011204404A1 (en) |
WO (1) | WO2011083463A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140093910A1 (en) * | 2010-06-10 | 2014-04-03 | Bengurion University Of The Negev Research And Development Authority | D5 desaturase-defective mutant gene and use thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090100536A1 (en) * | 2001-12-04 | 2009-04-16 | Monsanto Company | Transgenic plants with enhanced agronomic traits |
BRPI0714390B1 (en) * | 2006-07-19 | 2018-05-15 | Monsanto Technology Llc | POLYNUCLEOTIDE, DNA CONSTRUCTION, FUNGAL OR BACTERIAL HOST CELL, PROCESS FOR FOOD OR FOOD PRODUCTION AND COMPOSITION FOR FOOD OR FOOD PRODUCT |
-
2011
- 2011-01-05 US US13/520,607 patent/US20130019341A1/en not_active Abandoned
- 2011-01-05 WO PCT/IL2011/000006 patent/WO2011083463A2/en active Application Filing
- 2011-01-05 EP EP11731732.1A patent/EP2521440A4/en not_active Withdrawn
- 2011-01-05 AU AU2011204404A patent/AU2011204404A1/en not_active Abandoned
-
2015
- 2015-07-21 US US14/804,638 patent/US9315837B2/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
Accession AC B5DC82 (2008) * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140093910A1 (en) * | 2010-06-10 | 2014-04-03 | Bengurion University Of The Negev Research And Development Authority | D5 desaturase-defective mutant gene and use thereof |
Also Published As
Publication number | Publication date |
---|---|
US20160060662A1 (en) | 2016-03-03 |
EP2521440A4 (en) | 2013-10-23 |
WO2011083463A2 (en) | 2011-07-14 |
EP2521440A2 (en) | 2012-11-14 |
WO2011083463A3 (en) | 2011-10-13 |
AU2011204404A1 (en) | 2012-08-02 |
US9315837B2 (en) | 2016-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200002712A1 (en) | Fad4, fad5, fad5-2, and fad6, novel fatty acid desaturase family members and uses thereof | |
JP4087460B2 (en) | Methods and compositions for the synthesis of long chain polyunsaturated fatty acids in plants | |
Iskandarov et al. | Identification and characterization of Δ12, Δ6, and Δ5 desaturases from the green microalga Parietochloris incisa | |
Khozin-Goldberg et al. | Microalgae as a source for VLC-PUFA production | |
AU2002218447A1 (en) | Fad4, Fad5, Fad5-2, and Fad6, fatty acid desaturase family members and uses thereof | |
AU2013326297B2 (en) | Recombinant organisms | |
WO2011161678A2 (en) | Glycerol-3-phosphate acyltransferase and uses thereof | |
US9315837B2 (en) | Desaturases of a green microalga and uses thereof | |
US8802924B2 (en) | Polyunsaturated fatty acid elongase | |
CA2608848C (en) | Fad4, fad5, fad5-2, and fad6, novel fatty acid desaturase family members and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BEN GURION UNIVERSITY OF THE NEGEV RESEARCH AND DE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:UMIDJON, ISKANDAROV;KHOZIN GOLDBERG, INNA;HACOHEN, ZVI;SIGNING DATES FROM 20120704 TO 20120729;REEL/FRAME:028992/0708 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |